IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 1PROTOCOL
TITLE: Phase 2 study  of the combinat ion of ibrut inib plus venetoclax in 
subjects wi th treatm ent-naïve chronic lymphocyt ic leukemia / 
small lymphocy tic lympho ma
PROTOCOL NUMBER: PCYC -1142- CA
STUDY DRUG: Ibrutinib (PCI -
32765)
IND NUMBER: 102,688
Eudra CT NUMBER: 2016-002293-12
SPONSOR MEDICAL 
MONITOR:MD
Pharmacyclics LLC
Phone:
Email:
SPONSOR: Pharmacyclics LLC 
1000 Gateway  Boul evard
South San Francisco ,
CA 94080
United States of America
DATE FINAL:
Amendment 1:
Amendment 2:
Amendment 3:
Amendment 4:05July2016
25September 2017
29November 2018
11September 2019
02December 2022
Confidentiality Statement
This document contains confident ia
l information of Pharmacyclics LLC that must not be 
disclosed to any one other than the recipient study  staff and members of the inst itutional 
review board/ethics committee. This informat ion cannot be used for any other pur pose other 
than the evaluation or conduct of the clinical study without the prior written consent of 
Pharmacyclics LLC.
[STUDY_ID_REMOVED]

IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 2PROTOCOL APPROVAL PA GE
Study Title: Phase 2 study  of the combinat ion of ibrut inib plus venetoclax in 
subjects wi th treatm ent naïve chronic lymphocy tic leukemia / small 
lymphocy tic lympho ma
Study Number: PCYC -1142- CA
Protocol Date: 05July2016
Amendment 1 25 September 2017
Amendment 2 29 November 2018
Amendment 3 11 September 2019
Amendment 4 02December 2022
I have carefully  read Protocol  PCYC -
1142- CA entit led “ Phase 2 study  of the combinat ion of 
ibrutinib plus venetoclax in subjects wi th treatm ent naïve chronic lymphocy tic leukemia / small 
lymphocy tic lympho ma”I agree to conduct this study  as outlined herein and in complianc e with 
Good Clinical Pract ices (GCP) and all applicable regulatory requirements. Furthermore, 
Iunderstand that the Sponsor, Pharmacyclics, and the Institutional Review Board/Research 
Ethics Board/Independent Ethics Co mmittee (IRB/REB/IEC) must approve any changes to the 
protocol  in wri ting before implementation.
I agree not to divulge to any one, either during or after the terminat ion of the study , any  
confident ia
l information acquired regarding the investigational product and processes or methods 
of Pharma cyclics.  All data pertaining to this study will be provided to Pharmacyclics.  
Thepolicy of Pharmacyclics LLC requi res that any  presentati on or publication o f study  data by  
clinical Invest igators be reviewed by Pharmacyclics, before release, as specified in the protocol.
Principal Invest igator’s Signature Date
Print Nam e
The fo llowing Pharmacyclics LLC representative is authorized to sign the protocol and any 
amendments:
Medical Monitor’s Signature Date
 MD Clinical Science , Pharmacyclics LLC
Electronically signed by:
Reason: Reviewer
Date: Dec 6, 2022 03:07 PST
06-Dec-2022

IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 3TABLE OF CONTENT S
PROTOCOL APPROVAL PA GE........................................................................................... 2
TABLE OF CONTENTS .......................................................................................................... 3
LIST OF APPE NDICES ........................................................................................................... 9
LIST OF IN -TEXT TABL ES AND FIGURES ........................................................................ 9
SYNOPSIS ............................................................................................................................... 11
ABBREVIATIONS ................................................................................................................. 24
1. BACKGROUND ....................................................................................................... 27
1.1. Disease/Histol ogy....................................................................................................... 27
1.1.1. Disease Background .................................................................................................... 27
1.1.2. Current Treatment Options in Previously Untreated CLL ............................................ 28
1.2. Ibrutinib Overview ...................................................................................................... 30
1.2.1. Summary  of Nonclinical Data ..................................................................................... 30
1.2.1.1. Pharmaco logy............................................................................................................. 30
1.2.1.2. Safety Pharmaco logy and Toxi cology......................................................................... 31
1.2.2. Summary  of Clinical Data ........................................................................................... 31
1.2.2.1. Pharmacokinet ics and Product Metabolism .................................................................. 31
1.2.3. Summary  of Clinical Safet y......................................................................................... 32
1.2.3.1. Monotherapy  Studies ................................................................................................... 32
1.2.3.2. Combinat ion Studi es................................................................................................... 32
1.2.4. Risks ........................................................................................................................... 33
1.2.4.1. Cardi ac Arrhy thmias and Cardiac Failure .................................................................... 33
1.2.4.2. Bleeding- related Events ............................................................................................... 33
1.2.4.3. Cytopeni as.................................................................................................................. 34
1.2.4.4. Diarrhea ...................................................................................................................... 34
1.2.4.5. Infections .................................................................................................................... 34
1.2.4.6. Intersti tial Lung Disease (ILD) .................................................................................... 35
1.2.4.7. Leukostasi s................................................................................................................. 35
1.2.4.8. Lymphocy tosis............................................................................................................ 35
1.2.4.9. Non-melanoma Skin Cancer ........................................................................................ 35
1.2.4.10. Rash ............................................................................................................................ 35
1.2.4.11. Tumor Lysis Syndrom e............................................................................................... 35
1.2.4.12. Hypertensio n............................................................................................................... 36
1.3. Venetoclax Overview .................................................................................................. 36
1.3.1. Summary  of Nonclinical Data ..................................................................................... 37
1.3.2. Summary  of Venetoclax Clinical Data ......................................................................... 37
1.3.2.1. Clinical Pharmacokinet ics........................................................................................... 37
1.3.2.2. Summary  of Clinical Safet y......................................................................................... 38
1.3.3. Risks ........................................................................................................................... 38
1.3.3.1. Tumor Lysis Syndro me............................................................................................... 38
1.3.3.2. Neutropenia ................................................................................................................. 39
1.3.3.3. Immunizati on.............................................................................................................. 39
1.4. Study  Rati onale ........................................................................................................... 39
2. STUDY OBJECTIVE ............................................................................................... 43
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 42.1. Primary Object ive....................................................................................................... 43
2.2. Secondary  Object ive(s) ............................................................................................... 43
2.2.1. MRD Cohort ............................................................................................................... 43
2.2.2. Fixed Duration Cohort .................................................................................................43
2.3. MRD Cohort Exploratory  Object ives.......................................................................... 44
2.4. FD Cohort Exploratory  Object ive................................................................................ 44
3. STUDY DESIGN ....................................................................................................... 44
3.1. Overview of Study  Design .......................................................................................... 44
3.1.1. MRD Cohort: Pre-Randomization Phase ..................................................................... 45
3.1.2. MRD Cohort: Randomizat ion Phase (Including Re -introduction Period) ..................... 46
3.1.3. Fixed Duration Cohort .................................................................................................48
3.1.4. Post-PD Follow -Up Phase ........................................................................................... 48
3.2. Study  Schema; MRD Cohort ....................................................................................... 49
3.3. Study  Schema; Fixed Duration Cohort ........................................................................ 50
4. SUBJECT SELECTION ........................................................................................... 51
4.1. Inclusio n Cri teria......................................................................................................... 51
4.2. Exclusio n Cri teria........................................................................................................ 52
5. TREATMENT OF SUBJECT S................................................................................ 54
5.1. Treatment Allocat ion and Blinding .............................................................................. 54
5.2. Safety Run-in Period ................................................................................................... 54
5.2.1. Dose -Limit ing Toxicit y (DLT) .................................................................................... 55
5.2.2. Baseline TLS Assessment ........................................................................................... 56
5.3. Study  Treatm ent.......................................................................................................... 56
5.3.1. Pre-Rando mizat ion Phase ............................................................................................ 56
5.3.2. Randomization Phase .................................................................................................. 57
5.3.2.1. Randomization Phase –MRD -negat ive Subjects (Double -blind) .................................58
5.3.2.2. Randomization Phase –MRD -Positive Subjects (Open -Label ).................................... 58
5.3.3. Fixed Duration Cohort .................................................................................................59
5.3.4. Baseline TLS Assessment ........................................................................................... 61
5.4. Study  Medicat ion........................................................................................................ 61
5.4.1. Ibrutinib ...................................................................................................................... 61
5.4.1.1. Form ulation/Packaging/Storage ................................................................................... 61
5.4.1.2. Dose and Administration ............................................................................................. 61
5.4.1.3. Overdose ..................................................................................................................... 62
5.4.1.4. Dose Modificat ion for Adverse Reactions ................................................................... 62
5.4.1.5. Leukocy tosis/Leukostasis ............................................................................................ 64
5.4.1.6. Dose Modificat ion for Hepati c-Impaired Subjects ....................................................... 64
5.4.2. Venetoclax (ABT -199) ................................................................................................ 64
5.4.2.1. Form ulation/Packaging/Storage ................................................................................... 64
5.4.2.2. Prophylaxis and Management of Tumor Ly sis Syndrom e............................................ 65
5.4.2.3. Dose and Administration ............................................................................................. 67
5.4.2.4. Overdose ..................................................................................................................... 68
5.4.2.5. Dose Modificat ion for Adverse Reactions ................................................................... 68
5.4.2.6. Management of Neutropenia ....................................................................................... 70
5.4.2.7. Management of Hematologic Toxicit ies Other Than Neutropenia or Lymphopenia .....70
5.4.2.8. Management of Non -Hematol ogic Toxicit y.................................................................70
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 55.4.2.9. Management of Decrease in Spermatogenesis ............................................................. 70
5.4.2.10. Embryo -Fetal  Toxi city................................................................................................ 70
5.4.2.11. Immunizati on.............................................................................................................. 71
5.5. Criteria for Perm anent Discont inuat ion of Study  Drug ................................................ 71
6. CONCOMITANT MEDICATI ONS/PROCEDURES ............................................. 71
6.1. Permi tted Concomitant Medications ............................................................................ 71
6.2. Medicat ions to Be Used with Caut ion.......................................................................... 72
6.2.1. Drugs That May  Alter Ibrutinib and/or Venetoclax Plasma Concentrations ................. 72
6.2.1.1. Concomitant Use with Ibrutinib ................................................................................... 72
6.2.1.2. Concomitant Use with Venetoclax ............................................................................... 73
6.2.2. Drugs That May  Have Thei r Plasma Concentrati ons Al tered by Ibrut inib.................... 73
6.2.3. Drugs That May  Have Thei r Plasm a Concentrati ons Al tered by Venetocl ax................ 74
6.2.4. Antiplatelet Agents and Ant icoagulants ....................................................................... 74
6.3. Prohibited Conco mitant Medi cations and Products ...................................................... 74
6.3.1. Prohibited Conco mitant Medi cations and Products for Ibrutinib and/or Venetoclax .....74
6.4. Guidelines for Ibrutinib Management with Surgeries or Procedures ............................. 75
6.4.1. Minor Surgical Procedures .......................................................................................... 75
6.4.2. Major Surgi cal Procedures .......................................................................................... 75
6.4.3. Emergency  Procedures ................................................................................................ 75
7. STUDY EVALUATIONS ......................................................................................... 76
7.1. Description of Procedures ........................................................................................... 76
7.1.1. Assessments ................................................................................................................ 76
7.1.1.1. ICF.............................................................................................................................. 76
7.1.1.2. Confirm Eligibilit y...................................................................................................... 76
7.1.1.3. Medical History  and Dem ographics ............................................................................. 76
7.1.1.4. Prior and Concomi tant Medicat ions............................................................................. 76
7.1.1.5. Adverse Events ........................................................................................................... 76
7.1.1.6. Physi cal Examinat ion.................................................................................................. 77
7.1.1.7. ECOG ......................................................................................................................... 77
7.1.1.8. Vital Signs .................................................................................................................. 77
7.1.1.9. Tumor Lysis Syndrom e (TLS) Risk Assessment .......................................................... 77
7.1.1.10. Tumor Lysis Syndrom e (TLS) Prophylaxis .................................................................77
7.1.2. Laboratory ................................................................................................................... 78
7.1.2.1. Hem atology................................................................................................................. 78
7.1.2.2. Chemistry  (Serum )...................................................................................................... 78
7.1.2.3. Coagulation Studies ..................................................................................................... 78
7.1.2.4. Hepati tis Serol ogies ..................................................................................................... 78
7.1.2.5. Serum  β2-microglobulin .............................................................................................. 78
7.1.2.6. Pregnancy Test ............................................................................................................ 78
7.1.3. Diagnostics/Procedures ............................................................................................... 79
7.1.3.1. ECG ............................................................................................................................ 79
7.1.3.2. CT/MRI ...................................................................................................................... 79
7.1.3.3. Bone Marrow Biopsies and Aspirate ........................................................................... 79
7.1.3.4. FISH Assays ............................................................................................................... 83
7.1.3.5. Kary otype................................................................................................................... 83
7.1.4. P harmacokinet ics/ ..................................................................................... 83

IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 78.2.1.7. Cycle 16 Day  1 Vi sit.................................................................................................102
8.2.2. Cycle 17 Rando mizat ion Visit and Every  3 Cycles Thereafter ................................... 103
8.2.3. Suspected MRD- positive Relapse Visit (Any Time) .................................................. 104
8.3. Fixed Duration Cohort ............................................................................................... 104
8.3.1. Treatment Visit s........................................................................................................ 105
8.3.1.1. Cycle 1 Day  1 (C1D1) Visit ...................................................................................... 105
8.3.1.2. Cycles 2 and 3 Visits .................................................................................................106
8.3.1.3. Cycle 4 Vi sits............................................................................................................ 106
8.3.1.3.1. Pre-Cycle 4 (Pre -initiation of Venetoclax) ........................................................ 106
8.3.1.3.2. Cycle 4 Week 1 Day  1 ..................................................................................... 107
8.3.1.3.3. Cycle 4 Week 1 Day  2 ..................................................................................... 107
8.3.1.3. 4. Cycle 4 (Week 2 –Week 4) Visits .................................................................... 108
8.3.1.3.5. Cycle 4 Week 2 Day  2 ..................................................................................... 108
8.3.1.4. Cycle 5 Vi sits............................................................................................................ 109
8.3.1.4.1. Cycle 5 Week 1 and Week 3 Visits .................................................................. 109
8.3.1.5. Cycle 6 –Cycle 9 Visits ............................................................................................ 109
8.3.1.6. Cycle 10 and Cycle 13 Visit s..................................................................................... 110
8.3.2. Fixed Duration Cohort: Post treatment visits ............................................................. 111
8.4. Reintroduction of Study  Drug (MRD and FD Cohorts) .............................................. 111
8.5. Suspected PD Visit (Any Time) ................................................................................ 114
8.6. Suspected CR Visit ................................................................................................... 115
8.7. End-of-Treatm ent Visi t............................................................................................. 115
8.8. Response Fo llow-Up Vi sits....................................................................................... 115
8.9. Post-PD Follow -Up Phase ......................................................................................... 116
9. SUBJECT COMPLETION A ND WITHDRAWAL .............................................. 116
9.1. Com pletion............................................................................................................... 116
9.2. Withdrawal fro m Study  Treatm ent............................................................................ 116
9.3. Withdrawal fro m Study ............................................................................................. 117
10. STATISTICAL METHODS AND ANALYSIS ..................................................... 117
10.1. Subject Informat ion................................................................................................... 118
10.2. Endpoints .................................................................................................................. 118
10.2.1. MRD Cohort: ............................................................................................................ 118
10.2.2. Fixed Duration Cohort: .............................................................................................. 119
10.3. Sample Si ze Determinat ion....................................................................................... 119
10.4. Efficacy Analysis ...................................................................................................... 120
10.4.1. MRD -Negat ive Response Rate .................................................................................. 120
10.4.2. Disease -Free Survi val (DFS) ..................................................................................... 120
10.4.3. Overall Response Rate (ORR) ................................................................................... 121
10.4.4. Com plete Response Rate (CRR) ................................................................................ 121
10.4.5. Durati on of  Response (DOR) .................................................................................... 121
10.4.6. Progression -Free Survival (PFS) ............................................................................... 121
10.4.7. Overall Survival (OS) ................................................................................................ 122
10.4.8. Tumor Lysis Syndrom e (TLS) Risk Reduct ion Rate .................................................. 122
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 9LIST OF APPENDICES
Appendix A.Schedule of Assessments for MRD cohort ........................................................ 146
Appendix B.Schedule of Assessments for Fixed Duration Cohort ........................................ 151
Appendix C.Schedule of Assessments for Reintroduction of Ibrutinib (MRD and F D Cohorts)
........................................................................................................................ 155
Appendix D.Schedule of Assessments for Reintroduction of Venetoclax (MRD Cohort only)
........................................................................................................................ 157
Appendix E.Schedule of Assessments for Reintroduction of Ibrutinib + Venetoclax (FD 
Cohort only) ..................................................................................................... 159
Appendix F.ECOG Status Scores ........................................................................................ 161
Appendix G.Sample List of Cautionary  Medicat ions............................................................ 162
Appendix H.TLS Ri sk Category .......................................................................................... 164
Appendix I.Howard Cri teria1for Laboratory  and Clinical  TLS ........................................... 165
Appendix J.Example of Reco mmendat ions for Initial Management of El ectroly te 
Abnorm alities and Prevent ion of Tum or Ly sis Syndrom e (TLS) ...................... 166
Appendix K.Child -Pugh Score for Subjects with Liver Impairment ...................................... 170
Appendix L.Hem atologic Adverse Event Grading Scheme (Hallek 2008) ............................ 171
Appendix M.Rai Staging ...................................................................................................... 172
LIST OF IN -TEXT TABLES AND FIGURES
Tables
Table 1. Dose De -Escalation Schedule for Safet y Run-in................................................. 55
Table 2. Ibrutinib/ Placebo Dose Modific ations f or Events not Specified in Table 3 ......... 63
Table 3. Ibrutinib/Placebo Dose Modificat ions for Cardi ac Failure or Cardiac Arrhy thmias
.......................................................................................................................... 64
Table 4. TLS Prophylaxis Based on Tumor Burden from Clinical Trial Data (consider all 
co-morbidities before final determinat ion of prophylaxis and monitoring 
schedule) ............................................................................................................ 66
Table 5. Venetoclax Reco mmended Dose Modificat ions for Toxi citiesa........................... 69
Table 6. Dose Modificat ion for Toxi city during Venetocl ax Treatm ent............................ 69
Table 7. Management of Potential Ibrut inib and Venetoclax Interactions wit h CYP3A 
Inhibitors ........................................................................................................... 73
Table 8. Overall Response Assessment ............................................................................ 80
Table 9. MRD cohort: Bone Marrow Biopsy  and Aspirate Colle ction Times for Clinical 
Response ............................................................................................................ 80
Table 10. Fixed Duration cohort: Bone Marrow Biopsy and Aspirate Collect ion Times for 
Clinical Response ............................................................................................... 80
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 10Table 11. MRD Cohort: MRD Sample Co llection Schedule ............................................... 82
Table 12. Fixed Duration Cohort: MRD Sample Co llection Schedule ................................ 83
Table 13. Pharmacokinet ic Sample Schedule for Ibrutinib and Venetoclax (MRD Cohort 
Only) ................................................................................................................. 84
Table 14. Evaluable Parameter Requirements .................................................................... 89
Table 15. Criteria for C linical Response Categories ........................................................... 90
Figures
Figure 1. Venetoclax Dose Ramp -up................................................................................. 57
Figure 2. Reintroduction of Ibrut inib or Venetoclax for MRD Cohort ............................... 59
Figure 3. Reintroduction of Ibrut inib or I+V Therapy for FD Cohort .................................61
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 11SYNOPSIS
Study Title: Phase 2 study of the combination of ibrutinib plus venetoclax in 
subjects with treatment naïve chronic lymphocytic leukemia (CLL) / 
small lymphocytic lymphoma (SLL)
Protocol Number: PCYC -1142 -CA
Study Phase: 2
Study Duration: Estimated to be 12 years
Investigational Product 
and Reference Therapy:Ibrutinib will be supplied as 140 mg hard gelatin capsules for oral (PO) 
administration.
Venetoclax will be supplied as 10 mg, 50 mg, and 100 mg film coated 
tablets for oral (PO) administration.
Objectives: MRD Cohort
Primary Objective:
To evaluate if discontinuing ibrutinib, in the setting of a confirmed 
MRD -negative response with the combination of ibrutinib + venetoclax, 
allows for a treatment holiday as assessed by 1 -year disease -free 
survival (DFS) .
Secondary Objectives :
To evaluate:
Minima l Residual Disease (MRD) –negative rate
Overall response rate (ORR)
Complete response rate (Complete Response [CR], and CR with 
incomplete marrow recovery [CRi])
Duration of response (DOR)
Tumor Lysis Syndrome (TLS) risk reduction
Progression free survival (PFS)
Overall survival (OS)
Pharmacokinetics of ibrutinib and venetoclax when dosed in 
combination
Safety and tolerability
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 12Fixed Duration Cohort
Primary Objective :
To evaluate the depth of response with the combination of ibrutinib + 
venetoclax administered for a fixed duration of therapy by assessment 
of complete response (CR/CRi) rate.
Secondary Objectives :
To evaluate:
Duration ofResponse ( DOR )
Minima l Residual Disease ( MRD )-negative rate 
Overall response rate (ORR)
Tumor Lysis Syndrome (TLS) risk reduction
Progression free survival (PFS)
Overall survival (OS)
Safety and tolerability
Study Design: This is a multicenter, 2-cohort Phase 2 study assessing both MRD -
guided discontinuation and fixed duration therapy with the combination 
of ibrutinib + venetoclax in subjects with treatment -naïve CLL or SLL.
The study consists of a nMRD cohort and a Fixed D
uration cohort .
All subjects who discontinue treatment in the absence of disease 
progr ession will remain on study until confirmed disease progression or 
until study closure. All subjects who discontinue for disease progression 
will be followed for survival and subsequent anti -cancer therapies.
Details of the sequentially designed and enrolled MRD and Fixed 
Duration cohorts are below.
1.MRD Cohort :
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 13TheMRD cohort portion of the study consists of a pre -randomization 
phase (combination treatment phase), a n MRD -guided randomization 
phase, and a post -PD follow -up phase. Please see Section 3.1for full 
explanation of study design.
Investigator a ssessment of disease overall response and progression will 
be based upon IWCLL criteria ( Hallek 2008 , Hallek 2012 , 
Hallek 2013). Imaging will be collected and stored centrally.
The primary analysis will be performed at the point that all randomized 
subjects have had the opportunity to complete approximately 12 cycles 
of randomized treatment or follow -up. All safety and efficacy endpoints 
will be analyzed at the time of the primary an alysis. After the primary 
analysis , the Sponsor may elect to discontinue follow -up of specific 
MRD cohort treatment arms on PCYC -1142- CA. Subjects who are on 
ibrutinib at thetime of study arm closure may be offered a separate 
extension study to continue i brutinib.
Pre-randomization Phase
Approximately 150 subjects will be enrolled into this phase. The 
subjects will receive single -agent ibrutinib for 3 cycles followed by 
ibrutinib + venetoclax combination treatment for at least 12 cycles.
The safety of ibru tinib + venetoclax combination therapy will be 
assessed by a Data Review Committee (DRC). Approximately 
12subjects will be enrolled in a Safety Run -inPeriod to assess 
tolerability in the first 6 evaluable subjects who complete venetoclax 
dose escalation (3 cycles of ibrutinib treatment followed by the addition 
of venetoclax administered by standard 5 -week dose ramp -up, plus an 
additional week of follow up). Enrollment will be held until the safety 
and tolerability of the combination therapy is confirmed b y the DRC.
Subjects will be assessed for MRD status in peripheral blood (PB) every 
3cycles starting after completion of 6cycles ( C7D1
), and in bone 
marrow (BM) aspirate after c ompletion of Cycle 15 (C16D1). MRD 
assessment will be performed using flow cytometry with a sensitivity of 
≥10-4. An early assessment of the MRD -negative response rate for the 
combination therapy will be assessed among the first 30 subjects who 
complete 9 cycles of combination treatment. The sample size may be 
adjusted accordingly based on this early assessment to adequately 
power for the Randomization Phase primary endpoint.
MRD -negative response for randomization purposes must be confirmed 
serially over at least 3 cycles and is required to demonstrate negativity 
in both the bone m arrow and peripheral blood.
Randomization Phase
Eligible subjects will be randomized in a 1:1 ratio based on their MRD 
status (see below). Subjects will be stratified by immunoglobulin 
heavy-chain variable region (IGHV) status in each randomization strata.
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 14Randomization Phase -MRD -negative subjects (Double -blind):
Eligible subjects who achieve a confirmed MRD -negative response and 
who continue on ibrutinib will be randomized to receive blinded 
treatment of ibrutinib (venetoclax discontinued) vs placebo (ibrutinib
and venetoclax discontinued). The randomization will be stratified by 
IGHV status. Subjects will be assessed for disease -free survival as 
measured by continued MRD -negative response without progression or 
death at least 1year after randomization. MRD status will be evaluated 
every 3 cycles in PB. MRD should also be reassessed in BM aspirate 
after an additional 12 cycles. 
Randomization Phase -MRD -positive subjects (Open -label):
Those subjects who do not achieve a confi rmed MRD -negative 
response after 12 cycles of the combination and continue on treatment 
will be randomized to receive open label treatment of ibrutinib + 
venetoclax vs ibrutinib alone (venetoclax discontinued). The 
randomization will be stratified by IGHV status . Subjects will be 
assessed for MRD -negative response. MRD status will be evaluated 
every 3 cycles in PB. MRD should also be reassessed in BM aspirate 
after an additional 12 cycles and at any time in subjects who become 
MRD -negative in PB. For subjec ts receiving ibrutinib + venetoclax, 
venetoclax can be administered for up to approximately 2 years per 
treatment course ,until PDor unacceptable toxicity, or until this arm ’s 
study closure , whichever is earlier .Subjects who are continuing on 
ibrutinib at the time of study armclosure may be offered a separate 
extension study to continue ibrutinib. 
Reintroduction of therapy :
MRD -negative randomized subjects who experience confirmed 
MRD --positive relapse and/or confirmed disease progression may have 
their randomization unblinded, and mayreceive reintroduced therapy as 
follows: 
Placebo subjects : Subjects on the placebo arm will be offered the 
opportunity to reintroduce ibrutinib to assess if they can benefit from 
single -agent ibrutinib under the following circumstances:
For confirmed MRD -positive relapse and/or for disease 
progr ession by International Wor kshop on Chronic Lymphocytic 
Leukemia (IWCLL) criteria, subjects will receive ibrutinib until 
PD or unacceptable toxicity. Ibrutinib reintroduced subjec ts who 
subsequently have confirmed disease progression by IWCLL 
criteria may continue ibrutinib and add venetoclax per standard 
dose ramp up
Ibrutinib subjects : Subjects on the ibrutinib arm will be offered the 
opportunity to continue ibrutinib and reintro duce venetoclax treatment 
under the following circumstances:
For confirmed MRD -positive relapse and/or for confirmed 
disease progression by IWCLL criteria, subjects can continue 
ibrutinib and add venetoclax, per standard dose ramp up
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 15MRD -positive randomize d subjects can receive reintroduced therapy as 
follows: 
Ibrutinib only subjects : Subjects on the ibrutinib arm will be offered the 
opportunity to continue ibrutinib and reintroduce venetoclax treatment 
per standard dose ramp up under the following circums tances:
For confirmed disease progression by IWCLL criteria, subjects 
will receive ibrutinib and venetoclax
For MRD -negative and MRD -positive subjects who have reintroduced 
venetoclax , venetoclax can be administered for up to 2 years per 
treatment course , until PDor unacceptable toxicity, or until these arms ’
study closure , whichever is earlier .Subjects who are continuing on 
ibrutinib at time of study armclosure may be offered a separate 
extension study to continue ibrutinib.
Post- PD Follow -up Phase:
Subjects who have confirmed disease progression by IWCLL criteria 
and have discontinued study treatment will be followed for survival 
status and subsequent anti -cancer therapy until study closure. 
2. Fixed Duration Cohort
Approximately 125subjects without del17p will be enrolled into this 
cohort sequentially after the MRD cohort. Subjects will receive 
15cycles of open label therapy consisting of single -agent ibrutinib for 
3cycles followed by ibrutinib + venetoclax combination treatment for 
12cycles. 
Investigator a ssessment of tumor response and progression will be 
based upon IWCLL criteria ( Hallek 2008 , Hallek 2012 , Hallek 2013 ).
Imaging will be collected and stored centrally .
Subjects will be assessed for MRD status in peripheral blood (PB) every 
3cycles starting after completion of 6 cycles (C7D1), and in bone 
marrow (BM) aspirate after completion of 9 c ycles(C10D1) and 
3months after completion of the fixed duration of therapy (ie, C19) or 
earlier if BM is obtained perclinical indication . MRD assessments will 
be performed using flow cytometry with a sensitivity of ≥10-4. The 
primary analysis will be performed when a clinically meaningful 
evaluation of durable CR rate (12 months or longer) can be assessed in 
the study population . FD Cohort subjects will be followed for 
approximately  10 years. Subjects who are continuing on ibrutinib at FD 
cohort study closure may be offered a separate extension stu dy to 
continue ibrutinib.
Reintroduction of therapy :
Subjects with confirmed progression by IWCLL criteria after 
completion of the fixed duration regimen can be retreated with 
continuous single agent ibrutinib ,or retreatment with the ibrutinib + 
venetoclax fixed duration treatment regimen may be considered based 
on Investigator’s clinical discretion and Medical Monitor approval .
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 16Post- PD Follow -up Phase :
Subjects will be followed for progression, overall survival (OS) , and 
use of subsequent antican cer agents until study closure.
Population: Subjects who have treatment -naive CLL or SLL with active disease 
requiring therapy
Centers: Multiple, US vs. ex -US 
Inclusion Criteria:
Refer to Section 4for the 
complete and detailed list of 
inclusion/exclusion criteria.Disease Related
1.Diagnosis of CLL/SLL that meets IWCLL diagnostic criteria 
(Hallek 2008).
2.Activedisease meeting at least 1 of the following IWCLL criteria 
(Hallek 2008 ) for requiring treatment:
Evidence of progressive marrow failure as manifested by the 
development of, or worsening of, anemia and/or 
thrombocytopenia
Massive, progressive, or symptomatic splenomegaly
Massive nodes or progressive or symptomatic 
lymphadenopathy
Progressive lymphocytosis
Constitutional symptoms
3.Measurable nodal disease by computed tomography (CT).
Laboratory
4.Adequate hematologic function independent of transfusion and 
growth factor support for at least 7 days, (with the exception of 
pegylated G -CSF [pegfilgrastim ]and darbopoeitin which require at 
least 14 days )prior to screening laboratory assessment defined as: 
Absolute neutrophil count (ANC) >750/µL (750 cells/mm3or 
0.75 x 109/L)  
Platelet count >30,000 /µL (30,000 cells/mm3or 30 x109/L). 
Hemoglobin >8.0 g/dL
5.Adequate hepatic and renal function defined as:
Serum aspartate transaminase (AST) or alanine transaminase 
(ALT) ≤3.0 xupper limit of normal (ULN)
Creatinine Clearance (CrCl) ≥60 mL/min 
(eg,as estimated by Cockcroft -Gault)
Bilirubin ≤1.5 x ULN (unless bilirubin rise is due to Gilbert’s 
syndrome or of non -hepatic origin)
6.Prothrombin time (PT)/In ternational normal ratio (INR) 
<1.5 xULN and PTT (activated partial thromboplastin time 
[aPTT]) <1.5 x ULN (unless abnormalities are unrelated to 
coagulopathy or bleeding disorder). 
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 17Demographic
7.Men and women ≥18 and ≤70 year of age.
8.Eastern Cooperative Oncology Group (ECOG) performance status 
of 0-2.
Ethical/ Other
9.Fema le subjects who are of non -reproductive potential ( ie, post -
menopausal by history no menses for ≥1 year; OR history of 
hysterectomy; OR history of bilateral tubal ligation; OR history of 
bilateral oophorectomy). Female subjects of childbearing potential 
must have a negative serum pregnancy test upon study entry.
10.Male and female subjects of reproductive potential who agree to use 
both a highly effective method of birth control ( eg, implants, 
injectables, combined oral contraceptives, some intrauterine devices 
[IUDs], complete abstinence1, or sterilized partner) and a barrier 
method ( eg, condoms, cervical ring, sponge, etc.) during the period 
of therapy and for 90 days after the last dose of st udy drug. Male 
subjects must agree to refrain from sperm donation until 90 days 
after the last dose of study drug.
Exclusion Criteria: 1.Any prior therapy (including but not limited to chemotherapy, 
targeted therapy, immunomodulating therapy, radiotherapy, and/or 
monoclonal antibody) used for treatment of CLL or SLL.
2.History of othermalignancies, except: 
Malignancy treated with curative intent and with no known 
active disease present for ≥3 years before the first dose of study 
drug and felt to be at low risk for recurrence by the treating 
physician
Adequately treated non -mela noma skin cancer or lentigo 
maligna without current evidence of disease
Adequately treated carcinoma in situ without current evidence 
of disease 
3.Known or suspected history of Richter’s transformation.
4.Concurrent administration of >20 mg/day of prednisone within 
7days of initiation of study drug unless indicated for prophylaxis ,
or management of allergic reactions ( eg, contrast) .
5.Known hypersensitivity to one or more study drugs.
6.Known allergy to xanthine oxidase inhibitors and/or rasburicase .
Subjects who are allergic to xanthine oxidase inhibitors and cannot 
receive ra sburicas e will be excluded .
7.Vaccinated with live, attenuated vaccines within 4 weeks of first 
dose of study drug.
                                               
1Complete abstinence is a highly effective method only if defined as refraining from heterosexual intercourse 
during the entire period of risk associated with the study treatments. The reliability of sexual abstinence needs to be 
evaluated in relation to th e duration of the clinical trial and the preferred and usual lifestyle of the subject. 
http://www hma.eu/fileadmin/dateien/Human_Medicines/01 
About_HMA/Working_Groups/CTFG/2014_09_HMA_CTFG_Contraception.pdf
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 188.Recent infection requiring systemic treatment that is ongoing or 
was completed ≤14days before the first dose of study drug, or any 
uncontrolled activ e systemic infection.
9.Known bleeding disorders ( eg, von Willebrand’s disease or 
hemophilia).
10.History of stroke or intracranial hemorrhage within 6 months prior 
to enr ollment.
11.Known history of human immunodeficiency virus (HIV) or active 
infection with hepa titis C virus (HCV) or hepatitis B virus (HBV). 
Subjects who are positive for hepatitis B core antibody, hepatitis B 
surface antigen (HBs Ag), or hepatitis C antibody must have a 
negative polymerase chain reaction (PCR) result before enrollment.  
Those who are PCR positive will be excluded.
12.Major surgery within 4 weeks of first dose of study drug.
13.Any life -threatening illness, medical condition, or organ system 
dysfunction that, in the investigator’s opinion, could compromise 
the subject’s safety or put the study outcomes at undue risk.
14.Currently active, clinically significant cardiovascular disease, such 
as uncontrolled arrhythmia or Class 3 or 4 congestive heart failure 
as defined by the New York Heart Association Functional 
Classification; or a history of myocardial infarction, unstable 
angina, or acute coronary syndrome within 6 months prior to 
enrollment.
15.Unable to swallow capsules/tablets or malabsorption syndrome, 
disease significantly affecting gastrointestinal function, or resection 
of the stomach or small bowel, symptomatic inflammatory bowel 
disease or ulcerative colitis, or partial or complete bowel 
obstruction.
16.Concomitant use of warfarin or other vitamin K antag onists.
17.Requir es treatment with a strong cytochrome P450 (CYP) 3A 
inhibitor (see Appendix G).
18.Currently active, clinically significant hepatic impairment Child -
Pugh Class B or C according to the Child Pugh classification 
(see Appendix K).
19.Lactating or pregnant.
20.Unwilling or unable to participate in all required study evaluations 
and procedures.
21.Unable to understand the purpose and risks of the study and to 
provide a signed and dated informed consent form (ICF) and 
authorization to use protected health information (in accordance 
with national and local subject privacy regulations).
22.Uncontrolled autoimmune hemolytic anemia or idiopathic 
thrombocytopenia purpura, such as those subjects with a dec lining 
hemoglobin level or platelet count secondary to autoimmune 
destruction within the 4 weeks prior to first dose of study drug, or 
the need for daily prednisone >20 mg daily (or corticosteroid 
equivalent) to treat or control the autoimmune disease.
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 20OR
Placebo
 Orally once daily matching placebo capsules (3 capsules)
continuously until confirmed MRD -positive relapse, disease 
progr ession or unacceptable toxicity
Randomization Phase –MRD- positive subjects :
Ibrutinib + venetoclax
Orally once daily ibrutinib 420 mg (3 capsules) continuously until 
disease progression or unacceptable toxicity
plus
Orally once daily venetoclax 400 mg daily (four 100 mg tablets)
OR
Ibrutinib
Orally once dail y ibrutinib 420 mg (3 capsules) continuously until 
disease progression (post reintroduction when applicable ) or 
unacceptable toxicity
Reintroduction of ibrutinib or venetoclax:
Upon confirmed MRD -positive relapse in MRD -negative randomized 
subjects or confirmed disease progression by IWCLL criteria in any 
randomized subjects, ibrutinib and/or venetoclax may be reintroduced.
Subjects who are receiving placebo treatment, when MRD -positive 
relapse or disease progression are confirmed, may reintroduce oral daily 
ibrutinib until disease progression or unacceptable toxicity.
Subjects who are receiving oral daily ibrutinib may reintroduce oral 
daily venetoclax. Standard TLS risk assessment, venetoclax dose ramp 
up, and TLS management should be employed at venetoclax 
reintroduction ( VENCLEXTA®(venetoclax )prescribing information ).
2) Fixed Duration Cohort
Ibrutinib:
 Orally once daily ibrutinib 420 mg (3 capsules)
 Single -agent lead -in for 3 -cycles, then continued in combination 
for 12additional cycles until completion of Cycle 15
 Dose modification for adverse events are specified in 
Section 5.4.1.4
Venetoclax:
 Orally once daily venetoclax, with 5 -week dose ramp up 
(VENCLEXTA®(venetoclax )prescribing information ),to 400 mg 
daily, added to ongoing ibrutinib therapy starting at Cycle 4 and 
continuously for 12cycles until completion of Cycle 15
 Venetoclax and ibrutinib should be dosed t ogether at the same time 
each day with a meal and water
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 21 Dose modification for adverse events are specified in 
Section 5.4.2.5
NOTE: If dictated by emer ging data from this study, the duration of
combined ibrutinib + v enetoclax treatment may be modified to ensure 
appropria te risk -benefit is maintained , com pared to historical controls 
and other emerging data.
Subjects with confirmed progression by IWCLL criteria after 
completion of the fixed duration regimen can be retreated with 
continuous single agent ibrutinib ,or retreatment with the ibrutinib + 
venetoclax fixed duration treatment regimen may be considered based 
on Investigator ’sclinical discretion and M edical Monitor’s approval.
Concomitant Therapy: Refer to Section 6 for information on concomitant therapy.
Safety Plan: The safety of this study will be monitored in accordance with the 
Sponsor’s Pharmacovigilance Committee procedures. A Data Review 
Committee (DRC) will be organized to assess safety, tolerability, and 
make a recommendation regarding dosing after the Safety Run -in 
Period.
Safety Run -in Period:
Approximately 12 subjects will be enrolled in a Safety Run -in Period, 
defined as the date of first dose of ibrutinib at Cycle 1 Day 1 through 
the DLT evaluation period. The DLT evaluation period is defined as the 
5-week venetoclax dose ramp -up in combination with ibrutinib plus an
additional week of follow up. Enrollment will be held until safety is 
assessed by the DRC in the first 6 evaluable subjects who complete the 
Safety Run -in Period. Subjects’ laboratory results and A Es will be 
reviewed by the DRC. If ≤1 of the first evaluable 6 subjects experience 
aDLT, the study will continue. If 2 of the first 6 evaluable subjects 
experience a DLT, then the DRC will evaluate safety in the next 
3evaluable subjects. If 3 or more of the 9 subjects experience DLTs, 
the DRC may recommend the dose of the study drug(s) to be de -
escalated as per Table 1inSection 5.2.1 .The study will be deemed safe 
toproceed when 6 –9 subjects complete the Safety Run -in Period 
(DLT observation period) and if <33% ( ≤1 of 6, or ≤2 of 9) of subjects 
experience a DLT.
Any case of clinical TLS during the Safety Run -in Period will trigger a 
DRC review of that subject. Enroll ment will be staggered to no more 
than 3 subjects per week during the Safety Run -in Period in order to 
minimize patient exposure and risk duri ng this initial run -in period. A 
follow -up DRC review will occur after all subjects in the Safety Run -in 
Period ha ve either discontinued therapy and/or have completed the DLT 
evaluation period (venetoclax dose ramp -up plus 1
-week follow -up), 
then DRC may make a recommendation regarding dosing.
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 22General Safety Plan:
All subjects will be assessed for TLS risk at baseline and prior to 
commencement of venetoclax dosing using the previously described 
approach based on tumor burden ( Seymour 2014), consistent with the
VENCLEXTA® (venetoclax )prescribing information ,and noted in 
Section 5.4.2.2 . See Section 7.1.1.9 and Section 7.1.1.10 for TLS risk 
assessment and prophylaxis respectively.
Adverse events (AEs) and serious adverse events (SAEs) will be 
reviewed by the Sponsor on an ongoing basis to identify safety 
concerns. The safety will be monitored in accordance with the 
Sponsor’s routine Pharmacovigilance Committee procedures .
Statistical Methods and 
Data Analysis:1) MRD Cohort
Descriptive statistics and subject listings will be used to summarize the 
data. For continuous variables thenumber of observations, means, 
standard deviations, medians, and ranges will be reported . Fordiscr ete 
variables, frequencies and percentages will be summarized. For time -to-
event variables, Kaplan -Meier estimates will be provided. No 
infer ential tests will be performed for pre -randomization phase. The 
primary endp oint, 1-year disease -free rate in MRD -negative 
randomized subjects ,will be tested between placebo and ibrutinib arms 
at a 2 -sided alpha level of 0.05. Safety endpoints will be summarized 
descriptively based on subjects who received at least one dose of 
treatment.
2) Fixed Duration Cohort
Efficacy analyses will be based on the all -treated population without 
del17p . The 95% confidence interval will be estimated for complete 
response rate and MRD -negative response rate. D uration of response , 
PFS,and OS will be summarized using the Kaplan -Meier method. 
Summaries based on all -treated population will also be presented. 
Safety endpoints will be summarized descriptively based on subjects 
who received at least one dose of treatment.
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 23Sample Size 
Determination1) MRD Cohort
The study cohort will be powered based on the Randomization Phase 
primary endpoint of 1- year disease -free rate in MRD -negative 
randomized su bjects (ibrutinib vs placebo). The total sample size will 
be based on both MRD -negative response rate from the 
Pre-randomization Phase and the sample size assumption from the 
Randomization Phase.
Sixty randomized subjects with confirmed MRD -negative status will 
provide approximately 80% power to detect a 30% improvement in the 
1--year disease -free rate, assuming the 1 -year disease -free rate is 60% 
for the control (placebo) arm, at a 2 -sided significance level of 0.05.
Assuming a 40% MRD -negative response rate for the ibrutinib and 
venetoclax combination therapy in the Pre -randomization Phase, 
150subjects will be enrolled in the Pre -randomiza tion Phase in order to 
have 60 subjects achieving a confirmed MRD -negative response and to 
be randomized. The final sample size may be adjusted based on an early 
assessment of the MRD -negative response rate among the first 30 
subjects who complete 9 cycles of treatment in Pre -randomization 
Phase (See Section 3.1.1 ).
2) Fixed Duration Cohort
Assuming the CR rate for ibrutinib + venetoclax is 50%, 125subjects 
without del17p will provide 83 % power to ensure the rate is > 37% at 
1-side alpha 0.025. ACR rate of 50% would represent a significant 
improvement compared to the CR rate seen with the fixed duratio n 
combination of benda mustine + rituximab (31 %) and would 
demonstrate a clinically meaningful improvement over the CR rate seen 
with the most effective standard of care fixed duration regimen 
fludarabine, cyclophosphamide, and rituximab ( 40%) which were 
obtained in the CLL10 study ,which included only patients without 
del17p (Eichhorst 2016
).
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 24ABBREVIATIONS
AE adverse event 
AESI Adverse Events of Special Interest 
ALT alanine aminotransferase 
AML acute myeloid leukemia cells
ANC absolute neutrophil count 
ASCO Amer ican Society of Clinical Oncology
AST aspartate aminotransferase 
AUC area under the concentration -time curve
BCR B-cell receptor
BM bone marrow
BMA bone marrow aspirate
BR bendamustine +rituximab
BTK Bruton’s tyrosine kinase
CI confidence interval
CIT chemoimmunotherapy 
CLL chronic lymphocytic leukemia 
Cmax maximum observed plasma concentration
CR complete response 
CRR complete response rate
CRi Complete response with incomplete bone marrow recovery
CrCl creatinine clearance
CRF case report form (paper or electronic as appropriate for this study)
CT Computed Tomography
CTCAE NCI Common Terminology Criteria for Adverse Events
CTLS clinical tum or lysis syndrome
CYP cytochrome P450
del17p deletion of the short arm of chromosome 17
DFS Disease -free survival
DLBCL diffuse large B -cell lymphomas
DLT dose limiting toxicity
DOR Duration of Response
DRC Data Review Committee 
ECOG Eastern Cooperative Oncology Group
ECG Electrocardiogram
ECHO Echocardiogram
EDC electronic data capture
FCR fludarabine, cyclophosphamide and rituximab 
FD Fixed Duration
FDA Food and Drug Administration
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 25FISH fluorescense in situ hybridization
FL follicular lymphoma
GCP Good Clinical Practice
G-CSF Granulocyte colony stimulating factor
HBsAg hepatitis B surface antigen
HBV hepatitis B virus
HCV hepatitis C virus
HIV huma n immunodeficiency virus
HIPAA Health Insurance Portability and Accountability Act
IAC Interim Analysis Committee
IB Investigator's Brochure
IBR Ibrutinib
IC50 concentration that inhibits a process by 50%
ICF informed consent form
ICH International Conference on Harmonisation
IEC Independent Ethics Committee
IGHV immunoglobulin heavy- chain variable region
ILD interstitial lung disease 
INR International normal ratio
IRB Institutional Review Board
IRC Independent Review Committee
IRT Interactive Response Technology
ITT Intention -to treat
I+V ibrutinib plus venetoclax combination
IV intravenous
IWCLL International Workshop on Chronic Lymphocytic Leukemia
LDH lactate dehydrogenase
LN lymph node
MCL mantle cell lymphoma
MedDRA Medical Dictionary for Regulatory Activities
MRD minima l residual disease
MRI Magnetic Resonance Imaging
MRU medical resource utilization
MTD maximum tolerated dose
MUGA Multigated acquisition scan
nPR nodular partial response 
ORR overall response rate
OS overall survival
PB peripheral blood
PCR polymerase chain reaction
PD progr essive disease or disease progression
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 26PFS progr ession free survival
P-gp P-glycoprotein
PK Pharmacokinetics
PML progr essive multifocal leukoencephalopathy
PO Oral
PR partial response 
PRL PR with lymphocytosis 
aPTT activated partial thromboplastin time
PT prothrombin time 
QD once daily
QTc QT interval corrected for heart rate 
R-CHOP rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone   
REB Research Ethics Board
RS Richter’s syndrome
SAE serious adverse event
SAP statistical analysis plan
SD stable disease
SLL small lymphocytic lymphoma 
t1/2 half-life
Tmax time to maximum plasma concentration 
TEAE treatment -emer gent adverse event
TLS tumor lysis syndrome
ULN upper limit of normal
USPI United States package insert
VEN Venetoclax
WM Waldenström’s macroglobulinemia
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 271. BACKGROUND
1.1. Disease/Histology
1.1.1. Disease Background
Chronic lymphocy tic leukemia (CLL) i s the m ost frequent form  of adul t leukemia in the Western 
world. It i s a commo n and incurable condit ion, characterized by  a dist inct diversit y of clinical 
outcom es ranging from indolent to markedly aggressive ( Chiorazzi 2005 ). Wi th an est imated 
prevalence in the United States of approximately 106,000, it is largely a disease of the elderly . 
The m edian age at di agnosis is approximately sevent y years ( SEER 201 6).
The predominant ly olderand co -morbid popul ation, the incurable nature of the condit ion and the 
diversit y of diseas e vari ants combine to m ake CLL an important area of clinical research with an 
urgent need for innovat ive and novel treatment approaches for many patient sub -types.
Pathol ogically , CLL is defined by  an accumulation of phenoty pically  distinct mature monoclonal 
B cells in the blood, bone marrow, and secondary  lymph organs. Small lymphocy tic lympho ma 
(SLL) i s a condi tion possessing similar characteristics but without lymphocy tosis and is 
essent ially a variant of the same underlying disorder as CLL. Clinically, the two similar 
pathol ogies consti tute one dist inct disease (collect ively referred to as CLL hereafter) 
(Müller-Herm elink 2001).
The clinical course of CLL is extremely  variable, wi th a significant proporti on of  patients 
requi ring no treatment for decades, whilst more urgent intervent ion is indicated in others, 
particularly those with progressive, clinically  symptom atic disease. Bec ause the m ajority of 
patients are asymptom atic at presentation and as there is current ly no consensus on the optimal 
timing for init iation of treatm ent (
Dighiero 1998 ), International Workshop on Chronic 
Lymphocy tic Leukemia (IWCLL ) guidelines have been developed to define the clinical contexts 
in which treatment should be co mmenced ( Hallek 2008 ).
CLL is both pathologically and clinically heterogeneous, result ing in many pat ient subgroups 
who respond mark edly less favorably  to currently available treatm ent strategies, independent of 
age and co morbidity. In parti cular, one feature which has consistent ly been associated with the 
worst overall prognosis is delet ion of the short arm of chromoso me 17 (del17p) a nd/or a 
mutati on of  the TP53 tum or suppressor gene. These abnormalit ies occur in about 7 -10% of CLL 
cases at diagnosis ( Krober 2002) and this patient subgroup is characterized by rapid disease 
progression, poor response to therapy , and a very  limited m edian overall survival of less than 
three years ( Dohner 2000). In addit ion to del 17p/TP53, immunoglobulin heavy -chain vari able 
(IGHV) gene somat ic hypermutation status (IGHV- MS) is an important prognostic facto r. 
Unmutated IGHV, whi choccurs in about 40 -50% of CLL patients, is predict ive for time to first 
treatm ent(Wierda 2011) and is associated with a worse survival (Bulian 2012, Pflug 2014) .
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 281.1.2. Current Treatment Options in Previously Untreated CLL
The results of clinical studies in previously untreated CLL have demo nstrated major advances in 
therapy  over the l ast decade. The m ost active regimen described thus far, on the basis of a 
single- center experience at the MD Anderson Cancer Center ( Keating 2005 ) and subsequent 
rando mized CLL8 trial ( Hallek 2010 ), is the chemoimmunotherapeutic (CIT) combination o f 
fludarabine, cy clophosphamide, and ri tuximab (FCR). FCR resulted in significant improvement 
in PFS and OS compared with fludarabine and cyclophosphamide alo ne, wi th a hazard rati o for 
progression of 0.51 (95% CI: 0.39, 0.67) for patients les s than 70 years of age (N = 736) 
(Hallek 2010, Casak 2011). Al though numerous subsequent attempts have been made to improve 
on FCR eg, through the addit ion of mitoxantrone, alemtuzumab or granulocy te 
macrophage 
colony-stimulat ing factor ( Parikh 2011 , Bosch 2009 , Reynolds 2012 ),increasing the dose of 
rituximab (FCR3) ( O'Brien 2005 ), subs tituting cladribine or pentostatin for fludarabine 
(Wierda 2012, Bryan 2011), or combining rituximab wit h bendamust ine (Fischer 2012) so far 
FCR remains the m ost act ive regimen and regarded as a standard of ca re for young fit first line 
patients (Hillmen 2010 )
.
Despite the improved efficacy o f CIT, only  40-45% of  patients treated wi th these approaches 
currently achieve a complet e response (CR) and many pat ients (including those achieving CR) 
eventually relapse ( Hallek 2010, Tam 2008, Kay 2007 , Fischer 2016 ). In some pa tients, CIT has 
resul ted in attainment of undetectable minimal residual disease (MRD), defined as detecti on of  
<1 CLL cell in 10,000 normal leukocy tes by  either polymerase chain react ion assay  or 4 col or 
flow cy tometry. These MRD -negative remissions are associ ated wi th longer PFS and OS
(Bottcher 2012 , Strati 2014 ), however ,only 43-49% of  patients who are evaluated for MRD 
(27-43% of ITT patients) are able to achieve MRD -negat ive remissio ns(Bottcher 2012 , 
Strati 2014) . Addit ionally, MRD -negat ive remissio ns are achieved in a lower percent of 
unmutated vsmutated IGHV patients post CIT (33% vs 50.7% respectively of those evaluated)
(Thom pson 2016). Although some patients derive significant benefit fro m CIT ,fludarabine 
based CIT regimens resul t in substant ial toxicity including profound immunosuppressio n, 
prolonged cy topenias (which can restrict salvage th erapy opti ons at the time of recurrence), and a 
5-10% risk of therapy -related myelodysplasia (MDS) ( Tam 2008 , Keat ing2005, Ferrajo li2005 ). 
These toxi cities are probl emat ic since most CLL patients are >age 50 at diagnosis and many 
patients have co morbidities that limit their abilit y to receive CIT ( Hallek 2013). Even amo ng 
younger fi t CLL pati ents, >25% are unable to tolerate FCR -based CIT
.Phase 3 trial indicate that 
56% of patients experience Grade 3 -4 myelosuppressio n, 25% infect ious com plicat ion, 47% 
requi re dose reductions, and >25% of pat ients are unable to complete the intended 6 cy cles o f 
FCR induct ion even with dose reducti ons ( Hallek). While FCR has been a major advance in the 
CLL treatm ent, i t is associ ated wi th significant toxici ty that limi ts the benefit of this approach for 
many pat ients.
Recent ly, in the RESONATE -2 randomized trial, single -agent ibrut inib (administered daily unt il 
progression or unacceptable toxicit y) dem onstrated superi orPFS and OS compared to 
chlorambucil in previously  untreated CLL pati ents ( Burger 2015). At 18.4 months of fo llow up, 
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 29ibrutinib significant ly reduced the risk of progression or death by  84% com pared to chl orambucil  
(median PFS not reached vs. 18.9 months respect ively; hazard ratio, 0.16; P<0.001). Notably, the 
18-month PFS was 89% in both unmutated and mutated IGHV subgroups treated with ibrutinib , 
compared to 4 7% and 51% in the serespect ive subgroups treated with chlorambucil. 
Addit ionally , ibrutinib reduced the relative ri sk of death by  84% (hazard rati o, 0.16; P = 0.001). 
The overall response rate was higher with ibrutinib compared with chlorambucil (86% vs. 3 5%, 
P<0.001), and the rates of sustained increases fro m baseline values in the hemoglo bin and 
platelet levels were higher with ibrut inib. Adverse events of any grade that occurred in at least 
20% of the patients receiving ibrut inib included diarrhea, fatig ue, cough, and naus ea, and were 
mainly  Grade 1 -2. At 18.4 months of fo llow
-up, 87% of the patients in the ibrutinib group 
continued on therapy  (Burger 2015). Ibrutinib was appro ved by USFDA in March 2016 based 
on these data for the first line treatment of CLL.
Although ibrut inib has resulted in an improvement in PFS and OS in treatment -naïve patients 
(Burger 2015 ), and previously treated patients ( Byrd
2014), single- agent ibrut inib has rarely  
demonstrated the abilit y to induce undetectabl e MRD by  PCR or 4 col or flow cy tometry  with a 
sensit ivity of <1x10-
4. The addit ion of ibrut inib to bendamustine +rituximab (BR) resulted in a 
higher MRD -negat ive CR/CRi rate in previously treated CLL patients compared to placebo +BR 
(4.2% vs 1.5% by IRC; 9.3% vs 2.4% by  invest igator assessment) ( Chanan -Khan 2016). T he 
MRD -negat ive rate reached a plateau 9 months after com pletion ofplacebo +BR, however 
increased overtime with cont inued ibrut inib therapy (Fraser 2016
).
Phase 1 data of single -agent venetocl ax in relapsed CLL or SLL patients (n=56 in the dose 
escalat ion cohort and n=60 in the expansio n cohort) demonstrated reductio n of CLL burden in 
the blood, lymph nodes and bone marrow, with a po oled overall response rate (ORR) of 79% 
including 2 0% CR/CRi ( Roberts 201 5).The response rate did not differ by risk factors, including 
deletion 17p CLL, resist ance to fludarabine, unmutated IGHV, or bulky  disease. Im portantly , 
35% (6/17) of those patients who achieved CR and were evaluated for MRD in bone marrow 
became MRD -negat ive. In the dose -escalat ion cohort, tumor lysis syndro me (TLS) occurred in 
10 of 56 p
atients (18%), including clinical TLS in 3 patients and laboratory TLS in 7 patients. In 
the expansio n cohort, pati ents received an extended step -wise dose ramp -up schedule with TLS 
prophylaxis and hospi talizat ionaccording to their level of TLS risk , resul ting in no cases of 
clinical TLS and reduced laboratory  TLS . Adverse event of any grade that occurred in at least 
20% of patients included diarrhea, upper respiratory  tract infecti on, nausea, neutropenia, fat igue, 
cough, py rexia, anemia, headache, c onstipation,and thrombocy topeni a. Phase 2 data of single -
agent venetoclax in ultra high -risk rel apsed/refractory  del17p CLL (N=107) dem onstrated a 79% 
ORR including 7.5% CR /CRi (Stilgenbauer 2015 ). No detectable MRD was obs erved in 
peripheral  blood in 21% of responders with MRD assessments (17% of whole cohort).
Venetoclax received accelerated approv alfromUS FDA in April 2016 based on this data for 
patients wi th CLL wi th 17p del etion who have received at least one pri or th erapy .Venetoclax 
received condit ional approval fromthe European Commissio ns in December 2016 for the 
treatm ent of patients with CLL in the presence o f 17p del etion orTP53 mutationin adult patient 
who are unsuitable or have failed a B -cellreceptor pathway  inhibi tor,as well as for the treatment 
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 30of CLL in the absence of 17p deletion or TP53 mutation in adult patients who have failed both 
chemo -immunother apy and a B -cell receptor p athway inhibitor. Venetoclax, both as a single
agent and in combinat ion with other therapeuti c agents, conti nues to show promising efficacy in
oncol ogy subject popul ations. The ORR in subjects with CLL/SLL was 74% (IRC -assessed) and 
74% (invest igator -assessed) for single -agent venetoclax (Study  M12- 175 and Study  M13- 982, 
respective ly), ranged from  67% to 57% for subjects with ibrut inib-or idelalisib-resistant CLL in
Study  M14- 032, and was 86% for venetoclax administered in combinat ion with rituximab 
(Study M13 -365).
1.2. Ibrutinib Overview
Ibrutinib (I MBRUVICA®) is a fi rst-in-class, potent, orally  administered, coval ently binding 
inhibitor of Bruton’s ty rosine kinase (BTK) co -developed by Pharmacyclics LLC and Janssen 
Research & Development LLC for the treatment of patients wi th B-cell malignancies.  
Ibrutinib has been approved in many regio ns, including the (United States) US and (European 
Unio n)EU, for i ndicati ons including treatm ent of pati ents wi th mantle cell lymphoma (MCL) 
who have received at least 1 prior therapy , pati ents wi th chronic lymphocy tic leuke mia ( CLL)
/small lymphocy tic lympho ma(SLL) including CLL/ SLL with a del etion of the short arm of 
chromosome 17 (del 17p), pati ents wi th Waldenstr öm’s macroglobulinemia (WM), pati ents wi th 
marginal zone lympho ma (MZL) who require systemic therapy and have r eceived at l east one 
prior anti -CD20 -based therapy , and for pati ents with chronic graft versus host disease (cGVHD) 
after failure of one or more lines of systemic therapy . 
For the most up to date and comprehensive nonclinical and clinical informat ion rega rding 
ibrutinib background, safet y, efficacy , in vi tro and in vivo preclinical activit y and toxico logy of 
ibrutinib, always refer to the l atest versi on of  theibrutinib Invest igator's Brochure (IB)and/or the 
applicable regional labeling informat ion.
1.2.1. Summary of Nonclinical Data
1.2.1.1. Pharmacology 
Ibrutinib was designed as a selective and covalent inhibitor of the BTK (Pan 2007 ).In vitro, 
ibrutinib is a potent inhibitor of B TKactivity (IC 50= 0.39 nM). The irreversible binding o f 
ibrutinib to cysteine -481 in the active site of B TKresul ts in sustained inhibit ion of BTKcataly tic 
activit y and enhanced select ivity over other kinases that do not contain a cysteine at this position. 
When added directly to h uman whol e blood, ibrut inib inhibits signal transduct ion from the BCR
and blocks primary B -cell activation (IC 50= 80 nM) as assayed by ant i-IgM st imulation fo llowed 
by CD69 expressio n (Herm an 2011 ).
For m ore detailed and compreh ensive informat ion regarding nonclinical pharmaco logy and 
toxicology, please refer to the current ibrutinib IB.
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 311.2.1.2. Safety Pharmacology and Toxicology
No treatment -related effects were observed in the central nervous system or respi ratory  system  in 
rats at any  dose tested. Further, no treatment- related corrected QT interval (QTc) prolongation 
effect was observed at any  tested dose in a cardiovascular study  using tel emetry -monitored dogs.
Based on data from rat and dog including general  toxicity studi es up to 13 weeks duration, the 
greatest potential for human toxicit y with ibrutinib is predicted to be in lympho id tissues 
(lympho id deplet ion) and the gastrointest inal tract (soft feces/diarrhea wit h or without 
inflammat ion). Addit ional toxicity findings seen in only one species with no observed human 
correl ate in clinical studies to date include pancreatic acinar cell atrophy  (rat), minimally 
decreased trabecular and cortical bone (rat) and corneal dystrophy  (dog). In studies in pregnant 
rats and rabbits ,ibrut inib administration was associated with malformat ions (teratogenicit y) at 
ibrutinib dose s that resul t in approximately 14-and 2 -times the exposure ( area under the 
concentration -time curve [ AUC ]) in pat ients administered the do se of 560 mg daily, respect ively. 
Fetal  loss and reduced fetal body  weights were al so seen in treated pregnant animals.
Carcinogenicit y studi es have not been conducted with ibrut inib. In vitro and in vivo genet ic 
toxicity studies showed that ibrut inib is not genotoxic. No effects on fertilit y or reproductive 
capacit ies were observed in a study  in male and female rats.
For the most comprehensive information regarding nonclinical safety pharmaco logy and 
toxicology, please refer to the current ibrutinib IB.
1.2.2. Summary of Clinical Data
For the most comprehensive clinical informat ion regarding ibrut inib, please refer to the current 
versio n of the ibrut inib IB. 
1.2.2.1. Pharmacokinetics and Product Metabolism
Following oral  administrati on of  ibrutinib at doses ranging from 420 to 840 mg/day, exposure to 
ibrutinib increased proporti onally  to doses increased with substant ial intersubject vari abilit y.The 
mean half -life (t 1/2) of ibrutinib ranged fro m 4 to 13 hours, with a median time to maximum 
plasma concentration (T max) of 2 hours. Taking into account the approximate doubling in mean 
systemic exposure when dosed with food and the favorable safet y profile, ibrutinib can be dosed 
with or wi thout food. Ibruti nib is extensively metabo lized primarily by cytochrome 
P450 (CYP )3A4. The on -target effects of metabolite PCI -45227 are not considered clinically 
relevant. Steady -state exposure of ibrutinib and PCI -45227 was less than 2- fold of first dose 
exposure. Less than 1 % of ibrut inib is excreted renally . Ibrutinib exposure is not altered in 
patients wi th creatinine clearance (C rCl) >30 mL/min. Patients with severe renal impairment or 
patients on dialysis have not been studied. Following single dose administration, the AU C of 
ibrutinib increased 2.7 -, 8.2-and 9.8- fold in subjects with mild (Child -Pugh Class A), moderate 
(Child -Pugh Class B), and severe (Child- Pugh Class C) hepat ic impairment compared to subjects 
with norm al liver funct ion. A higher proportion of Grade 3 o r higher adverse react ions were 
reported in patients with B -cell malignancies (CLL, MCL and WM) with mild hepat ic 
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 32impairment based on NCI organ dy sfunct ion working group (NCI -ODWG) criteria for hepat ic 
dysfunct ion compared to patients with normal hepatic f unction.
For the most comprehensive information regarding pharmacokinetics (PK) and product 
metabo lism, please refer to the current versio n of the ibrut inibIB.
1.2.3. Summary of Clinical Safety
A brief summary  of safet y data from  monotherapy  and combinat ion therapy  studi es is provi ded 
below. For the most up to date and most comprehensive safety  informat ionregarding ibrut inib,
please refer to the current ibrut inib IB. Addi tional safety informat ion may be available for
approved indications in regional prescribing labels where the study  is conducted ( eg, USPI, 
SmPC).
1.2.3.1. Monotherapy Studies
Pooled safet y data f roma total  of 1318 subjects treated with ibrutinib mo notherapy  in 13 studi es 
that have completed primary  analysis or final analysis as of the 31 May  2016 cutoff date for the 
current IB update in B-cell malignancies are summarized below.
The m ost frequently reported treatment -emergent adverse events (TEAEs) in subjects receiving 
ibrutinib as mo notherapy (N=1 318):
1.2.3.2. Combination Studies
Pooled safet y data for a total of 423 subjects treated with various therapies in co mbinat ion with 
ibrutinib fro m 4 studi esconducted in B -cellmalignancies are briefly summarized below. Most Frequently Reported 
TEAEs ≥15%a  Most Frequently Reported 
Grade 3 or 4 TEAEs ≥3%bMost Frequently Reported 
Serious TEAEs ≥2%c
Diarrhea Neutropenia Pneumonia
Fatigue Pneumonia Atrial fibrillation
Nausea Thrombocytopenia Febrile neutropenia
Cough Anemia Pyrexia
Pyrexia Hypertension
Anemia Diarrhea
Neutropenia Atrial fibrillation
Upper respiratory tract infection
Thrombocytopenia
Oedema peripheral
a. Source is Table 6 of IB (v10), bSource is Table 8 of IB (v10), cSource is Table 9 of IB (v10).
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 33Therapies used in co mbinat ion with ibrutinib in these studies, included BR (bendamust ine and 
rituximab ), FCR (fludarabine, cyclophosphamide, and rituximab) , ofatum umab, and R-CHOP 
(rituximab, cy clophosphamide, doxorubicin, vincristine, and prednisone) . 
The m ost frequently reported TEAEs in subjects receiving ibrut inib in co mbinat ion therapy  
(N=423):
Most Frequently Reported 
TEAEs ≥20%aMost Frequently Reported 
Grade 3 or 4 TEAEs ≥3%bMost Frequently Reported 
Serious TEAEs ≥2%c
Neutropenia Neutropenia Pneumonia
Diarrhea Thrombocytopenia Febrile neutropenia
Nausea Febrile neutropenia Atrial fibrillation
Thrombocytopenia Pneumonia Pyrexia
Fatigue Neutrophil count decreased Cellulitis
Anemia Anemia
Pyrexia Fatigue
Hypertension
Diarrhea
a.Source is Table 10 ofIB (v10), bSource is Table 12 of IB (v10), cSource is Table 13 of IB (v10).
1.2.4. Risks
For the most comprehensive safet y informat ion regarding ibrut inib, please refer to the current 
versio n of the ibrut inib IB .
1.2.4.1. Cardiac Arrhythmias and Cardiac Failure
Atrial fibrillat ion,atrial flutter , cardiac failure , and cases of ventricular tachyarrhyt hmia 
including so me fatal events, have been reported in subjects treated with ibrut inib, particularly in 
subjects wi th cardi ac risk factors, hy pertensi on, acute i nfect ions, and a previous history  of 
cardi ac arrhy thmia. Peri odically  monitor subj ects clinically  for cardi ac arrhy thmiaand cardi ac 
failure .  Subjects who develop arrhyt hmic symptoms ( eg, palpitations, lightheadedness , syncope, 
chest disco mfortor new onset of dyspnea )shoul d be evaluated clinically , and if indicate d, have 
an ECG performed. For cardiac arrhythmias and cardiac failure which persist, consider the risks 
and benefits of ibrut inib treatment and fo llow the protocol  dose m odificat ion gui delines (see 
Secti on 5.4.1.4 ).
1.2.4.2. Bleeding- related Events 
There have been reports of hemorrhagic events in subjects treated with ibrut inib, both with and 
without thrombocy topeni a. These include minor hemorrhagic events such as contusion, epistaxis, 
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 34and petechiae; and major hemorrhagic events, some fatal, includin g gastrointestinal bleeding, 
intracranial  hemorrhage, and hematuri a. Initially, subjects were excluded fro m participat ion in 
ibrutinib Phase 2 and 3 studies if they required warfarin or other vi tamin K antagonists. Warfarin 
orother vitamin K antagonists s hould not be administered concomitant ly wit h ibrut inib. 
Suppl ements such as fish oil and vitamin E preparations should be avoided. In an in vitro platelet 
funct ion study , inhibi tory effects of ibrutinib on collagen- induced platelet aggregation were 
observed. Use of ibrut inib in subjects requiring other anticoagulants or medicat ions that inhibit 
platelet function may increase the risk of bleeding. Ibrutinib should be held at least 3 to 7 days 
pre-surgery and at least 3 to 7 day s post-surgery  depending upon t he ty pe of surgery  and ri sk of  
bleeding. Subjects with congeni tal bleeding diathesis have not been studied. See Secti on 6.2.4
for guidance on conco mitant use of ant icoagulants, antiplatelet therapy  and/or suppl ements. See 
Secti on 6.4for guidance on ibrutinib management with surgeries or proced ures. 
1.2.4.3. Cytopenias 
Treatment -emergent Grade 3 or 4 cytopenias (neutropenia, thrombocytopenia, and anemia) were 
reported in subjects treated with ibrut inib. Subjects should be monitored for fever, weakness, or 
easy bruising and/or bl eeding.
1.2.4.4. Diarrhea 
Diarrhea is the m ost frequent ly reported non -hematol ogic AE wi th ibrutinib monotherapy and 
combinat ion therapy . Other frequent ly reported gastrointestinal events include nausea, vo miting, 
and const ipation. These events are rarely severe and are generally managed with supportive 
therapi es including ant idiarrheals and antiemet ics. Subjects should be monitored carefully for 
gastrointestinal AEs and cautioned to maintain adequate fluid intake to avoid dehydrat ion. 
Medical evaluat ion should be made to rule out other e tiologies such as Clostridium difficile or 
other infect ious agents. Should symptoms be severe or prolonged fo llow the protocol dose 
modificati on guidelines (see Section 5.4.1.4 ). 
1.2.4.5. Infections 
Infections (including sepsis, bacterial, viral, or fungal infect ions) were observed in subjects 
treated with ibrut inib therapy. Some of these reported infect ions have been asso ciated wi th 
hospi talizati on and death . Consi der prophylaxis according to standard of care in subjects who are 
at increased risk for opportunist ic infect ions (reference Secti on 6.1). Although causalit y has not 
been established, cases o f progressive mult ifocal leukoencephalopathy  (PML) and hepat itis B 
reactivat ionhave occurred in subjects treated wi th ibrutinib. Subjects should be monitored for 
signs and symptoms (fever, chills, weakness, confusion , vomi ting and j aundice ) and appropri ate 
therapy  shoul d be inst ituted as indicated.
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 351.2.4.6. Interstitial Lung Disease (ILD)
Cases of interstit ial lung disease (ILD) have been reported in subjects treated wi th ibrutinib. 
Moni tor subjects for pulmonary  symptom s indicat ive of ILD. Ifsymptom s develop , interrupt 
ibrutinib and manage ILD appropriately . If symptoms persist, consider the risks and benefit s of 
ibrutinib treatment and followthe protocol  dose modificat ion gui delines (see Secti on 5.4.1.4 ).
1.2.4.7. Leukostasis 
There were i solated cases of leukostasis reported in subjects treated with ibrutinib . A high 
number of circulat ing lymphocy tes (>400,000/µL) may confer increased risk. For subject and 
ibrutinib management guidance, refer to Section 5.4.1.5 .
1.2.4.8. Lympho cytosis
Upon init iation of treatm ent, a reversible increase in lymphocy te counts ( ie, ≥50% increase fro m 
baseline and an abso lute count >5000/µL), often associated with reduction o f lymphadenopathy, 
has been observed in 66% of subjects wi th CLL/ small  lymphocy tic lymphoma (SLL) treated 
with ibrutinib. This observed lymphocy tosis i s a pharmacodynamic effect and should not be 
considered progressive disease in the absence of other clinical findings (Hallek 2008, 
Hallek 2012, Hallek 2013 ). The onset of iso lated lymphocy tosis occurs during the first month of
ibrutinib therapy  and resolves by a m edian of 14 weeks (range, 0.1 to 104 weeks). When 
ibrutinib was administered with chemo immunotherapy  (bendamustine + rituximab [BR]), 
lymphocy tosis was 7% wi th ibrutinib + BR versus 6% with placebo + BR.
1.2.4.9. Non-melanoma Skin Cancer
Non-melanoma skin cancers have occurred in subjects treated wi th ibrutinib. Monit or subjects 
for the appearance of non -melanoma skin cancer.
1.2.4.10. Rash
Rash has been co mmo nly reported in subjects treated with either single- agent ibrutinib or in 
combinat ion with chem otherapy . Most rashes were mild to moderate in severit y. Isolated cases 
of severe cutaneous adverse react ions (SCARs) including Stevens -Johnson syndro me (SJS) have 
been reported in subjects treated with ibrut inib. Subjects shoul d be cl osely m onitored f or signs 
and symptoms suggest ive of SCAR including SJS. Subjects receiving ibrut inib should be 
observed closely  for rashes and treated symptomatically, including interruption of the suspected 
agent as appropriate. In addit ion, hypersensit ivity-related events including ery thema, urti caria, 
and angioedema have been reported .
1.2.4.11. Tumor Lysis Syndrome
There have been reports of tumor lysis syndrome (TLS) events in subjects treated with single -
agent ibrutinib or in co mbinat ion with chem otherapy . Subjects at ri sk of  TLS are those with 
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 36comorbidi ties and/or risk factors such as high tumor bur den prior to treatment, increased uric 
acid (hyperuri cemia), el evated l actate dehy drogenase (LDH), bulky disease at baseline, and pre -
exist ing kidney abnormalit ies.
1.2.4.12. Hypertension
Hypertensio n has been co mmo nly reported in subjects treated with ibrutinib. Mo nitor subj ects 
for new onset of hypertensio n or hy pertensio n that is not adequately  controlled after starti ng 
ibrutinib. Adjust existing ant i-hypertensive medications and/or init iate anti -hypertensive 
treatm ent as appropri ate.
1.3. Venetoclax Overview
Venetocla x (VENCLEXTA™) is a potent, orally administered inhibitor of B-cell lympho ma 2
(BCL -2) co -developed by AbbVie Inc and Genentech Inc for the treatment of B -cell 
malignancies.  
Venetoclax is approved in the US for the treatment of pat ients with CLL or SLL, with or without 
17p del etion, who have received at least one prior therapy. Venetoclax isalso approv ed in the 
EU and other regions for the treatm ent of adult patients with CLL when used as monotherapy
the presence o f 17p del etion or TP53 mutation in adult patients who are unsuitable or have failed 
a B-cell receptor pathway  inhibitor orforthetreatment of CLL in the absence of 17p delet ion of 
TP53 m utation in adult patients who have failed both chemo -immunotherapy  and a B -cell 
receptor pathway  inhibi tor,and in combinat ion with rituximab for the treatm ent of adult p atients 
with CLL who have received at least one prior therapy .Venetocl ax has also been approved in the 
US in combinat ion with azaci tidine, or deci tabine, or l ow-dose cy tarabine to treat adults with 
newly -diagnosed acute myelo id leukemia (AML) who are 75 y ears of age or older,orhave other 
medical condit ions that prevent the use of standard chemotherapy.
The Bcl -2 family proteins are important regulators of th e intrinsic apoptosis pathway . The Bcl -2 
oncogene was first ident ified in fo llicular lymphoma (FL) where the t(14;18) chromoso mal 
transl ocati on resul ts in si gnificant over -express ion of the protein in B -cells. The Bcl -2 family of 
genes encodes a family of closely related proteins that possess either pro -apoptotic or anti -
apoptoti c act ivity and share up to four Bcl -2 Hom ology  (BH) domains ( Willis 2003 , Cory 2002, 
Borner 2003 , Cory 2003 ).Bcl-2 overexpressi on is a m ajor contri butor to the pathogenesis o f 
some types of  lympho id malignancies. Bcl-2 is also overexpressed i n acute and chronic 
leukemias. Chronic lymph ocytic leukemia (CLL) is a genet ic disease where the microRNAs 
miR15a and miR16 -1 that negatively regulate the transcript ion of Bcl -2 are deleted or 
down -regulated, result ing in uncontrolled expression of Bcl -2 (Cimmino 2005
, Calin 2008 ).
Venetoclax (also known as ABT -199) is a novel, orally  available, small mo lecule Bcl -2 family 
protein inhibitor that binds with high affinit y (Ki<0.010 nM) to Bcl -2 and wi th lower affini ty to 
other Bcl -2 family proteins Bcl-XLand Bcl -w (>4,000 -fold and >2,000- to >20,000 -fold lower 
affinit y than to Bcl -2, respectively) ( Souers 2013 ). Selective inhibit ion by venetoclax disrupts 
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 37Bcl-2 signaling and rapidly  induces m ultiple hallmarks of apoptotic c ell death in 
Bcl-2-dependent human tumor cell lines ( venetoclax IB). Im portantly, venetoclax inhibit ion of 
Bcl-2 isindependent of p53 activit y.
1.3.1. Summary of Nonclinical Data
In vitro, venetoclax demonstrated broad cell killing activit y against patient-derived CLL and 
acute myelo id leukemia (AML) cells, and a variet y of lympho ma and leukemia cell lines
including B -cell fo llicular lympho mas (FLs), mantle cell lympho mas (MCLs), diffuse large 
B-cell lympho mas (DLBCLs ), AMLs, and m ultiple myel oma cell lines . Venetocl axwas 
especially  potent against cell lines expressing high levels of Bcl -2. A detailed discussio n of the 
non-clinical toxi cology, m etabo lism, and pharmacology  can be found in the venetoclax IB.
1.3.2. Summary of Venetoclax Clinical Data
1.3.2.1. Clinical Pharmacokinetics
Following m ultiple oral  administrati ons under fed condi tions, m aximum plasma concentration of 
venetoclax was reached 5 -8 hours after dose. Venetoclax stea dy state AUC increased 
proporti onally over the dose range of 150- 800 m g. Food can increase venetoclax exposure 
(3.4-fold wit h a low-fat meal and 5.1 -to 5.3 -fold with a high -fat meal). Venetocl ax shoul d be 
administered with a meal. The populat ion est imate for the terminal eliminat ion half -life of 
venetoclax was approximately 26 hours. In vitro studies demonstrated that venetoclax is 
predominant ly metabo lized by CYP3A4/5. Less than 0.1% of venetoclax is excreted renally. 
Venetoclax exposures in subjects wit h mild or moderate renal impairment are similar to those 
with norm al renal functi on. The pharmacokinet ics of venetoclax has not been studied in subjects 
with severe renal impairment (CrCl <30 mL/min) or subjects on dialysis. Venetoclax exposures 
are simila r in subjects wi th mild and m oderate hepati c impai rment and norm al hepati c function 
based on the NCI Organ Dy sfunct ion Working Group criteria. Mild hepat ic impairment was 
defined as normal total bilirubin and aspartate transaminase (AST) > upper limit of n ormal 
(ULN) or total bilirubin >1.0 to 1.5 times ULN, moderate hepatic impairment as total bilirubin 
>1.5 to 3.0 times ULN, and severe hepat ic impairment as total bilirubin >3.0 times ULN. The 
pharmacokinet ics of venetocl ax has not been studied in subjects with severe hepatic impairment.
Based on preliminary  data from  thiscombinat ion study of ibrutinib and venetoclax in CLL 
(PCYC -1142- CA),venetoclax exposure (AUC) at 400 mg QD appears to be ~1.6 -fold higher 
when co -administered with ibrut inibat 420 m g QD (N = 32), compared to historic venetoclax 
single agent exposure. Ibrutinib exposure was similar prior to, and in co mbinat ion with 
venetoclax administration.  To date, no new safet y signals have been ident ified.
For the most comprehensive information rega rding pharmacokinetics (PK) and product 
metabo lism, please refer to the current versio n of the venetoclax IB.
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 381.3.2.2. Summary of Clinical Safety 
Doses administered in venetoclax clinical studies have ranged fro m 20 m g to 1200 m g.
As of 28 November 2016, and versio n 8of the Investigator’s Brochure, on the basis o f data 
available in the AbbVie and Genentech/Roche clinical databases, a total of 2759 subjects have 
been exposed to at least 1 dose of venetoclax in the oncology  and immun ol
ogy devel opment 
programs. A total of 2534 oncol ogy subjects have data available in AbbVie and 
Genentech/Roche studies as of 28 November 2016. Of these 2534, there are 1435 subjects with
CLL/ SLL, 626subjects withNHL, 178subjects withMM, 295withAML. An addit ional
127subjects arehealt hy 
volunteers. A total of 663oncol ogy subjects received the drug as 
monotherapy , 1871 have received the drug in co mbinat ion with other therapi es, and 1 subject
received venetoclax as a single dose in a drug-drug i nteracti on study  and di d not re -enroll into a
subsequent monotherapy  study . Addi tionally, 98 subjects have been exposed to at l east 1 dose of 
venetoclax in the AbbVie immuno logy study , Study  M13 -093, as of 28 November 2016.
Of the 1435 subjects with CLL/SL L that have been treated in the venetoclax oncology  clinical  
program: 416patients have received venetoclax monotherapy  and 1019 have received venetocl ax 
in combinat ion with other agents including rituximab, obinutuzumab, and bendamustine.
The safet y profi le of venetoclax was similar across CLL subjects, inclu ding subjects with 17p del 
or TP53 mutation and subjects who have failed prior B -cell receptor inhibitors (BCRi), such as 
ibr
utinib and i delalisib. The m ost comm on adverse events (incidence >20%) reported for all 
subjects in CLL/SLL monotherapy  studi es(N=410) were diarrhea ( 42.2%), neutropenia ( 41.0%), 
nausea ( 40.2%), fatigue (30.5%), anemia (28.8%), upper respi ratory  tract infection ( 27.3%), and 
thrombocy topenia (20.7%) . The m ost comm on Grade 3 and above adverse events were 
neutrope nia (36.8%),anemia ( 15.6%)
, and thrombocytopenia ( 13.4%).The most commo n 
serious adverse events were pneumonia ( 6.8%), malignant ne oplasm progressi on (5.9%), and 
febrile neutropeni a (5.4%) .The safety  profile in combinat ion studies (N=1019) is consistent with 
that observed in mo notherapy  studi es and combinati on backbone r egimens . 
Addit ional safet y and efficacy  data are described in detail in the venetoclax IB.
1.3.3. Risks
1.3.3.1. Tumor Lysis Syndrome
Tumor lysis syndrom e (TLS) i s an important risk, particularly in subjects with CLL. Tumor lysis 
syndro me, including fatal events and renal failure requiring dialysis, have occurred in previously  
treated CLL patients with high tumor burden when treated with venetoclax. As a result of 
on-target effects, the potential for TLS with venetoclax was ident ified early in the program when 
the init ial 3 subjects with relapsed/ref ractory CLL/SLL r eceived starting doses of 100 mg or 
200mg and experienced TLS, which was reported as an adverse event for each. The starting 
dose was reduced to 50 mg and prophylaxis and mon itoring reduced, with 3 -week ram p-up. 
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 39Subsequently, 2 fatal events in the setting of TLS and another event of clinical TLS in subjects 
with CLL /SLL occurred in December 2012. After comprehensive review of all safet y data 
available fro m studi es wi th venetocl ax, a revised dosing regimen wit h a ram p-up peri od of  
5weeks and enhanced TLS prophylaxis and monit oring m easures were implemented in all CLL 
studi es.A subsequent analysis of data fro m subjects wi th CLL/SLL following the 
implementation of prophylaxis measures, who completed monotherapy ,indicated a marked 
reduction in severit y and frequency  of TLS when com pared to the previous analysis. None of the 
subjects experienced any  serious (including fatal) or non -serious event of clinical TLS (CTLS) or 
had study  treatm ent discont inued because of TLS. Overall, the clin ical data strongly  support that 
the risk of TLS with venetoclax in CLL/SLL subjects is highest when init iating venetoclax 
dosing, especially wit h a higher init ial dose of venetoclax, as well as being greater in subjects 
with a large tum or burden.
The ri sk of TLS is a continuum based on mult iple factors, including tumor burden and 
comorbidi ties. Reduced renal function (CrCl <80 mL/min) further increases the risk. Patients 
shoul d be assessed for ri sk and shoul d receive appropri ate prophylaxis for TLS, includi
ng 
hydrat ion and ant i-hyperuri cemics. Changes in blood chemistries consistent with TLS that 
requi re prom pt management can occur as early as 6 to 8 hours following the first dose of 
venetoclax and at each dose increase. Monitor blood chemistries and manage abnorm alities 
prom ptly. Interrupt dosing if needed. Emplo y more intensive measures (intravenous hydration, 
frequent monitoring, and hospitalizat ion) as overall risk increases (see Section 5.4.2.2 for 
Prophylaxis and Management of TLS) .
1.3.3.2. Neutropenia
Grade 3 or 4 neutropenia occurred in 41% (98/240) of patients treated with venetoclax in the 
pivotal  previ ously treated CLL 17p del etion study . Moni tor com plete bl ood counts throughout 
the treatment period. Interrupt dosing or reduce dose for severe neutropenia. Consider supportive 
measures including ant imicrobials for signs of infection and use of growth factors ( eg, G-CSF) .
1.3.3.3. Immunization
Do not administer live attenuated vaccines prior to, during, or after treatment with venetoclax 
until B-cell recovery  occurs. The safet y and efficacy  of immunizat ion with live attenuated 
vaccines during or following venetoclax therapy  have not been studied . Advise pat ients that 
vaccinations may be less effect ive.
1.4. Study Rationale
Despite the impressive survival efficacy (90% PFS at 18 months [Burger 2015 ]; 94.7% 2-year 
survival est imate [IMBRUVICA USPI ]) and safety results with single -agent ibrutinib in the 
rando mized Phase 3 RESONATE -2 study  in previously untreated CLL patients, complete 
responses remain low (Burger 2015 , IMBRUVICA®USPI ), and broader questions remain
regarding the optimal duration o f ibrutinib therapy. This is particularly relevant among younger 
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 40patients who may  not wi sh to continue therapy  indefini tely or in those seeking a drug holiday . In 
such patients, an all oral truncated combination regimen appro ach with the abilit y to induce deep 
and durable remissions would be desirable. 
Pre-clinical studies support the combinat ion of ibrutinib wit h venetoclax, and suggest potential 
enhanced activit y vs.each agent alone. Ex vivo experiments in ibrutinib treate d CLL patients 
demonstrated that BCL2 expressio n rem ains strong throughout the 6 months of ibrut inib 
treatm ent (Rawstron 2015 ). In vitro experiments on previously untreated CLL patient samples 
suggest that ibrutinib increases the dependence of CLL cells on BCL -2 (Deng 2015). 
Addit ionally , ex vivo experiments on CLL cells from patients demonstrated that ibrutinib 
exposure retained sensit ivity to ven etoclax, that venetocl axinduced potent CLL cell death 
(median 62% at week 4) in patients being treated with ibrut inib, and that cytotoxicit y was greater 
than each agent alone ( Cervantes -Gomez 2015). 
As ofthe time of protocol design, i n the rel apsed CLL setting, single -agent ven etoclax had 
induced a 79% ORR, including 20% CR in previo usly treated CLL patients in a Phase 1 study . 
Of the CR pati ents evaluated for minimal residual disease (MRD) in bone marrow, 35% (or 5% 
of the total  study  popul ation) became MRD -negat ive via flow cy tometry  (Roberts 2015). In a 
Phase 2 study  in patients with relapsed deleti on 17p CLL, the IRC assessed response was 69% 
including 7.5% CR/CRi, and MRD -negativit y in peri pheral  blood was achieve d in 21% (18/85) 
of responders ( Stilgenbauer 2015). MRD -negative response in the bone marrow was achieved in 
53% (26/49 ) of patients, including 75% (15/20) of patients who achieved CR or CRi with the 
combinat ion of venetocla x plus rituximab in previously treated CLL patients ( Ma2015). Clinical 
remission has been maintained after ven
etoclax discontinuat ion in six pat ients who achieved 
MRD -negat ive CR, with a med ian fo llow up of 15 mo nths off therapy  (range 4-24 m onths). 
Despite impressive response rates and the abilit y to achieve MRD -negativit y in so me patients, 
PFS has rem ainsrelatively  short wi th single -agent venetoclax (66% -72% at 12 -15 m onths) and 
combinat ion therapy  mayafford a better long -term outcom e (84% PFS at 24 months with 
rituximab in the relapsed setting ).
At the time of protocol design, t here waslittle data wi th venetoclax in treatm ent naïve CLL. 
Safety run-in results for the ongoing CLL14 study  of venetoclax wi th obinutuzumab 
demonstra ted that the combinat ion was tolerable wit h 15% of pat ients developing Grade 3 -4 
infusio n related reacti ons wi th obinutuzum ab, and 15% developing Grade 3 -4 laboratory  tumor 
lysis syndrome (TLS) ( Fischer 2015). As infusio n -related reacti onsare not a concern wit h 
ibrutinib , an ibrut inib lead-in to debulk tumor, fo llowed by  the combinat ion of ibrut inib wit h 
venetoclax may afford better tolerabilit y. The combinat ion of ibrut inib wit h venetoclax may be 
an effective strategy  to achieve deep and durable MRD -negat ive responses in treatment naïve 
CLL pat ients.The German CLL Study  Group is also planning a study  of venetoclax, ibrut inib, 
plus obinutuzum ab (CLL2 -GiVe, [STUDY_ID_REMOVED]) in physically  fit previ ously untreated CLL.
At the time of pr otocol  design ,PCYC -1142-CA was the first clinical trial to study  the 
combinat ion of ibrut inib +venetoclax (I+V) in subjects with treatm ent naïve 
CLL, therefore a 
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 41Safety Run-in Period will be inst itutedto eval uate safet y and tolerabilit y of the combinat ion, and 
determinat ion of the recommended doses . Addi tionally , venetocl ax will  be introduced after 
3cycles(1 cycle = 28 days) of single -agent ibrutinib lead-in, represent ing the period after the 
ibrutinib -induced lymphocy tosis peak and where most treated subjects will have experienced 
significant reducti on in lymphadenopathy . Utilizing the prev iously published calculat ions to 
determine TLS risk categories for venetoclax based on tum or burden (Seymour 2014 , 
Append ixHasnoted in the VENCLEXTA®(venetocl ax)prescribing informat ion, TLS ri sk at 
baseline and at first assessment were calculated utilizing CT scans after 4 cy cles of ibrut inib 
from the RESONATE -2 ibrut inib treatment naïve Phase 3 CLL study (N=135) and after 2 cy cles 
of ibrutinib in PCYC -1102 Phase 1b/2 treatment naïve cohorts (N=27) .The percent of subjects at 
high or m oderate -risk for tum or lysis syndrome (TLS) at baseline was reduced f rom 81% to 59%
after 2-4cycles of ibrut inib, and the percent of subjects at high-risk for TLS at baseline was 
reduced from 28% to 7% after 2-4cycles o f ibrut inib. Due to transi ent increase in ALC, a 
minori ty (5%) of pati ents increased from  low to medi um risk at first assessment, however no 
patients increased from low or medium to hi gh risk. For patients with treatm ent-naïve CLL or 
SLL with CrCl  <80 mL/min, 36% (25/ 69) with medium TLS risk at baseline were reduced to 
low risk by  first assessment and 26% ( 10
/30) with high TLS risk at baseline were reduced to low 
risk by fi rst assessment, further reducing the overall percent of patients requirin g hospi talizat ion
(Wierda 2017) . Therefore , emplo ying a 3 -cycle ibrutinib lead -in and sequencing ibrut inib prior 
to venetocl ax shoul dprovi detumordebulking and convert high er TLS risk subjects to lower 
TLS risksubjects .
At the time of protocol design, p reliminary  clinical data from an ongoing investigator -initiated 
study  of the combinati on of  ibrutinib and venetoclax (I+V) in subjects with high -risk, 
relapsed/refractory  CLL (CLARITY Study , ISCRTN: 13751862) indicate dthat the co mbinat ion 
is highly  effect ive, with rapid clearance of disease and an acceptable safet y profile (presented at 
the American Societ y of Hematol ogy [ASH] Annual  Meet ing, December 2017 ; Hillmen 2017 ). 
In thi s study , the ibrutinib lead-in is 8 weeks, after which the ibrut inib + venetoclax (I+V) 
combinat ion starts. Treatment continues for a period of 14 to 26 months, depending on MRD -
negat ive status. Median baseline CLL burden in PB, as assessed by the MRD assay in the first 
46subjects, was 54.5 x109/L. This declined down to 0.001 x109/L in the 37 subjects who have 
completed 8 m onths of therapy  (including 6 months of the combinat ion I+V). All evaluable 
subjects at the 8- month time po int (38/38) had an object ive response (100% ORR), 18/38 (47%) 
achieved CR or CRi. Peripheral blood was MRD negative in 15/38 (37% )and BM was MRD 
negat ive in 12/3 8 (32%). The combinat ion of I+ V was reported to have an acceptable safet y 
profile, with most AEs being Grade 1 or 2. Two biochemical TLS events were reported, but only 
1 case m et the definit ion of laboratory  TLS. Dosing of venetoclax was interrupted until the 
biochemical abnormalit ies reso lved and the patients subsequent ly escalated to 400 mg/day  of 
venetoclax.
At the time of protocol design, t he Phase 2 invest igator -initiated study conducted at the 
Universit y of Texas MD Anderson Cancer Center ( Study  [STUDY_ID_REMOVED]) i s inve stigating the 
combinat ion of I+ V in subjects with relapsed/refractory  CLL (n=33) and in treatment naive 
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 42(n=39) subjects with CLL wit h at l east 1 of the fo llowing high -risk features: del17p, mutated 
TP53, del11q, unmutated IGHV, or ≥ 65 years of age. Subjects are treated with single agent 
ibrutinib (420 mg daily) for 3 months, fo llowed by addi tion of  venetocl ax. As presented at the 
American Societ y of Hematol ogy [ASH] Annual Meet ing, December 2017 ( Jain2017 ), three 
months of single agent ibrut inib therapy reduced the TLS risk category in 31 of 61 evaluable 
subjects (51%). In the 16 sub jects with relapsed/refractory CLL who completed at least 6 months 
of combinat ion therapy , 100% had a response (69% CR/CRi) , and 13% were MRD -negat ive in 
BM. In the 20 subjects with treatment naive, high -risk CLL who completed at least 6 months of 
thecombination, 100% had a response (75% CR/CRi), and 45% were MRD -negat ivein BM . 
One pat ient had l aboratory  TLS, none had clinical TLS.
Addit ion of a Fixed Duration cohort to thi sstudy  is based upon promising preliminary response 
data (CR, ORR, MRD negative ra tes) foribrut inib-venetoclax combinat ion therapy  from PCYC, 
investi gator -sponsored trials, and other invest igator-led studies . After 9 cycles of therapy
(6cycles of I +Vcombinat ion), 5of thefirst7subjects in the MRD cohort of this study  have 
achieved MRD -negat ivity (<0.01%) in the peripheral blood with the remaining 2subject shaving 
only 0.01% MRD .
Together, the sepreliminary  data indicate the combinat ionof ibrutinib and venetoclax has the 
potential for use as a fixed duration regimen .The primary  object ive of this study  is to 
demonstrate a hi gh CR rate in reference to historical data with fixed durat ion 
chemo -immunotherapy , tested i n a similar populat ion. This fixed duration I +V regimen woul d be 
of value for several reasons, particularly given the barriers to MRD testing in the communit y and 
the acceptance of fixed duration standard chemo immunotherapy  regimens. If effect ive, the fixed 
durati on I+V therapy  woul d also provi de benefit to the patien t as well  as economic benefit s 
given the shorter treatment administration, alleviating the need for long -term dose adherence, 
and providing treatment ho lidays wit h the option for treatm ent following progressi on.
MRD -negat ive remissio n is associated with su perior PFS and OS with chemo immunotherapy  
(CIT) in pat ients with CLL (Thompson 2016) , however whether confirmed MRD -negat ive 
remissions with novel non -CIT regimens will also translate into a survival benefit is not y et 
known. Addit ionally , it will  be important to understand if extended treatment with ibrutinib in 
patients wi thout confirmed MRD negat ive remissions after 15 cy cles can lead to deeper 
responses and attainment of MRD -negativity. This Phase 2 pl acebo -controlled study  will
investigate the activit y of ibrutinib plus venetoclax in treatm ent-naive CLL subjects by  assessing 
the abilit y to achieve complete clini cal response, MRD -negat ive response, and the durabilit y of
response in the setting of ibrut inib discontinuat ion.  
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 432. STUDY OBJECTIVE
2.1. Primary Objective
MRD Cohort
To evaluate if discontinuing ibrut inib, in the setting of a confirmed MRD -negat ive
response wit h the combinat ion of ibrut inib + venetoclax (I+V) , allows for a treatm ent 
holiday as assessed by 1- year disease -free survival. 1 -year disease -free survival is defined 
as continue dMRD -negative response without progressio n or death at least one year after 
rando mizat ion.  
Fixed Duration Cohort
To evaluate the depth of response wit h the combination of ibrut inib + venetoclax (I+V) 
administered for a fixed duration of therapy  by assessment of com plete response
(CR/CRi) rate.
2.2. Secondary Objective(s)
2.2.1. MRD Cohort
Minimal Residual Disease ( MRD ) -negative rate
Overall response rate (ORR)
Com plete response rate (Com plete Response [ CR], and CR wi th incomplete marrow 
recovery  [CRi]
)
Durati on of  response (DOR)
Tumor Lysis Syndrom e (TLS)risk reducti on
Progression free survival (PFS)
Overall survival (OS)
Pharmacokinet ics of ibrutinib and venetocl ax when dosed in combinat ion
Safety and tol erabilit y
2.2.2. Fixed Duration Cohort
Durati on of  Response ( DOR )
Minimal Residual Disease ( MRD )
-negat ive rate
Overall response rate (ORR)
Tumor Lysis Syndrom e (TLS)risk reducti on
Progression free survival (PFS)
Overall survival (OS)
Safety and tol erabilit y
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 442.3. MRD Cohort Exploratory Objectives
2.4. FD Cohort Exploratory Objective
3. STUDY DESIGN
3.1. Overview of Study Design
This is a mult icenter, 2-cohort Phase 2 study assessing both MRD -guided discont inuat ion and 
fixed duration therapy  with the combinat ion of ibrutinib + venetoclax in subjects with treatment -
naïve CLL or SLL.
TheMRD cohort consists of a pre -randomizat ion phase (combinat ion treatment), a n MRD -
guidedrando mization phase which includes reintroduction of therapy , and post -PD fol low-up 
phase.
The Fixed Duration cohort is an open label, 1 arm cohort ofibrut inib + venetoclax combinat ion 
therapy  for a fixed durati on.
All subjects who discont inue treatment in the absence o f disease progressi on will remain on 
study  until  confi rmed disease progression or until study  closure. All  subjects who discont inue for 
disease progressi on will be fo llowed for survival and subsequent anti -cancer therapies.
Invest igator assessment of disease overall response and progression will be based upon IWCL L 
criteria wi th the m odificati on that isol ated treatm ent-related lymphocy tosis in the absence of 
other si gns or symptom s of disease progression will notbe considered PD ( Hallek 2008, 
Hallek 2012 , Hallek 2013 , Cheson 2012 ). The Investigator will evaluate sites of disease by
radiological  imaging, physical examinat ion or other procedures as necessary , review of 
hematol ogy resul ts, di sease -related symptom s and bone marrow examinat ions (where 
appropriate). The same methods of assessment used to assess disease at baseline should be used 
throughout the study . 
Imaging will be collected and stored centrally . Assessment of efficacy may be confirmed based
on evaluat ion by an Independent Review Committee (IRC). Detailed procedures will be 
described in a separate charter.

IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 45For the MRD cohort, t he primary analysis of the randomized phase will be perform ed at the 
point that all rando mized subjects have had the opportunit y to com plete at least 12 cy cles of 
rando mized treatment or follow -up. All safet y and efficacy  endpoints will be analyzed at the 
time of the primary  analysis. After the primary  analysis, the Sponsor m ay elect to discont inue 
follow
-up of  specific MRD cohort treatment arms on PCYC -1142 -CA. Subjects who are 
continuing on ibrutinib at time of study  arm closure may be offered a separate extension study to 
continue ibrut inib.
For the FD cohort, the primary  analysis will be performed when a clinically meaningful 
evaluat ion of durable CR rate (12 months or longer) can be assessed in the study  popul ation. FD 
Cohort subjects will be fo llowed f or approximately  10years . All subjects who are continuing on 
ibrutinib at the time of FD cohort study  closure may  be of fered a separate extensio n study  to 
continue ibrut inib.
The clinical study  report for the study  will be generated once the primary analyses of both the 
MRD cohort and FD cohor ts are completed.
The rati onale for the study  concept i s provi ded in Secti on 1.4.
Details o f the sequentially designed and enrolled cohorts, MRD coh ort and Fixed Duration 
cohort, are below.
3.1.1. MRD Cohort: Pre-Randomization Phase
Approximately  150 subjects will be enrolled into this phase. The subjects will receive single -
agent ibrutinib for 3 cy cles (1 cycle = 28 day s) followed by  ibrutinib + venetoclax combinat ion 
treatm ent for at l east12 cycles. 
The safet y of ibrutinib + venetoclax co mbinat ion therapy will be assessed by a Data Review 
Committee (DRC). Approximately 12 subjects will be enro lled in a Safet y Run-in Period, 
defined as the date of first dos e of ibrut inib at Cycle 1 Day 1 thr ough the DLT evaluat ion peri od. 
The DLT evaluat ion peri od is defined as the 5 -week venetoclax dose ramp up in co mbinat ion 
with ibrutinib, plus an addit ional week of fo llow up (6 weeks total ). 
Enrollment will then be held 
until safet y is assessed by the DRC in the first 6 evaluable subjects who complete the Safet y 
Run-in Period . Subjects’ laboratory  resul ts and AEs will  be reviewed by  the DRC.  If ≤1 of the 
first 6 eval uable subjects experience a DLT, the study  will cont inue. If 2 of the first 6 evaluable 
subjects experience a DLT, then the DRC will evaluate safet y in the next 3 evaluable subjects 
(9subjects total). The study  will be deemed safe to proceed when 6 –9 subjects com plete the 
Safety Run-in Period (DLT evaluat ion period) and if <33% ( ≤1 of 6, or ≤2 of 9) of subjects 
experience a DLT. The DRC will meet and review safet y data after all 12 subjects in the Safet y 
Run-in Period have either discont inued therapy and/or have co mpleted the DLT evaluat ion 
period (venetocl ax dose ram p up pl us 1 week fo llow up), then DRC may make a 
recommendat ion regarding dosing.
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 46Subjects will be assessed for MRD status in peripheral blood every 3 cycles on the combinat ion 
therapy  starting after complet ion of Cycle 6 (C7D1 ), and in bone marrow aspirate after 
completion of Cycle 15 (C16D1) . MRD assessment will be performed using flow cyto metry with 
a sensit ivity of ≥10-4. An early  assessment of the MRD -negat ive response rate of the 
combinat ion therapy  will be assessed amo ng the first 30 subjects who complete 9 cy cles of 
treatm ent. The sample size may be adjusted accordingly  based on thi s early  assessment to 
adequately  power the Randomization Phase primary  endpoint.
MRD -negat ive response for randomization purposes must be confirmed serially over a t least 
3cycles, and i s requi red to dem onstrate negativit y in both bone marrow and peripheral blood.
Subjects who complete at least 12 cy cles of co mbinat ion therapy  and subjects who di scont inue 
venetoclax in the Pre -randomizat ion Phase due to reasons othe r than PD (but continue on 
ibrutinib single agent treatment and achieve confirmed MRD -negat ivity by the end of Cycle 16) 
are eligible for randomization. Subjects who have discontinued ibrutinib and subjects that are 
MRD -positive and have discont inued venet oclax are not eligible to be randomized but will 
continue the tolerated open label treatment until PD or unacceptable toxicit y.
3.1.2. MRD Cohort: Randomization Phase (Including Re -introduction Period)
Eligible subjects will be rando mized in a 1:1 ratio based on their MRD status (see below). 
Subjects will be stratified by immunoglobulin heavy- chain vari able regi on (IGHV) status in each 
rando mizat ion strat a.
Randomization Phase -MRD -negat ive subjects (Double -blind):
Eligible subjects who achieve a confirmed MRD -negative response will be rando mized to 
receive blinded treatment of ibrutinib (venetoclax discontinued) vs placebo (ibrutinib and 
venetoclax discontinued). The rando mizat ion will be stratified by  IGHV status. Subjects will be 
assessed for disease -free survi val as measured by  continued MRD- negat ive response without 
progression or death at least 1 y ear after randomization. MRD status will be evaluated every  
3cycles in PB. MRD should also be reassessed in BM aspirate after an addit ional 12 cycles.
Randomizatio n Phase -MRD -positive subjects (Open -label):
Those subjects who do not achieve a confirmed MRD -negat ive response (MRD -positive) after 
12 cy cles o f the combinat ion will be rando mized to receive open label treatment of I+V vs 
ibrutinib alo ne (venetoclax dis continued). The randomizat ion will be stratified by  
immunogl obulin heavy -chain vari able regi on (IGHV) status. Subjects will subsequently be 
assessed for MRD -negative response. MRD status will be evaluated every  3 cycles in peri pheral  
blood. MRD should also be reassessed in BM aspirate after an additional 12 cycles and at any 
time in subjects who beco me MRD negative in PB. For subjects receiving I+V, venetoclax can 
be administered for up to approximately 2 years per treatment course, until PD or unacceptable
toxicity, or until  this arm’s study  closure, whichever is earlier. Subjects who are continuing on 
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 47ibrutinib at time of study  arm closure may be offered a separate extension study  to continue 
ibrutinib.
Reintroduction of therapy :
Subjects who wish to reintroduce therapy  for MRD -positive relapse (see definit ion in 
Secti on7.2.1.4.2 ) and/or for disease progression must undergo a CT scan for re- staging (unless 
previously done within approximately 6 weeks prior to reintroduction).  For MRD -negat ive and 
MRD -positive subject s who reintroduce venetoclax, venetoclax can be administered for up to 
2years per treatment course, un til PD or unacceptable toxicit y, or until these arms’ study  
closure, whichever i s earlier. Subjects who are continuing on ibrutinib at time of study  arm 
closure m ay be of fered a separate extensio n study  to conti nue ibrutinib. Any non -study  therapy  
shoul d only  be administered fo llowing docum ented IWCLL confirmed PD.
MRD -negat iverando mized subjects who experience confirmed MRD -positive rel apse and/or 
confir med disease progression may  have their randomizat ion unblinded, and receive 
reintroduced therapy  as fo llows: 
Placebo subjects: Subjects on the placebo arm will be offered the opportunit y to reintroduce 
ibrutinib to assess if they can benefit fro m single -agent ibrut inib under the fo llowing 
circumstances:
For confirmed MRD -positive relapse and/or for disease progression by IWCLL criteria, subjects 
will receive ibrutinib unt il PD or unacceptable toxicit y. Ibrutinib reintroduced subjects who 
subsequent ly have confirmed disease progression by  IWCLL cri teria may cont inue ibrut inib and 
add venetoclax per standard dose ramp up
Ibrutinib subjects: Subjects on the ibrut inib arm will be o ffered the opportunit y to conti nue 
ibrutinib and reintroduce venetoclax treatment under the following circumstances:
For confirmed MRD -positive relapse and/or for confirmed disease progression by IWCLL 
criteria, subjects can cont inue ibrut inib and add venetoclax per standard dose ramp up.
MRD -positiverando mized subjects can receive re introduced therapy  as fo llows: 
Ibrutinib only subjects : Subj ects on the ibrut inib arm will be offered the opportunit y to continue 
ibrutinib and reintroduce venetoclax treatment per standard dose ramp up under the fo llowing 
circumstances:
For confirmed dis ease progressi on by IWCLL criteria, subjects can add venetoclax to 
ongoing ibrut inib
For subjects who have confirmed disease progression and reintroduced therapy , a new 
baseline for response assessment will be collected and utilized for calculat ing time to
next PD on reintroduced therapy .
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 483.1.3. Fixed Duration Cohort
Approximately  125 subjects without del 17p will be enrolled into this cohort sequent ially after 
the MRD cohort. Subjects will receive 15cycles of therapy  consist ing of single -agent ibrutinib 
for 3 cyc les followed by  ibrutinib + venetoclax combinat ion treatment for 12cycles. If emerging 
data from  this study  indicate, the durati on of  combined ibrut inib + venetoclax treatment may be 
modified to ensure appropriate risk -benefit is maintained, compared to h istorical controls and 
other emerging data.
All subjects will be assessed for MRD status in peripheral blood (PB) every 3 -12 cycles starting 
after com pletion of 6 cy cles (C7D1), and in bone marrow (BM) aspirate after com pletion of  
9cycles ( C10D1)and 3 m onths after complet ion of the fixed durat ion Cycle 15 (ie, C19) , or 
earlier if BM is indicated for confirmat ion of CR per IWCLL response c riteria. MRD 
assessments will be performed using flow cyto metry with a sensit ivity(lower limi t of detecti on)
of1 CLL cell in 10,000 leukocy tes(10-4). 
Reintroduction of therapy
Subjects with confirmed progression per IWCLL criteria after complet ion of the fixed duration 
regimen can be retreated with cont inuous single agent ibrut inib unt il disease progression or 
unacceptable toxicit y because it is an established standard of care for treatment of relapsed CLL. 
For subjects that experience durable efficacy after I+V (ie, time to progression after fixed 
durati on regimen is completed of >2 y ears), the I+V fixed duratio n treatm ent regimen may  be 
repeated based on Invest igator’s clinical discret ion and Medical Monitor’s approval.  
Retreatment is for 15 cy
cles, unt il PD or unacceptable toxicit y, whichever i s earlier.
Subjects will be fo llowed f or progressi on, overall survi val(OS) , and use of subsequent 
anticancer agents unt il study  closure.
3.1.4. Post-PD Follow -Up Phase
Subjects who have confirmed disease progression by IWCLL criteria and have discont inued 
study  treatm ent will be fo llowed for survival status and subsequent ant i-cancer therapy  until  
study  closure.
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 514. SUBJECT SELECTION 
4.1. Inclusion Criteria
Prior to enrollment, each potential subject must satisfy all o f the following inclusio n criteria. 
Disease Related
1.Diagnosis of CLL/SLL that meets IWCLL diagnostic criteria ( Hallek 2008 ).
2.Active disease meet ing at least 1 of the fo llowing IWCLL criteria ( Hallek 2008 ) for requi ring
treatm ent:
Evidence of progressive marrow failure as manifested by  the development of, or 
worsening of, anemia and/or thrombocy topeni a
Massive, progressive, or symptomatic spleno megaly
Massiv e nodes or progressive or symptomat ic lymphadenopathy
Progressive lymphocy tosis
Const itutional symptom s
3.Measurable nodal disease by co mputed tomography (CT).
Laboratory
4.Adequate hematologic funct ion independent of transfusion and growth factor support for at 
least 7 day s (with the except ion of pegylated G -CSF [pegfilgrast im]and darbopoeit in which 
requi re at l east 14 days )prior to screening laboratory  assessment defined as:
Absolute neutrophil count (ANC) >750 cells/µL (750 cells/mm3 or 0.75 x109/L)
Platelet coun t >30,000/µL (30,000 cells/mm3 or 30 x 109/L)
Hem oglobin >8.0 g/dL
5.Adequate hepat ic and renal funct ion defined as:
Serum  aspartate transaminase (AST) or alanine transaminase (ALT) ≤3.0 x upper limit of 
norm al (ULN)
Creatinine Clearance (CrCl) ≥60 mL/min ( eg, asestimated by Cockcroft -Gault)
Bilirubin ≤1.5 x ULN (unless bilirubin rise is due to Gilbert’s syndrome or of non -hepatic 
origin)
6.Prothrombin t ime (PT)/International normal rat io (INR) <1.5 x (upper limit of nor mal) ULN 
and PTT (activated par tial thrombopl astin time [aPTT]) <1.5 x ULN (unless abnormalit ies 
are unrelated to coagulopathy  or bl eeding disorder) .
Demographic
7.Men and wo men ≥18 and ≤70 years of age.
8.Eastern Cooperative Oncology  Group (ECOG) performance status of 0-2.
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 52Ethical/Other
9. F emale subjects who are of non -reproductive potent ial (ie, post -menopausal by history  - no 
menses for ≥1 year; OR history  of hysterectomy; OR history  of bilateral  tubal  ligat ion; OR 
history  of bilateral  oophorectomy ). Female subjects of reproductive potential must have a 
negat ive serum pregnancy test upon study  entry .
10.Male and female subjects of reproductive potential who agree to use both a highly effective 
method of birth control ( eg,implants, injectables, combined oral contraceptives, some 
intrauterine devices [IUDs], complete abst inence2, or sterilized partner) and a barrier method 
(eg, condom , cervical ring, sponge, etc.) during the period of therapy  and for 90 days after 
the last dose of study  drug. Mal e subjects m ust agree to refrain from sperm donat ion unt il 
90days after the l ast dose of study  drug.
4.2. Exclusion Criteria
To be enrolled in the study , potenti al subjects m ust meet NONE of the fo llowing exclusio n 
criteria:
1.Any pri or therapy  (including but not limited to chemotherapy , targeted therapy , 
immuno modulating therapy, radiotherapy, and/or mo noclonal antibody ) used for treatm ent of  
CLL or SLL.
2.History  of other m alignancies, except: 
Malignancy  treated wi th curative intent and with no known active disease present for 
≥3years before the first dos e of study drug and felt to be at low risk for recurrence by the 
treating physician
Adequately treated non -melanoma skin cancer or lent igo maligna wit hout evidence of 
disease
Adequately treated carcinoma in situ without evidence o f disease
3.Known or suspect ed history  of Richter’s transformation.
4.Concurrent administration of >20 mg/day o f prednisone within 7 days o f initiation of study  
drug unl ess indicated for prophylaxis or management of allergic reactions ( eg, contrast).
5.Known hypersensit ivity to one or mo re study  drugs.
6.Known allergy  to xanthine oxi dase inhibitors and/or rasburicase. Subjects who are allergic to 
xanthine oxidase inhibitors and cannot receive rasburicase will be excluded.
7.Vaccinated with live, attenuated vaccines within 4 weeks of first dos e of study drug.
8.Recent infect ion requiring systemic treatment that is ongo ing or was completed ≤14 days 
before the first dose of study  drug , or any  uncontrolled act ive systemic infection .
                                               
2Complete abstinence is a highly effective metho d only  if defined as refraining from heterosexual intercourse 
during the entire period of risk associated with the study treatments. The reliability of sexual abstinence needs to be 
evaluated in relation to the duration of the clinical trial and the prefer red and usual lifestyle of the subject. 
http://www hma.eu/fileadmin/dateien/Human_Medicines/01 
About_HMA/Working_Groups/CTFG/2014_09_HMA_CTFG_Contraception.pdf
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 539.Known bleeding disorders ( eg, von Willebrand’s disease or hemophili a).
10.History  of stroke or intracranial hemorrhage wit hin 6 m onths pri or to enrollment.
11.Known history  of human immunodeficiency  virus (HIV) or active infection wit h hepatit is C 
virus (HCV) or hepatit is B virus (HBV). Subjects who are posit ive for hepat itis Bcore 
antibody , hepat itis B surface antigen (HBsAg), or hepat itis C ant ibody  must have a negat ive 
polymerase chain react ion (PCR) resul t before enrollment. Those who are PCR posit ive will 
be excluded.
12.Major surgery  within 4 weeks of first dose of study  drug.
13.Any life -threatening illness, medical condit ion, or organ sy stem  dysfunct ion that, in the 
investigator’s opinion, could co mpro mise the subject’s safet y or put the study  outcom es at 
undue risk.
14.Current ly act ive, clinically significant cardiovascular dis ease, such as uncontrolled 
arrhy thmia or Cl ass 3 or 4 congest ive heart failure as defined by the New York Heart 
Associ ation Functional Classificat ion; or a history  of myocardial infarct ion, unstable angina, 
or acute coronary  syndrom e within 6 mo nths prior to enrollment.
15.Unable to swallow capsules/tablets or malabsorption syndrome, disease significantly 
affect ing gastrointest inal funct ion, or resection of the stomach or small bowel, symptomat ic 
inflammatory  bowel  disease or ulcerative co litis, or partial or complete bowel obstruction.
16.Concomitant use of warfarin or other vitamin K antagonists.
17.Requi res treatm ent wi th a strong cy tochrom e P450 (CYP) 3A inhibitor (see Appendix G).
18.Current ly act ive, clinically significant hepat ic impairment Child- Pugh Class B or C 
according to the Child Pugh classificat ion (Appendix K).
19.Lactating or pregnant.
20.Unwilling or unable to participate in all required study  evaluat ions and procedures.
21.Unable to understand the purpose and risks of the study  and to provi de a signed and dated 
inform ed cons ent form (ICF) and authori zation to use protected health information (in 
accordance with nat ional and local subject privacy regulat ions).
22.Uncontrolled autoimmune hemo lytic anemia or idiopathic thrombocy topeni a purpura, such 
as those subjects with a declini ng hemoglo bin level or platelet count secondary  to 
autoimmune destruction within the 4 weeks prior to first dose of study  drug, or the need for 
daily  prednisone >20 m g daily (or corticosteroid equivalent) to treat or control the 
autoimmune disease .
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 545. TREATMENT OF SUBJECTS
MRD Cohort
5.1. Treatment Allocation and Blinding
Eligible subjects will be enro lled to a pre -randomization phase and receive open -label ibrutinib 
capsules and venetoclax tablets (single -agent ibrutinib for 3 cy cles f ollowed by ibrut inib + 
venetoclax combinat ion treatment for at least 12 cycles). Subjects will then be randomized by 
two separate schemes according to MRD status.
Subjects who achieve confirmed MRD -negat ive response and who co ntinue ibrut inib will be 
rando mized to receive double blind study treatment wit
h either placebo or ibrutinib; Subjects 
who do not achieve confirmed MRD -negat iveresponse and who con tinue both study  drugs will 
be randomized to receive open label treatment e ither single -agent ibrutinib or ibrutinib + 
venetoclax combinat ion treatment. In each scheme, the randomization will be in 1:1 ratio and 
stratified by IGHV status .
5.2. Safety Run -inPeriod
Approximately  12 subjects will be enrolled in a Safet y Run-inPeriod, defined as the date of first 
dose of ibrutinib at Cycle 1 Day 1 thr ough the DLT eval uation peri od. The DLT evaluat ion 
periodis defined as the 5 -week venetoclax dose ramp -up in combinat ion with ibrutinib , plus an 
additional week of  follow-up (6 weeks total) . Enrollment will be held unt il safet y is assessed by 
the DRC in the first 6 evaluable subjects who complete the Safet y Run-in Period . Subjects will 
be considered evaluable for DLT assessment if they receive at least 85% of the combined 
therapy at the targeted doses during the DLT evaluation period , or if they experience a DLT af ter 
the first venetoclax dose. Subjects’ laboratory results and A Es will be reviewed by  the DRC. If 
≤1of the first 6evaluable subjects experience a DLT, the study  will cont inue. If 2 of the first 
6evaluable subjects experience a DLT, then the DRC will evaluate safet y in the next 3 evaluable 
subjects (9subjects total) . The study  will be deemed safe to proceed when 6 –9 subjects com plete 
the Safet y Run-in Period and if <33% ( ≤
1 of6 or ≤2 of 9) of subjects experience a DLT.
Enrollment will be staggered to no more than 3 subjects per week during the Safet y Run-in 
Period in order to minimize patient exposure and risk during this init ial run in period.
All subjects will be assessed for TLS risk prior to init iation of venetoclax. See Secti on7.1.1.9
and Section 7.1.1.10 for TLS ri sk assessment and prophylaxis respect ively. Any cas e of clinical  
TLS (See Appendix Hfor TLS cri teria) during the Safet y Run-in Period will trigge r a DRC 
review of that subject. The DRC will meet an d review safet y data after all subjects in the Safet y 
Run-in Period have ei ther discont inued therapy and/or have co mpleted the DLT evaluat ion 
period (venetoclax dose ramp-up pl us 1-week follow -up), then DRC may make a 
recommendat ion regarding dosing .
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 555.2.1. Dose- Limiting Toxicity (DLT)
Dose -limit ing toxicit ies (DLT) are defined as clinical TLS per the Howard Criteria ( Appendix I) 
or any new CTCAE Grade 3 or higher possibl y related non-hematol ogic or Grade 4 hematologic 
adverse event occurri ngduring the DLT evaluation peri od(defined as the 5-week venetoclax 
dose ramp -
upplus 1-week follow-up) with the addit ionalclarificat ionsbelow (which will be 
considered DLTs) : 
Non-hematol ogic
:
Grade 4 diarrhea and vo miting
Grade 3 nausea, vo miting or diarrhea despite maximum medical supportive care and 
persisting >3 days
Grade 3 fat igue persist ing>7 days
Grade 3 rash last ing>7 days that does not resolve with appropriate clinical m anagement
Hem atologic(per IWCLL Criteria , Appendix L):
Grade 4 neutropenia (ANC <500 µL) last ing for >7daysdurati on (irrespective of 
adequate growth factor support)
Grade 4 thrombocy topeni athat persi sts for >7days
Grade 3 thrombocy topeni a associated with clinically  significant bleeding
If 2 of the first 6 evaluable subjects experience a DLT, then the DRC will evaluate safet y in the 
next 3 evaluable subjects. If 3 or more of the 9subjects experience DLTs, the DRC may 
recommend the dose of the study  drug(s) to be de -escalated as shown in Table 1. However ,if 
DLTs occur at a lower dose of venetoclax, the DRC m ay recommend that the protocol  be 
amended to adj ust the venetoclax dose ramp-up (eg,starting dose or length of ramp-up). If 
modificati ons are m ade to the treatment schedule or dose to mit igate dose -limit ing toxicit ybased 
on the number of DLTs during the Safet y Run-inPeriod, safet y data will be further assessed in 
an addit ional 6 evaluable subjects ,until the DRC can make a reco mmendat ion(provi des 
recommended doses for the combinat ion). 
Table 1. Dose De - Escalation Schedule for Safety Run -in
Dose Level Ibrutinib Daily dose Venetoclax (Target dose)
0 420 mg 400 mg
-1 420mg 300 mg
-2 280 mg 300 mg
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 57Venetoclax: 
Orally once daily venetoclax , with 5-week dose ramp up, added to ongoing ibrutinib 
therapy  starting at Cy cle 4 and cont inuedfor at least 12 cy cles t ill completion of 
Cycle 16, utilizing the dose ramp - upschedule inSecti on 5.4.2.3 andFigure 1.
Figure 1. Venetoclax Dose Ramp -up
Venetoclax and ibrut inib shoul d be dosed together at the same time wit h a m ealand 
water.
○For subjects not able to swallow all ibrut inib capsules and venetoclax pills at the same 
time, administration should be co mpleted within a 60-minute window. On days of PK 
sample collect ion (C2D1 and C6D1), ibrutin ib and venetocl ax shoul d be administered 
at the sam e time or as close together in t ime as possible.
Dose m odificat ion for adverse events are specified in Section 5.4.2.5
5.3.2. Randomization Phase
Subjects will be rando mized in a 1:1 ratiobased on their MRD status (see below) after at least 
12cycles o f ibrutinib + venetoclax co mbination therapy. Subjects will be stratified by IGHV 
status in each rando mizat ion strata.
   
      
  
       
 
  
 
 
 
 
      
   
 
     
   
    
      
     
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 585.3.2.1. Randomization Phase –MRD -negative Subjects (Double -blind)
In the Rando mizat ion Phase, subjects who are MRD -negat ive will be rando mized in a blinded 
fashio n to ibrutinib or placebo .
Ibrutinib
Orally once daily ibrut inib 420 mg (3 capsules) cont inuously until disease progression
(post reintroduction when applicable) or unacceptable toxicit y
OR
Placebo
Orally once daily matching placebo capsules (3 capsules) continuously unt il confi rmed 
MRD -positive relapse, disease progressi on,or unacceptable toxicit y
5.3.2.2. Randomization Phase –MRD -Positive Subjects (Open -Label)
In the Rando mizat ion Phase, subjects who do not achieve confi rmedMRD -negat iveresponse
(MRD -positive) will be rando mized to receive open label treatment of I+V vs ibrut inib alo ne 
(venetoclax discont inued) .For subjects receiving I+V, ven etoclax can be administered for up to 
approximately  2 years per treatm ent course , until PDor unacceptable toxicit y,or until  this arm’s 
study closure , whichever i s earlier . Subjects continuing on ibrutinib at time of study  arm closure 
may be offered a separate extensio n study  to continue ibrut inib. The rando mizat ion will be 
stratified by IGHV status.
Ibrutinib + Venetoclax
Orally once daily ibrut inib 420 mg (3 capsules) cont inuously until disease progression or 
unacceptable toxicit y
plus
Orally  once daily venetoclax 400 m g (four 100 m g tablets) 
OR
Ibrutinib
Orally once daily ibrut inib 420 mg (3 capsules) cont inuously until disease progressi onor 
unacceptable toxicit y
Reintroduction of Ibrutinib or Venetoclax (MRD Cohort)
Upon confirmed MRD -positive relapse in MRD -negative rando mized subjects or confirmed 
disease progressi on by  IWCLL cri teria in any randomized subjects, ibrutinib an d/or venetocl ax 
may be reintroduced (Figure 2).
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 59Subjects who are receiving placebo treatment ,when MRD -positive relapse or disease 
progression are confirmed, may reintroduce oral daily  ibrut inib unt il disease progression or 
unacceptable toxicit y.
Subjects who are receiving oral daily  ibrutinib, when MRD -positive rel apse or disease 
progression are confirmed, may reintroduce oral daily  venetocl ax.Standard TLS risk assessment, 
venetoclax dose ramp up, and TLS management should be emplo yed at venetoclax 
reintroduction.
For t hose subjects who were treated with reduced dose(s) of ibrutinib or venetocl ax during the 
Pre-randomizat ion or Randomizat ion Treatm ent Phase , a dose adjust ment at the init iation of the 
Reintroduction period may be required , with escalati on to f ull dose as tolerated.
The primary  analysis for the MRD cohort will be performed at the point that all rando mized 
subjects have had the opp ortunit y to com plete at l east 12 cy cles o f rando mized treatment or 
follow-up, and at that time the Sponsor may elect to discont inue follow -upof specific MRD 
cohort treatm ent arms on PCYC -1142- CA. For subjects receiving I+V, venetoclax can be 
administered for up to approximately 2 years per treatment course , until PDorunacceptable 
toxicity,
oruntil these arm’s study closure , whichever is earlier . Subjects who are continuing on 
ibrutinib at thetime of study  arm closure may be offered a separate extensio n study  to continue 
ibrutinib.
Figu re2. Reintroduction of Ibrutinib or Venetoclax for MRD Cohort
5.3.3. Fixed Duration Cohort
Eligible subjects will receive s ingle -agent ibrut inib (420 mg/day PO) as lead-in treatment for 
3cycles. Starting at Cy cle 4, venetocl ax will  be initiated ( wit
h the standard dose ramp up to the 
target dose of 400 mg/d) utilizing the dose ramp-up schedule in Section 5.4.2.3 Figure 1and 
  
  
 
    
 
 
 
 
   
 
 
  
   
 
 
          
  
   
  
   
  
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 60added to the ibrutinib (420 mg/day  PO) regimen . The co mbinat ion will be administered
continuously for 12cycles ,until completion of Cycle 15unless discont inued early for toxicity.
Venetoclax and ibrut inib shoul d be dosed together at the same time each day  with a meal  
and water
○For subjects not able to swallow all ibrut inib capsules and venetoclax pills at the same 
time, administration should be co mpleted within a 60 -minute window. 
Dose m odificat ion for adverse events are specified in Section 5.4.2.5 .
NOTE: If dictated by emerging data from this study, the duration of combined ibrutinib + v enetoclax 
treatment may be modified to ensure appropria te risk -benefit is maintained, compared to historical 
controls and other emerging data. 
Reintroduction of Ibrutinib or Ibrutinib + Venetoclax (FD Cohort):
Subjects with confirmed progression per IWCLL criteriaafter com pletion of the fixed duration 
regimen can be retreated with continuous single agent ibrut inib until disease progression or 
unacceptable toxicit ybecause it is an established standard of care for treatment of relapsed CLL. 
For subjects that experi ence durable efficacy afterI+V (ie,time to progression after fixed 
durati on regimen is completed of>2 years), retreatment with theI+V fixed duration treatment 
regimen may be considered based on Investigator’s clinical discret ion and Medical Monitor’s 
approval . Retreatm ent is for 15 cy cles, PD or unacceptable toxicit y, whichever is earlier
(Figure 3).
For t hose subjects who were treated with reduced dose(s) of ibrutinib or venetocl ax during the 
fixed duration treatment phase , a dose adjust ment at the init iation of the Reintrod uction period
may be required, with escalat ion to full doses as tolerated .
 
      
       
    
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 62shoul d be taken to gether at the same t ime, with 8 ounces of water and with a meal (or within 
30minutes after the complet ion of a meal). For subjects not able to swallow all ibrut inib 
capsules and venetoclax tablet s at the same t ime, administration should be co mpleted withi n a 
60-minute window. The use of strong CYP3A inhibitors/inducers, and grapefruit ,Seville 
oranges , and starfruit shoul d be avoi ded f or the durati on of  the study  (Appendix G).
If a dose i s not taken at the scheduled time , it can be taken as soon as possible on the same day  
with a return to the normal schedule the following day . The subjec t shoul d not take extra 
capsules to make up the missed dose.
The first dose will be delivered in the clinic on Day 1, after which subsequent dosing is typically 
on an outpatient basis . On days of PK sample co llection (C2D1 and C6D1), ibrutinib and 
venetoclax should be administered at the sam e time or as close together in t ime as possible in the 
clinic. Ibrutinib will be dispensed to subject s in bottles at each visit. Unused ibrut inib dispensed 
during previous visits must be returned to the site and drug accountabilit y records ( Section12.8) 
updated at each visit. Returned capsules must not be redispensed to any one.
5.4.1.3. Overdose
Any dose of study  drug administered in excess of that specified in this protocol is considered to 
be an overdose. Signs and symptoms of an overdose that meet any SAE criterion must be 
reported as a SAE in the appropriate time frame and documented as clinical sequelae to an 
overdose.
There i s no specific expe rience in the m anagement of ibrut inib overdose in subjects . No 
maximum tolerated dose ( MTD) was reached in the Phase 1 study in which subjects received up 
to 12.5 mg/kg/day (1400 mg /day). Heal thy subjects were exposed up to single dose of 1680 mg. 
One heal thy subject experienced reversible Grade 4 hepat ic enzyme increases (AST and ALT) 
after a dose of 1680 mg. Subjects who ingested more than the recommended dosage should be 
closely  monitored and given appropri ate supporti ve treatment.
Refer to Section 11.4 for further inform ation regarding AE reporting. 
5.4.1.4. Dose Modification for Adverse Reactions
The dose of study  drug mustbe modified according to the dose modificat ionguidance in Table 2
andTable 3if any o f the following toxi cities occur:
Grade 3 or greater neutropenia wit h infect ion or fever
Grade 4 neutropenia ( ANC <500/µL) for more than 7 days. See Section 6.1for 
instructi ons regarding the use of growth factor support. 
Grade 3 thrombocy topeni a (platelets <50,000/µL) in the presence of clinically significant 
bleeding events.
Grade 4 thrombocy topen ia (platelets <25,000/µL).
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 63Grade 3 or greater n on-hematol ogical toxi city (Note: Table 3includes recommendations 
for cardi ac failure and cardi ac arrhy thmias)
Grade 2 cardiac failure ( Table 3)
Any other Grade 4 or unmanageable Grade 3 hematol ogical toxicity.
If clinically indicated, the use of anticoagulants or antiplatelet agents may be considered for the 
thromboprophylaxis of atrial fibrillation ( Section 6.2.4).
In the event that the invest igator feels deviat ion from the reco mmendat ions above is required, 
please consult the Medical Monitor.
Dose cha nges must be recorded in the Dose Administration eCRF . 
Study  treatm ent shoul d be 
discontinued in the event of an ibrut inib-related toxicit y requiring dose hol d lasting more than 
28days, unless reviewed and acknowledged by the Medi cal Monitor.
Note: Temporary withhol ding of sing le-agent ibrutinib for as litt le as 7 days can cause a transient 
worsening of disease and/or of const itutional symptom s. Study  drug shoul d be re -started as soon 
as clinically appropriate.
Table 2. Ibrutinib /PlaceboDose Modifications for Events not Specified in Table 3
Occurrence Action to be Taken 
FirstWithhold study drug until recovery to Grade ≤1 or baseline; may restart at original 
dose levela
SecondWithhold study drug until recovery to Grade ≤1 or baseline; may restart at 1 dose level 
lower
(ie, 280 mg/day for 420 mg/day dose )
ThirdWithhold study drug until recovery to Grade ≤1 or baseline; may restart at 1 dose level 
lower
(ie, 140 mg/day for 420 mg/day dose )
Fourth Discontinue study drug
a. When resuming treatment, restart at the same or lower dose based on benefit -risk evaluation. If the toxicity reoccurs, reduce 
daily  dose by  140 mg.
For requi red dose m odificat ion for hepatic impairment refer to Secti on5.4.1.6 and for 
concomitant treatment with CYP3A inhibitors refer to Secti on6.2.1.1 .
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 64Table 3. Ibrutinib/Placebo Dose Modifications for Cardiac Failure or Cardiac 
Arrhythmias
Events Occurrence Action
Grade 2 cardiac failureFirstHold study drug until recover y to Grade ≤ 1 or baseline; restart 
at 1 dose level lower (2 capsules [ie, 280 mg daily])
SecondHold study drug until recover y to Grade ≤ 1 or baseline; restart 
at 1 dose level lower (1 capsules [ie, 140 mg daily])
Third Discontinue study drug
Grade 3 cardiac arrhythmiasFirstHold study drug until recover y to Grade ≤ 1 or baseline; restart 
at 1 dose level lower (2 capsules [ie, 280 mg daily])a
Second Discontinue study drug
Grade 3 or 4 cardiac failure
Grade 4 cardiac arrhythmiasFirst Discontinue study drug
a. Evaluate the benefit -risk before resuming treatment.
5.4.1.5. Leukocytosis/Leukostasis
A high number of circulat ing malignant cells (>400,000/ µL) may confer increased risk o f 
leukostasis ; these subjects should be closely  monitored. Administer supportive care such as 
hydrat ion and/or leukophoresis as indicated. Ibrutinib may be tem porarily  held, and Medical 
Monitor shoul d be contacted.
5.4.1.6. Dose Modification for Hepatic -Impaired Subjects
Ibruti nib is metabo lized in the liver and therefore subjects with clinically significant hepat ic 
impairment at the time of screening (Child -Pugh Class B or C) are excluded fro m study  
participat ion. For subj ects who develop mild liver impairment while on study  (Child-Pugh 
ClassA), the recommended dose reducti on for ibrutinib /placebo is to a l evel of 280 m g daily 
(two capsules). For subjects who develop moderate liver impairment while on study  (Child -Pugh 
Class B), the recommended dose reduction isto a level of 140 m g daily  (one capsule). Subjects 
who develop severe hepat ic impairment (Child
-Pugh Class C) m ust hol d study  drug unt il 
resolved to moderate impairment (Child -Pugh Class B) or better. Monitor subjects for signs of 
toxicity and f ollow dose m odificat ion guidance as needed (Refer to Appendix K).
5.4.2. Venetoclax (ABT -199)
5.4.2.1. Formulation/Packaging/Storage 
Venetoclax tablets are provided as film coated tablets containing 10 mg, 50 mg, or 100 mg of 
venetoclax. 
The venetocl axtablets will be packaged in blister packs during init ial dose ramp up period and in 
high densit y polyethylene (HDPE) plast ic bottles thereafter to accommodate the study design. 
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 65Each container will be labeled as required per country  requi rements. Labels must rem ain affixed 
to the container.
The venetocl ax supplied in this study  is for invest igational use only, and must only be used 
within this study . All study  drug m ust be m aintained under adequate security  and stored under 
condi tions specified on the label unt
il dispensed for subject use or returned to Pharmacyclics or 
representative.
The tablets must be stored at a controlled room temperature of 15° to 25°C (59° to 77°F).
5.4.2.2. Prophylaxis and Management of Tumor Lysis Syndrome 
Venetoclax can cause rapid reduct ion in tumor and thus poses a risk for TLS in the init ial 5-week 
ramp-up phase. Changes in electroly tes consistent wi th TLS that requi re prom pt management 
can occur as early as 6 -8 hours following the first dose of venetoclax and at each dose increase. 
Therisk of TLS is a continuum based on mult iple factors, including tumor burden and 
comorbidi ties. Subjects with high tum or burden are a greater risk of TLS when init iating 
venetoclax. Reduced renal funct ionfurther increases the risk. The risk may decrease as tum or 
burden decreases with venetoclax treatment.
Subjects athigh risk of TLS (at least one lesio n ≥10 cm ; or at l east one lesio n ≥5 cm  plus
circulat ing lymphocy tes >25,000 cells/µL) will be hospitalized during the first 24 -48 hours of 
treatm ent for TL S monitoring and hydration. Hospitalizat ion shoul d be consi dered f or subj ects 
with medium risk of TLS and baseline creat inine clearance <80 mL/min. Hospitalizat ion for 
subjects lacking immediate access to a facilit y capable of correcting TLS prompt ly or fo r 
subjects who are otherwise considered at risk for TLS is allowed at the discret ion of the 
investigator.
In all subjects, p erform  tumor burden assessments, including radiographic evaluat ion (eg, CT 
scan), assess blood chemistry  (potassi um, uric acid, phosphorus, calcium, and creatinine ) and 
correct pre -exist ing abnormalit ies pri or to init iation of treatment with venetoclax in Cycle 4.
In all subjects, a ssess patient -specific factors for level of risk of TLS and provide prophylactic 
hydrat ion and ant i-hyperuri cemics to subjects prior to first dose of venetoclax to reduce risk of 
TLS. Emplo y more intensive measures (intravenous hydrat ion, frequent monitoring, and 
hospi talizati on) as overall risk increases . 
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 66Table 4. TLS Prophylaxis Based on Tumor Burden from Clinical Trial Data 
(consider all co- morbidities before final determination of prophylaxis and 
monitoring schedule)
Tumor BurdenProphylaxis Blood Chemistry Monitoringc,d
HydrationaAnti -
hyperuricemicsSetting and Frequency of
Assessments
Low All LN <5 cm AND 
ALC <25 x109/LOral (1.5 -2 L) AllopurinolbOutpatient
Pre-dose, 6 to 8 hours, 24 hours at 
first dose of 20 mg and 50 mg
Pre-dose at subsequent ramp-up 
doses
Medium Any LN 5 cm to 
<10cm
OR
ALC ≥25 x109/LOral (1.5 -2 L) 
and consider 
additional 
intravenousAllopurinolbOutpatient
Pre-dose, 6 to 8 hours, 24 hours at 
first dose of 20 mg and 50 mg
Pre-dose at subsequent ramp-up 
doses
Consider hospitalization for 
subjects with CrCl <80mL/min at 
first dose of 20 mg and 50 mg; s ee 
below for monitoring in hospital
High Any LN ≥10 cm
OR
ALC ≥25 x109/L
AND
any LN ≥5 cm Oral (1.5 -2 L) 
and intravenous 
(150-200 mL/hr 
as tolerated)Allopurinolb; 
consider 
rasburicase if 
baseline uric acid 
is elevatedIn hospital at first dose of 20 mg and 
50mg
Pre-dose, 4, 8,12 and 24 hours
Outpatient at subsequent ramp -up 
doses
Pre-dose, 6 to 8 , and 24hours
ALC = absolute lymphocyte count; LN = lymph node
a. Administer intravenous hydration for any patient who cannot tolerate oral hydration.
b.Start allopurinol or xanthine oxidase inhibitor 2 to 3 days prior to initiation of venetoclax.
c. Evaluate blood chemistries (potassium, uric acid, phosphorus, calcium, and creatinine); review in real time.
d. For subjects at risk of TLS, monitor blood che mistries at 6 to 8 hours and at 24 hours at each subsequent ramp -up dose.
A±30-minute window is acceptable for the 4 and 8hr chemistry assessments , a ±1 hr window is acceptable for the 12-hour 
chemistry assessments, and a ±2-hour window is acceptable for the 24 -hour chemistry assessment s
.
e. Hematology and Serum Chemistry may be collected up to 24 hours prior to each venetoclax ramp -up (Cycle 4Weeks 2-4 
and Cy cle 5 Week 1), to allow for flexibility in start of ramp -up dose.  Hematology and serum chemistr y can be drawn on 
day of dosing to allow for comparisons, but results are not required before dosing decision is made
Hydration: Ensure adequate hy dration pri or to initi ating therapy wit h venetoclax and throughout 
the ram p-up phase, especially the first day  of each ram p-up dose. Administer intravenous (IV) 
fluids as indicated based on overall risk of TLS or for those who cannot maintain adequate oral 
hydrat ion.
Anti
-hyperuricemic agents: Administer u ric acid red ucing agents ( eg, allopurino l).
Start 2-3days prior to init iation of venetoclax; consider continuing through the ramp -up phase . 
Laboratory Assessments:
Pre-dose: Assess blood chemistries (specifically creatinine, uric acid, potassium, phosphorus, 
and calcium) prior to init iating venetoclax to evaluate kidney funct ion and correct pre -exist ing 
hyperuricemia, hyperkalemia, hyperphosphatemia, or hy pocal cemia to norm allevels before 
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 67administering venetoclax. Reassess blood chemistries before starting each subsequent ramp-up 
dose of venetoclax.
Post-dose: For subjects at low or medium risk of TLS, monitor blood chemistries at 6 -8hours 
and at 24 hours after init iating ve netocl ax at the 20 m g and 50 m g doses. For subjects at high risk 
of TLS, m onitor bl ood chemistries in the hospital at 4, 8, 12 ,and 24 hours after init iating 
venetoclax at the 20 mg and 50 mg doses; subsequent ramp -up doses can be administered in the 
outpa tient setting wi th monitoring of blood chemistries at 6- 8 hours and at 24 hours after 
initiating venetoclax. Electrolyte abnormalit ies should be corrected prompt ly. The next dose of 
venetoclax should n ot be administered until the 24 -hour bl ood chemistry  results have been 
evaluated and hyperuricemia, hyperkalemia, hyperphosphatemia, or hy pocal cemia are corrected 
to norm al levels .
Hospitalization: Based on invest igator assessment of TLS risk, subjects at high risk of TLS 
requi re hospi talizati on on the day  of the first dose of venetoclax 20 m g and 50 m g doses for more 
intensive prophylaxis and monitoring through the first 24 hours. Subsequent ramp -up doses can 
be administered on an outpatient basis ;however ,hospitalization may be considered based on 
reassessment of risk. See Appendix Hfor TLS Ri sk Categori es and Appendix Jfor
Reco mmendat ions for Initial Management of Electroly te Abnorm alities and Prevent ion of Tum or 
Lysis.
5.4.2.3. Dose and Administration 
Venetoclax tablets aretaken orally once daily wit h a m eal and water. Venetoclax tablets should 
be swallowed who le and not chewed, crushed, or broken prior to swallowing. During cy cles wi th 
ibrutinib co mbinat ion dosing, ibrut inib and venetoclax should be taken together at the same time, 
with 8 ounces of water and with a meal (or within 30 minutes after the complet ionof a meal). 
For subjects not able to swallow all ibrut inib capsules and venetoclax tablet s at the same time, 
administration should be co mpleted wi thin a 60-minute window. If the subject misses a dose of 
venetoclax within 8 hours of the time it is usually taken, the subject should take the missed dose 
as soon as possible on the same day and resume the normal daily dosing schedule. If a subject
misses a dose by  more than 8 hours, the subject shoul d not take the missed dose and resume the 
usual dosing schedule the fo llowing day .
In cases of vo miting after taking venetoclax, no addit ional dose (tablets) should be taken that 
day. The next dose should be taken at the usual time the following day .
The first dose of venetoclax will be delivered in the clinic (or in the hospital depending on TLS 
risk category ) on Cy cle 4 Day 1. Seven doses of daily venetoclax must be taken at each dose 
level in the venetoclax dose ramp up, thus each level of the ramp up m ay requi re more than 
7days if doses are missed o rheld. Aftercompletion of the 5
-week dose ramp up, subsequent 
dosing is t ypically on an outpatient basis. On days of PK sample co llection (C2D1 and C6D1), 
ibrutinib and venetoclax should be administer ed at the same t ime or as close together in time as 
possible in the clinic. Venetocl axwill be dispensed to subject s in blister packs through the dose 
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 68ramp up period, and in bottl es at each subsequent visit. Unused venetoclax d ispensed during 
previous visi ts must be returned to the site and drug accountabilit y records ( Secti on 12.8) 
updated at each visit. Returned tablet s must not be redi spensed to a nyone.
Assess subject -specific factors for level of risk of TLS and provide prophylact ic hydration and 
anti-hyperuricemics to subjects prior to fi rst dose of venetoclax to reduce risk of TLS . 
Venetoclax will be administered orally once daily (QD) beginning with a dose ramp -up peri od.  
As shown in Figure 1,the init ial venetocl ax dose is 20 mg QD. After one week of treatment at 
20mg QD, the dose will be escalated to 50 mg QD fo llowed by  subsequent increases, each after 
one week, to 100 mg QD, 200 mg QD and the maximum dose of 400 mg QD. The 5 -week ramp -
up dosing schedule is designed to gradu ally reduce tumor burden (debulk) and decrease the risk 
ofTLS.All study  subject s will be categorized in Cycle 3 according to their risk for developing 
TLS. Their dose management including during the dose ramp -up peri od will be conducted in 
accordance wit h their risk for developing TLS (see Secti on 5.4.2.5 ) and may include dose delay 
and/or dose reduction as required for prophylaxis and management of TLS.
5.4.2.4. Overdose
There i s no specific antidote for venetoclax. For subjects who experience overdose, closely  
monitor and provi de appropri ate supportive treatment; during ramp -up phase interrupt 
venetoclax and mo nitor carefully for signs and symptoms of TLS a long wit h other toxicit ies (see 
Secti on 1.3.3andSecti on 5.4.2 ). Based on venetoclax large vo lume of distribut ion and extensive 
protein binding, dialysis is unlikely to result in significant removal o f venetoclax .
5.4.2.5. Dose Modification for Adverse Reactions
Dosing interruption and/or dose reductio n may be required. See Table 5for dose modifications 
for hematol ogic and other toxicit ies rel ated to venetoclax. For subjects who have had a dosing 
interrupti on greater than 1 week during the first 5 weeks of ramp -up phas e or greater than 
2weeks when at the daily dose of 400 mg, reassess for risk of TLS to determine if reinit iation 
with a reduced dose i s necessary ( eg, all or some levels o f the dose ram p-up schedule) .
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 69Table 5. Venetoclax Recommende d Dose Modifications for Toxicitiesa
Event Occurrence Action
Tumor Lysis Syndrome
Blood chemistry 
changes or symptoms 
suggestive of TLS (see 
Howard Criteria in 
Appendix I)Any Withhold the next day’s dose. If resolved within 
24-48hours of last dose, resume at the same dose.
For any blood chemistry changes requiring more than 
48hours to resolve, resume at a reduced dose (see
Table 6).
For any events of clinical TLS b, resume at a reduced 
dose following resolution (see Table 6).
Non-Hematologic Toxicities
Grade 3 or 4 non -
hematologic toxicities 1stoccurrence Interrupt venetoclax
Once the toxicity has resolved to Grade 1 or baseline 
level, venetoclax therapy may be resumed at the same 
dose. No dose modification is required. 
2ndand 
subsequent 
occurrences Interrupt venetoclax.
Follow dose reduction guidelines in Table 6when 
resuming treatment with venetoclax after resolution. A 
larger dose reduction may occur at the discretion of the 
investigator
Hematologic Toxicities
ANC <1000/µL with 
infection or fever; or 
CTCAE Grade 4 
hematologic toxicities 
(ANC <500/µL, WBC 
<1000/µL, platelet s 
<25,000/µL, life 
threatening anemia)1stoccurrence Interrupt venetoclax.
To reduce the infection risks associated with 
neutropenia, granulocyte -colony stimulating factor 
(G-CSF) m ay be administered with venetoclax if 
clinically indicated. Once the toxicity has resolved to 
ANC >1500/µL or baseline level, venetoclax therapy 
may be resumed at the same dose.
2ndand 
subsequent 
occurrence Interrupt venetoclax.
Consider using G -CSF as clinically indicated.
Follow dose reduction guidelines in Table 6when 
resuming treatment with venetoclax after resolution. 
Additional dose reductions may occur at the discretion 
of the physician.
Consider discontinuing venetoclax for subjects who require dose reductions to less than 100 mg for more than 2 weeks.
a. Adverse reactions were graded using NCI CT CAE version 4.03.
b. Clinical TLS was defined as laboratory TLS with clinical consequences such as acute renal failure, cardiac arrhythmias, or 
sudden death and/or seizures.
Table 6. Dose Modification for Toxicity during Venetoclax Treatment
Dose at Interruption, m g Restart Dose, m ga
400 300
300 200
200 100
100 50
50 20
20 10
a. During the ramp -up phase, continue the reduced dose for 1 week before increasing the dose.
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 70For requi red dose m odificat ion for concomitant treatment with CYP3A inhibitors refer to 
Secti on6.2.1.2 .
5.4.2.6. Management of Neutropenia
Nonclinical and clinical experience indicates that venetoclax may cause neutropenia. Subjects 
with a history  of neutropenia who have received mult iple pri or therapi es and/or have significant 
bone marrow involvement may be at a particularly high risk.
CTCAE Grade 3 or 4 ne utropeni a has been reported in pat ients treated with venetoclax. 
Com plete bl ood counts shoul d be m onitored throughout the treatment period. Dose interruptions 
or dose reductions are recommended for subjects with severe neutropenia. Supportive measures 
including antimicrobials for any  signs of infecti on and prophylactic use of growth factors 
(eg, G-CSF) should be considered.
5.4.2.7. Management of Hematologic Toxicities Other Than Neutropenia or 
Lymphopenia 
Venetoclax treatment should be wit hheld for any  CTCAE Grade 4 hematologic toxicit y. Once 
the toxicit y has reso lved to Grade 1 or baseline level (recovery ), venetocl ax may  be re -started at 
the sam e dose. If the toxicit y recurs, the dose reduction guidelines in Table 5shoul d be f ollowed 
when resuming study  treatm ent following resol ution. Addi tional dose reducti ons m ay occur at 
the discret ion of the physician.
5.4.2.8. Management of Non -Hematologic Toxicity
Venetoclax treatm ent shoul d be wi thheld for any  clinically  relevant CTCAE Grade ≥3 non -
hematol ogic toxici ty. Once the toxi city has resolved to Grade 1 or baseline level (recovery ), 
venetoclax may be re- started at the same dose.  If the toxicit y recurs, the dose redu ction 
guidelines in Table 5shoul d be f ollowed when resuming study  treatm ent following resol ution. 
Addit ional dose reductions may occur at the discreti on of  the physician.
5.4.2.9. Management of Decrease in Spermatogenesis
Venetoclax may cause a decrease in spermatogenesis. Male subjects considering preservation o f 
fertilit y shoul d bank sperm  before ini tiating treatm ent wi th venetocl ax.
5.4.2.10. Embryo -Fetal Toxicity
Base d on i ts mechanism  of action and findings in animals, venetoclax may cause embry o-fetal 
harm when administered to a pregnant woman. In an embryo -fetal study  conducted in mice, 
administration of venetoclax to pregnant animals at exposures equivalent to that observed in 
patients at the recommended dose of 400 mg daily  resul ted in post -implantation loss and 
decreased fetal weight. There are no adequate and well- controlled studies in pregnant woman 
using venetoclax. Advise females of reproductive potential to a void pregnancy during treatment. 
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 71If venetoclax is used during pregnancy or if the subject beco mes pregnant while taking 
venetoclax, the subject shoul d be apprised of the potential hazard to the fetus.
5.4.2.11. Immunization 
The safet y and efficacy  of immunizat ion with live or attenuated viral vaccines during or 
following venetoclax therapy  have not been studi ed. Imm unizati on wi th live virus vaccines is not 
recommended during treatment and thereafter until B- cell recovery.
5.5. Criteria for Permanent Discontinuation of Study Drug
Invest igators are encouraged to keep a subject who is experiencing clinical benefit in the study 
unless significant toxicit y puts the subject at risk or routine noncompliance puts the study  
outcom es at r isk. If a subject discont inues one study drug for reasons other than disease 
progression, the other study  drug shoul d be continued per protocol. Refer to Study  Design details 
in Secti on 3.1.1 and Secti on 3.1.2 .For a complete list of criteria for permanent discontinuation of 
study  treatm ent, re fer to Section 9.2.
AnEnd-of-Treatment Vi sit (Secti on8.7) is requi red for all subjects except for those subjects 
who have withdrawn full consent .
6. CONCOMITANT MEDICATI ONS/PROCEDURES
Concomitant therapies must be recorded from the time of ICF signing until 30 days after the last 
dose of study  drug.
6.1. Permitted Con comitant Med ications
Supportive medicat ions in accordance with standard practice (such as for emesis, diarrhea, etc.) 
are permitted and patient should receive full supportive care during study participati on (incl uding 
fluids and el ectroly te repl acement, and antibiot ics when appropriate). Use of neutrophil growth 
factors (filgrast im and pegfilgrastim) or red bl ood cell growth factors (ery thropoi etin)is 
permitted per inst itutional po licy and in accordance wi th the ASCO guidelines ( Smith 2006 )
except as outlined in Section 6.2below. Transfusio ns may be given in accordance with 
institutional policy.
After consultation wit h the Medical Monitor the foll owing m ay be considered; localized,
horm onal or bone sparing trea tment for non -B-cell malignancies, and localized radiotherapy  for 
medical condit ions other than the underlying B -cell malignancies.
Short courses ( <14 day s) of steroi d treatm ent for non -cancer related medical reasons ( eg, joint 
inflammat ion, asthma exacerb ation, rash, ant iemetic use ,and infusio n reactions) at doses that do 
not exceed 100 mg per day  of predniso ne or equivalent are permitted.
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 72Treatment for autoimmune cy topeni as are permi tted for <14 days at doses that do not exceed 
100mg per day  of predniso ne or equivalent .
6.2. Med ications to Be Used with Caution
A sample list of caut ionary medicat ions wi th ibrutinib and venetoclax is provided in
Appendix G.Refer to Table 7below for management of potential ibrutinib and ven etoclax 
interact ions wit h CYP3A inhibitors.
6.2.1. Drugs That May Alter Ibrutinib and/or Venetoclax Plasma Concentrations
6.2.1.1. Concomitant Use with Ibrutinib
Ibrutinib is metabo lized primarily by CYP3A 4. Avoi d co-administration with strong CYP3A or 
moderate CYP3A inhibitors and consider alternat ive agents with less CYP3A inhibit ion. Avoid 
grapefruit and Seville oranges during ibrut inib/placebo treatment, as these contain moderate 
inhibitors of CYP3A (see Secti on5.4.1.2 ).
If a strong CYP3A inhibitor must be used short -term (such as ant i
-infect ives for seven 
days or less), interrupt ibrut inib for the durati on of  inhibi tor use.
If a strong CYP3A inhibitor must be used, the benefit outweighs the risk, and longer term 
dosing is required ( for more than 7 days ),reduce ibrutinib dose to 140 mg for the 
durati on of  inhibitor use . 
oIf posaconazo le at higher doses (suspensio n >200 mg twice daily), or IV or 
delayed -release form ulations m ust be used, reduce ibrutinib dose to 140 mg for 
the duration of azo le use
If a moderate CYP3A inhibitor must be used, reduce ibrutinib to 280mg for the durati on 
of the inhibitor use.
oIf voriconazo le, or doses ≤200 mg twi ce daily  of posaconazol e suspensio n are 
requi red, reduce ibrut inib dose to 140 mg for the duration of inhibitor use.
No dose adjust ment is required in co mbinat ion with mild inhibitors.
Subjects should be monitored closely for signs of ibrutinib toxicit y
After di scontinuat ion of a CYP3A inhibitor, resume previous dose of ibrut inib
Avoid conco mitant use of strong CYP3A inducers ( eg, carbamazepine, rifampin, phenyto in, and 
St. John’s Wort) as these medications/products could decrease ibrut inib concentration s. Consider 
alternat ive agents with less CYP3A induct ion.
In vitro studies indicated that ibrut inib is not a substrate of P -glycoprotein (P -gp).
A list of commo n CYP3A inhibitors andinducers is provided in Appendix G
.For further 
inform ation, please refer to the current version of the ibrut inib IB.
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 736.2.1.2. Concomitant Use with Venetoclax
Concomitant use of venetoclax with strong CYP3A inhibitors at init iation and during 
ramp-up phase increases the risk for TLS. Concomitant use of venetoclax wit h strong 
CYP3A inhibitors at init iation and during ramp
-up phase is contraindicated. 
For subj ects who have com pleted the ram p-up phase and are on a steady  daily  dose of 
venetoclax, reduce the venetoclax dose by at least 75% when used concomitant ly with a 
strong CYP3A inhibitor. See Section 6.3.1 for prohibited CYP3A inhibitors.
Avoid conco mitant use of moderate CYP3A inhibitors with venetoclax. Consider 
alternat ive treatments. If a moderate CYP3A inhibitor must be used, reduce the doses of 
venetoclax by at least 50%. Monit or subjects more closely for signs of toxicit ies.
Avoid conco mitant use of strong CYP3A inhibitors with venetoclax. Consider alter native 
treatm ents. If a strong CYP3A inhibitor must be used, reduce the doses of venetoclax by 
at least 75%. Moni tor subj ects more closely for si gns of  toxicities.
Resume the venetoclax dose that was used prior to init iating the CYP3A inhibitor 2 to 3days 
after di scontinuati on of  the inhibi tor.
A listof commo n CYP3A inhibitors, CYP3A inducers , and cautionary medicat ionsis provided 
in Appendix G
.
For preliminary venetoclax PK resul ts wi th concurrent ibrut inibadministrati on, see 
Secti on1.3.2.1 . For further information, please refer to the current versio n of the venetocl axIB.
Table 7. Management of Potential Ibrutinib and Venetoclax Interactions with 
CYP3A Inhibitors
InhibitorsVenetoclax Ibrutinib
Initiation and
Ramp -up PhaseSteady Daily Dose
(After Ramp -up Phase) At any time
Strong CYP3A 
InhibitorContraindicatedAvoid inhibitor use, 
consider  alternate. If must 
be used, reduce the 
venetoclax dose by at least 
75%Avoid inhibitor use, consider 
alternative agent. If must be 
used, withhold ibrutinib for 
duration of inhibitor use, or 
reduce ibrutinib to 140 mg
Moderate 
CYP3A 
InhibitorAvoid inhibitor use, consider alternative agent. 
If must be used, reduce the venetoclax dose by 
at least 50%Avoid inhibitor use, consider 
alternative agent. If must be 
used, reduce ibrutinib to 280mg
6.2.2. Drugs That May Have Their Plasma Concentrations Altered by Ibrutinib
In vitro studies indicated that ibrut inib is not a substrate of P -glycoprotein (P -gp), but is a mild 
inhibitor. Ibrutinib is not expected to have systemic drug -drug interactions wit h P-gp substrates. 
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 74However, it cannot be excluded that ibrut inib could inhibit intest inal P -gp after a therapeutic 
dose. There is no clinical data available . Therefore, to avoid a potential interact ion in the GI 
tract, narrow therapeutic range P-gp substrates such as digoxin, should be taken at least 6 hours 
before or after ibrut inib. 
6.2.3. Drugs That May Have Their Plasma Concentrations Altered by Venetoclax 
Venetoclax is a P -gp and BCRP substrate as well as a P -gp and BCRP inhibitor and weak OATP1B1 
inhibitor in vitro. To avoid a potential interaction in the gastrointestinal tract, co -administration of 
narrow therapeutic index P -gp substrates such as digoxin with venetoclax should be avoided. If a 
narrow therapeutic index P -gp substrate must be used, it should be taken at least 6 hours before 
venetoclax.
6.2.4. Antiplatelet Agents and Anticoagulant s
Warfarin or vitamin K antagonists should not be administered concomitant ly wit h ibrut inib. 
Suppl ements such as fish oil and vitamin E preparations should be avoided .In an in vitro platelet 
funct ion study , inhibi tory effects of ibrutinib on collagen- induce d platel et aggregati on were 
observed. Use of ibrut inib in subjects requiring other anticoagulants or medicat ions that inhibit 
platelet functionmay increase the risk of bleeding . Subj ects wi th congeni tal bleeding di athesis 
have not been studied. For guidan ce on ibrutinib and the use of anticoagulants during 
procedures/surgeries see Secti on 6.4.
Subjects requiring the init iation of therapeutic ant icoagulat ion therapy  (eg,atrial fibrillat ion),
consider the risk s and benefits of cont inuing ibrut inib treatment. If therapeuti c anticoagul ation is 
clinically indicated, treatm ent wi th ibrutinibshould be held and not be restarted until the subject 
is clinica lly stable and has no signs of bleeding. Subjects should be observed closely for signs 
and symptoms of bleeding. No dose reduction is required when study  drug i s restarted.
In a drug -drug interaction study  in healt hy subjects, administration of a single dose of venetoclax 
with warf arin resulted in an 18% to 28% increase in C maxand AUC ∞of R-warfarin and 
S-warfarin. Because venetoclax was not dosed to steady state, it is reco mmended that the 
internat ional norm alized rati o (INR) be m onitored cl osely  in subjects receiving warfarin.
6.3. Prohibited Concomitant Medications and Products
6.3.1. Prohibited Concomitant Medications and Products for Ibrutinib and/or 
Venetoclax
Any non-study  protoco l related chemotherapy, ant i-cancer immunotherapy , experimental  
therapy , or radi otherapy  for the underlying B -cell malignancy are prohibited while the subject is 
receiving ibrutinib treatment.
Corti costeroi ds for the treatm ent of  the underlying malignancy areprohibited (Refer to 
Secti on6.1for further gui dance) .
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 75The Sponsor must be notified in advance (or as soon as possible thereafter) of any instances in 
which prohibited therapies are administered.
Use of strong CYP3A inhibit ors is contraindicated during venetoclax init iation and dose 
ramp-up. Subjects may not consume grapefruit or grapefruit products, Seville oranges (including 
marmalade containing Seville oranges) or starfruit within the 3 -day period pri or to the first 
venet oclax administration and unt il the last day of treatment is completed due to possible 
CYP3A mediated metabo lic interacti on.
6.4. Guidelines for Ibrutinib Management with Surgeries or Procedures
Ibrutinib may  increase ri sk of bleeding with invasive procedures or surgery . The fo llowing 
guidance shoul d be applied to the use of ibrut inib in the peri operative peri od for subject s who 
requi re surgi cal interventi on or an invasive procedure while receivin g ibrut inib:
6.4.1. Minor Surgical Procedures
For minor procedures (such as a central line placement, needle biopsy, lumbar puncture [other 
than shunt reservoir access], thoracentesis, or paracentesis) ibrut inib shoul d be held for at l east 
3days prior to the pro cedure and should not be restarted for at least 3 days after the procedure. 
For bone m arrow bi opsies that are performed while the subject is on ibrutinib, it is not necessary  
to hol d ibrut inib.
6.4.2. Major Surgical Procedures
For any  surgery  or invasive procedur e requiring sutures or staples for closure, ibrut inib shoul d be 
held at least 7 day s prior to the intervent ion and shoul d be held at l east 7 day s after the procedure 
and restarted at the discret ion of the invest igator when the surgical site is reasonably h ealed 
without serosanguineous drainage or the need for drainage tubes.
6.4.3. Emergency Procedures
For em ergency procedures, ibrutinib should be held as soon as possible and unt il the surgical site 
is reasonably healed or for at least 7 days after the urgent surg ical procedure, whi chever is 
longer.
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 767. STUDY EVALUATIONS
7.1. Description of Procedures
7.1.1. Assessments
7.1.1.1. ICF
The subject must read, understand, and sign the Institutional Review Board/Research Ethics 
Board/Independent Ethics Committee (IRB/REB/IEC) approved ICF confirming his or her 
willingness to participate in this study  before any study -specific screening proc edures are 
performed. Subjects m ust al so grant permission to use protected health information per the 
Health Insurance Portabilit y and Accountabilit y Act (HIPAA) . In addi tion, subjects must sign all 
approved ICF amendments per the site IRB/REB/IEC guidelin es during the course of the study .
7.1.1.2. Confirm Eligibility
All necessary  procedures and evaluat ions must be performed to document that the subject meets 
all of the inclusion criteria and none of the exclusion criteria prior to fi rst dose on Day  1
(Secti on4).
7.1.1.3. Medical History and Demographics
The subject’s relevant m edical history  through review of medical records and by  interview will  
be co llected and recorded. The medi cal history  collect ion peri od is defined as disease hist ory up 
until first dose. Concurrent medical signs and symptoms must be documented to establish 
baseline severit ies. A disease history , including the date of init ial diagnosis , Rai  staging 
(Appendix M)within 28 days of first dose with study  drug will be recorded.
7.1.1.4. Prior and Concomitant Medications
All active medications f rom the signing of ICF or at l east 14 days prior to first dose through 
30days after the l ast dose of study  drug will be documented. 
7.1.1.5. Adverse Events
The accepted regulatory  defini tion for an adverse event (AE)is provided in Secti on 11.1. The 
occurrence of AE from the time the ICF is signed unt il first dose shoul d be recorded under 
medical history  in the eCRF form. Allmedical occurrences after the first dose wi th study  drug
until 30 days after the last dose of study  drug that meet the AEdefinit ion must be recorded as 
AEs in the eCRF . Laboratory  abnorm alities designated clinically  significant by  the invest igator 
will also be docum ented as AEs. Addi tional important requi rements for AEand SAE reporting 
are explained in Section11.4.
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 777.1.1.6. Physical Examination
The Screening and End -of-Treatment physical examinat ion will include, at a minimum, the 
general appearance o f the subject, height (screening only) and weight, and examinat ion of the 
skin, eyes, ears, nose, throat, lungs, heart, abdomen, extremit ies, musculoskeletal system, 
nervous system, a nd lymphat ic system.
7.1.1.7. ECOG
The ECOG performance status is provided in Appendix F.Performance status will only  be 
collected unt il disease progression.
7.1.1.8. Vital Signs
Vital signs will  include bl ood pressure, heart rate, and body  temperature after the subject has 
rested in a sitting posit ion for at least 3 minutes .
7.1.1.9. Tumor Lysis Syndrome (TLS) Risk Assessment
At baseline and pri or to i nitiating venetoclax in Cycle 4 , all study  subjects will be assessed for 
risk of developing TLS. Ongoing risk of TLS should be assessed at all ramp up visits . The ri sk of  
TLS is a continuum based on mult iple factors, including comorbidit ies. Subjects with high tumor 
burden ( eg, any  lymp h node with a diameter ≥5 cm or high absolute lymphocyte count (ALC) 
[ALC ≥25x 109/L]) are at greater risk of TLS when init iating venetoclax. Reduced renal 
funct ion (creatinine clearance [CrCl] <80 mL/m in) further increases the risk. The ri sk may 
decrease as tum or burden decreases wit h venetocl ax treatm ent.
Tumor burden assessments, including radiographic evaluat ion (eg, CT scans) as well as blood 
chemistry  (creatinine, uri c acid, potassi um, phosphorus, and cal cium) assessments will be 
perform ed in all sub jects pri or to init iating venetoclax treatment .
Appropriate venetoclax dosing and management of subjects throughout their study treatment is 
guided by  their individual risk for developing TLS. Risk -based TLS prophylaxis and 
management measures are describe d in Secti on 5.4.2.2 .
7.1.1.10. Tumor Lysis Syndrome (TLS) Prophylaxis
For subjects at risk of TLS per invest igator assessment, the prophylaxis measures liste d in 
Secti on 5.4.2.2 shoul d be fo llowed and more intensive m easures (including hospitalizat ion) 
shoul d be empl oyed as overall risk increases. These measures should be performed prior to 
initiating therapy with venetoclax (2 -3 day s prior to first dose) and through out the ram p-up 
phase, especially  the first day  of each ram p-up dose. Refer to Schedule of Assessments 
(Appendix A, Appendix B, Appendix D, and Appendix E) for specific t imepo ints of 
assessments.
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 787.1.2. Laboratory
7.1.2.1. Hematology
Hem atology parameters will include acomplete blood count: white blood cells, red blood cells, 
hemoglo bin, hematocrit, platelets, neutrophils, bands, lymphocy tes, prolymphocy tes, aty pical 
lymphocy tes(if found on routine CBC review) , monocytes, eosinophils, and basophils. 
Hem atology samples will be collected and tested by  local laboratory .
7.1.2.2. Chemistry ( Serum)
Serum  chemistry  parameters will include :sodium, potassi um, chloride, bl ood urea ni trogen 
(BUN )/Urea, creatinine, glucose, calcium, total protein, albumin, AST, ALT, alkaline 
phosphatase, total bilirubin, LDH, phosphate /inorganic phosphorus , uric acid, m agnesium ,and 
bicarbonate. Chemistry samples will be co llected and tested by  local laboratory .
7.1.2.3. Coagulation Studies
Measurement of PT/INR and aPTT will be performed at Screening and Reintroduction using a 
local laboratory .
7.1.2.4. Hepatitis Serologies
Hepati tis serol ogies include hepat itis C ant ibody , hepatit is B surface ant ibody, hepat itis B core 
antibody , and hepat itis B surface ant igen (HBsAg) . If hepat itis B core antibody ,hepat itis B 
surface antigen, or hepatit is C ant ibody  is posit ive, then PCR to quantitate hepatit is B DNA or 
hepat itis CRNA must be performed and m ust be negative prior to enrollment . Subjects who are 
HBsAg posit ive are excluded. Hepat itis serologies will be co llected and tested by  local 
laboratory .
7.1.2.5. Serum β2-microglobulin
One blood sample for β2- microglobulin will be co llected and tested by  local laboratory  at C1D1 
and Cycle 10 for subjects in the FD Cohort (see Appendix B).
7.1.2.6. Pregnancy Test
Serum  pregnancy test will be required at Screening by  local laboratory  only for wom en of 
childbe aring potenti al. A urine pregnancy test will also be performed on Day  1 pri or to fi rst dose. 
If posi tive, pregnancy must be ruled out by  ultrasound to be eligible. This test may  be perf ormed 
more frequent ly if required by local regulatory  authori ties.
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 797.1.3. Diag nostics/Procedures
7.1.3.1. ECG
Electrocardiograms shoul d be performed at the investigator’s discret ion, parti cularly in subjects 
with arrhy thmic symptoms ( eg, palpitations, lightheadedness) or new onset dy spnea.
During visit s in which both ECGs and blood draws are performed, ECGs should be performed 
first.
At Screening, and if clinically indicated during the conduct of the study , 12-lead ECG will be 
done in triplicate (≥1 minute apart) in supine positio n after resting at least 10 minutes .
Abnorm alities noted at Scr eening should be included in the medical history .
7.1.3.2. CT/MRI
CT scans of the neck, chest, abdomen and pelvis will be performed throughout the study unt il 
disease progressi on is confirmed. MRI may  be used to eval uate si tes of  disease that cannot be 
adequately  imaged using CT (in cases where MRI is desirable, the MRI must be obtained at 
baseline and at all subsequent response evaluations). If MRI is required for any  other reason, this 
must first be discussed with the study  
Medical Monitor.
De-ident ified c opies of all imaging will be submitted to the Sponsor or designee .
7.1.3.3. Bone Marrow Biopsies and Aspirate 
Bone m arrow biopsy and aspirate samples will  be assessed locally and used for disease 
assessment by Invest igator , to confirm co mplete response, to confirm cytopen ic progression
attributable to CLL, and dist inguish autoimmune and treatment -related cy topenias. Bone m arrow 
components shoul d be evaluated for com plete response per 2008 IWCLL criteria including 
relative cellularit y for pati ent’s age, % lymphocy tes, and for the presence of Blymphoid 
nodul es.
In the MRD cohort: Bone marrow aspirate will be used for MRD assessment by  central  lab flow 
cytometry at C16D1 and visits with CR assessments . A Cycle 29 bone marrow aspirate should be 
obtained to confirm ongo ing MRD-negat ivity or attainment of new MRD -negativity(see below 
for addi tional details).
In the Fixed Duration cohort: Bone marrow aspirate will be used for MRD assessment by  central  
lab flow cy tometry atthe following: C10D1, visits with CR assessments, and t heC19D1
assessment (3-months after the complet ion of Cycle 15)(see below for addit ional details).
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 81At Screening (MRD and FD Cohorts)
A unilateral bone marrow biopsy must be obtained at Screening or up to 90days before 
enrollment for disease confirmat ion.
The fo llowing m aterial will be sent to the central laboratory :
Bone m arrow trephine (≥1 cm ) in a container of neutral buffered formalin (no other 
fixative allowed); NOTE: The bone marrow trephine will be split in half with one porti on 
toremain at the site for local assessment and the other half sent to the central laboratory
Bone m arrow aspirate
If insufficient marrow biopsy  material  or sli des are available to be submitted, high resolut ion 
images of the available representative slides should be acquired and submitted instead.
Copi es of  redacted bone marrow pathology reports for samples reviewed l ocally will  be collected 
and may  be reviewed by  the Sponsor and/or IRC. 
For Response Evaluation (MRD and FD Cohorts)
At every Overall  Response Assessment wi th a schedul ed BM evaluat ion(Table 9for MRD 
cohort and Table 10for FD cohort ), or if the subject’s physical examinat ion findings, l aboratory  
evaluat ions, and radiographic evaluat ions suggest that CR has been achieved in all response 
param eters at other time po ints (Suspected CR) , a bone marrow aspirate and biopsy  must be 
obtained to confirm the CR and to evaluate minimal resi dual disease.
Bone m arrow collected to confirm CR musthave minimal residual disease ( MRD )assessed by 
flow cy tometry on the aspi rate(see below for more details) . In cases where cytopenic 
progression is suspected, thebone marrow aspirate or biopsy  shoul d be used to dist inguish 
autoimmune and drug- related cy topeni as.
The fo llowing m aterial will be sent to the central laboratory :
Bone m arrow trephine ( ≥1 cm ) in a container of neutral buffered formalin (no other 
fixativeallowed) NOTE: The bone marrow trephine will be split in half wit h one porti on 
to rem ain at the si te for local assessment and the other half sent to the central laboratory
Bone m arrow aspi rate
If insufficient marrow biopsy  material  or sli des are availabl e to be submitted, high resolut ion
images of the available representative slides should be acquired and submitted instead.
Copi es of  redacted local bone marrow pathology reports for samples reviewed locally will be 
collected and may  be reviewed by  the Spon sor and/or IRC.
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 82Quantitative Minimal Residual Disease (MRD) Assessment by Central lab
A C1D1 PB sample will be submitted for MRD evaluat ion to establish a baseline 
immunoph enotypic profile. Starting fro m C7D1 on, MRD will be assessed by PB every  
3-12 cycles. Refer to Table 11and Table 12for MRD sample collect ion schedule.
In the MRD Cohort:
A bone marrow aspirate will be collected from all subjects for assessment of MRD status at 
Cycle 16 (±14 days) unless collected previously i n those wi th a docum ented CR and MRD -neg 
confirmed in BM after the start of study  treatm ent. An addit ional bone marrow aspirate should be 
collected at Cy cle 29 (±14 day s) in randomized subjects, andin anysubject with MRD -neg
conversio n in PB .
In subjects who consent, an addit ional bone marrow aspirate (after s uspected CR or C16) can be 
collected prior to randomizat ion to serially confirm MRD -negat ivity in the BM co mpartment.
Table 11. MRD Cohort: MRD Sample Collection Schedule
C1D1
C7D1 C10D1 C13D1C16D1
(±14 
days)C20-
C29D1    
Q3 
cycles
(±14 
days)C35D1 and 
Q6 cycles 
thereafterTo 
Confirm 
CRTo 
Confirm 
MRD+ 
RelapseEnd of 
Treatment
BM 
AspirateXaX 
(C29) 
a,b,cX
Peripheral 
BloodX X X X X X X X X X
a. Unless collected prior for CR assessment, and were MRD -neg in BM
b. Collected in randomized subjects, and in any subject w/ MRD -neg conversion in PB
c. ±14 day window applies to BM aspirate only
In the Fixed Duration Cohort:
A bone marrow aspirate will be collected from all subjects for assessment of MRD status at 
Cycle 10 and 3 m onths af ter the complet ion of Cycle 15 (ie, C19) . Bone m arrow assessments can 
be perform ed if needed to confirm CR.
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 84uninterrupted 7 days of dosing. In cases of dose reduction, p harmacokinet icsampling shoul d be 
delayed unt il completion of an uninterrupted 7 days of consistent dosing.
Pharmacokinet ics of ibrutinib and venetocl ax when dosed in combinat ion will be also 
determined at steady -state on Day  1 of Cycle 6at time -points specified in Table 13below.
Table 13. Pharmacokine tic Sample Schedule for Ibrutinib and Venetoclax
(MRD Cohort Only)
Study Drug 
PK CyclefDayPre-
dose 
PKc& 
MealdStudy 
Drug 
DoseeTime after ibrutinib or ibrutinib +venetoclax
1 hour
(± 15 min)2 hour 
(± 15 min)4 hour 
(± 30 min)6 hour
(± 30 min)8 hour
(± 1 h)
Ibrutinib 2a1 X X X X X X X
Ibrutinib &
Venetoclax6b1 X X X X X X X
a. Ibrutinib single -agent only steady -state PK
b. Ibrutinib and venetoclax combination steady -state PK
c
.Predose samples should be collected 30 minutes prior to the administration of ibrutinib (lead -in period) or ibrutinib and 
venetoclax (combination period)  
d. The meal to be completed within 30 minutes
e
. Ibrutinib/ venetoclax to be dosed 30 minutes after the start of the meal
f. PK should only be drawn when ibrutinib (C2), and ibrutinib with venetoclax (C6) are at steady state plasma levels. If any 
dose of ibrutinib and/or venetoclax were withheld in the week prior to C2D1, an d C6D1, then PK assessment should be 
rescheduled to the next study visit day after doses have been consistently administered for ≥1 week
Example:
Predose PK --7:00a
Breakfast ----7: 00a to 7:30a
Dose ---------- 7:30a
1 hr PK ------ 8:30a
2 hr PK ------ 9:30a
4 hr PK ------11:30a
6 hr PK ------ 1:30p
8 hr PK ------ 3:30p
Refer to the laboratory  binder for instructions on collect ing and processing these samples. On the 
day of the sampling visit, the clinical staff will instruct the subject to not take a dose before 
arrival at the clinic. Study  drug intake will be observed by clinic staff. The actual time (versus 
requested time) that each sample is drawn must be recorded using a 24 -hour format. The same 
clock shoul d be used for recording the time of dosin g.In the event that medical management is 
needed during the PK collect ion peri od, administration of concomi tant m edicat ions should be 
recorded .
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 85Pharmacokinetics Sample Collection for Subjects Treated with a Concomitant CYP3A 
Inhibitor While on Ibrutinib and/orVenetoclax Treatment
For subjects who must start a moderate or strong CYP3A inhibitor while on treatment with 
ibrutinib and /orvenetoclax, addit ional PK blood samples for evaluat ion of ibrut inib and /or
venetoclax exposure are requested approximately one week post -initiation of conco mitant 
CYP3A inhibitor . PK samples will be co llected at:
Pre-dose (If possible, sample should be obtained 22 -24 hours post the previous day’s 
dose and before dosing on the day  of the scheduled visit)
1 hour ± 15 min
2 hour s ± 15 min
4 hours ± 30 min
6 hours ± 30 min
8 hours ± 1 h
7.1.4.2.
7.1.4.3.
7.1.4.4.

IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 867.2. Efficacy Evaluations
Clinical d isease evaluat ions will include :
Physical examinat ion (which will focus on the presence/absence of size increase/ 
decrease in lymph nodes, liver, and spleen)
Hem atologic parameters by  CBC perform ed at a locallaboratory
Radiographic evaluat ion (CT or MRI scan of the neck, chest, abdomen, and pelvis)
Bone m arrow bi opsy  (as app ropri ate)if there is evidence of CR in the other response 
param eters
If study  drug i s held before a scheduled clinical response assessment ,then the response 
assessment can be delayed up to 4 weeks to allow re -initiation of study  drug for 2 weeks (or as 
long as possible) prior to performing scheduled response assessment.
Clinical e fficacy  assessments, for the purpose of the study  resul t analyses, will be performed by 
Invest igators .For response assessments not requiring a CT scan, the Invest igator should
evaluate response based on available clinical data, including physical e xaminat ion and laboratory  
resul ts.  For the MRD and Fixed Durat ion cohorts, imaging will be collected and stored centrally. 
The Sponsor may  utilize IRC for independent review of effic acy with details to be outlined in the 
separate IRC charter.

IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 87MRD Evaluat ions:
Samples for MRD analysis will be sent to a central laboratory  that has a validated flow 
cytometry assay that has a limit of detection of 10-4. MRD will be assessed in the fo llowing 
compartments:
Bone m arrow 
Peripheral  blood
7.2.1. Definitions
7.2.1.1. Measurable Disease
Subjects m ust have at l east 1 m easurable site of disease to participate in this study . Measurable 
sites of  disease are defined as lymph nodes, or lymph node masses. Ameasurable site of disease 
must be greater than 1.5 cm in the lo ngest di ameter. Measurem ent m ust be determined by  
imaging evaluat ion.
Tumor lesi ons that are si tuated in a previously irradiated area might or might not be considered 
measurable. If there are tumor lesions in previously  irradiated areas and progression has 
occurred, these lesions will be considered measurable. If tumor lesio ns in previously  irradiated 
areas are present and have been stable, then these lesio ns are not considered measurable. If tumor 
lesions in previ ously  irradiated areas progress during the study , then disease progression will be 
considered as having occurred provided progression is confirmed by the Investi gator .
All other sites of disease will be considered assessable. Assessable disease includes object ive 
evidence of disease that is identified by  radiological  imaging, physical examinat ion, or other 
procedures, as necessary , including peri pheral  blood counts.
7.2.1.2. Treatment -
Related Lymphocytosis
Treatment -related lymphocytosis, for t he purposes of this protocol, is defined as an elevat ion in 
blood lymphocy te count of ≥50% com pared to baseline and ≥5000/µL that occurs in the setting 
of unequivocal improvement in at least one other disease -related parameter including lymph 
node si ze, spleen size, hematologic parameters ( hemoglo binor platelet count), or di sease -related 
symptoms. Given the known mechanism of act ion of BCR -inhibit ing agents including ibrut inib, 
treatm ent-related lymphocy tosis i s an expected and frequent pharmacodynamic p heno menon 
observed wit h initiation (or re -initiation) of ibrut inib.
Response assessment in CLL subjects treated with novel agents has been clarified by the authors 
of the IWCLL 2008 guidelines and is outlined in the NCCN NHL 2016 guidelines, supporting 
that subjects with iso lated lymphocy tosis in the setting of improvement in other disease 
param eters shoul d not be consi dered to have clinical progressive disease or treatment failure 
(Cheson 2012).
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 887.2.1.3. Richter’s Tra nsformation
Richter's syndrom e(RS) is lympho matous transformat ion to a more aggressive histology  in a 
subject with CLL or SLL. RS is most often characterized by the development of high -grade NHL 
or Hodgkin’s disease. Symptoms of Richter’s transformat ion can incl ude new or progressive 
lymphadenopathy  or organom egaly , fever, l oss of wei ght and m uscle m ass, and other health 
probl ems. Ri chter's transform ation can be suggested by  a CT/PET scan, but should be confirmed 
with a biopsy ( eg, lymph node) demonstratin g the histol ogic transform ation.
7.2.1.4. Minimal Residual Disease (MRD)
MRD is a l ow-level o f disease that persi sts, and which is not detectable wit h routine imaging nor 
routi nelaboratory  tests ,but can be demo nstrated in PB or BM with more sensit ive flow 
cytometry assays.
7.2.1.4.1. MRD -Negativity 
MRD -negat ivity is defined as <1 CLL cell per 10,000 leukocy tes(<1 x 10-4), as assessed by flow 
cytometry of a peri pheral  blood (PB) or bone m arrow (BM) aspi ratesample. 
Confirm edMRD -negat ive response for randomizati on purposes requires MRD -negat ivity 
serially over at least 3 cycles, withnegat ivityin both BMand PB .Subjects who do not achieve 
confirmed MRD -negat ive status are not considered to have a MRD -negat ive response for 
rando mizat ion purposes in the MRD cohort . See Section 7.1.3.3 for MRD assessment schedule.
7.2.1.4.2. MRD -Positive Relapse (MRD Cohort Only)
MRD -positive relapse is defined as an increase in CLL cells ≥1 per 100 leukocytes (≥1 x 10-2) 
confirmed on two separate serial occasi ons, after a confirmed MRD -negat ive response , as 
assessed by  flow cy tometry  of a PB or BM aspi ratesample. 
7.2.2. Guidelines for Clinical Disease Evaluation
Object ive response will be categori zed as CR, CR wi th incomplete bone marrow recovery  (CRi), 
nodul ar parti al response ( nPR), parti al response (PR), PR wi th lymphocy tosis (PRL), stable 
disease (SD) , or progressive disease (PD) —all based upon IWCLL criteria ( Hallek 2008 , 
Hallek 2012, Hallek 2013 , Cheson 2012 ). All responses must be maintained for at least 2 months 
to be considered confirmed. CRs must be confirmed by bone m arrow bi opsy/aspirate. Response 
assessments on treatment arms will occur independent of ongoing therapy .For purpos es of this 
protocol , 2 m onths equals 2 cycles (56 days) with each cy cle equaling 28 days.
Given the known mechanism o f action of  BCR -inhibit ing agents, including ibrutinib, and the 
treatm ent-related lymphocy tosis frequently observed during treatment with ibrut inib, isol ated 
treatm ent-related lymphocytosis (in absence of other clinical, CT, or l aboratory  evidence of 
disease progressi on) will not be considered progressive disease. This approach is supported by  
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 89both the authors of the IWCLL 2008 and 2017 guidelines ( Hallek 2012 , Cheson 2012 ) and the 
NCCN.
The requi rement for each param eter at baseline to be evaluable throughout the study  is outlined 
in Table 14.
Table 14. Evaluable Parameter Requirements
Parameter Requirements to be Evaluable for Response
Measurable Disease (required for all subjects) Lymph Node >1.5cm
Splenomegaly Enlarged spleen
Hepatomegaly Enlarged liver
Absolute Lymphocyte Count (ALC) ≥4,000/µL
Platelets ≤100,000/µL
Absolute Neutrophil Count (ANC) ≤1500/µL
Hemoglobin ≤11.0 g/dL
7.2.3. Clinical Response Categories
Invest igator a ssessment of response should include physical examinat ion, radiographic imaging, 
and evaluat ion of blood and marrow (if applicable). For response assessments not requiring a CT 
scan, the Investigator should evaluate response based on available clinical dat a, including 
physical examinat ions and laboratory  resul ts.  Definit ion of response for CR, CRi, nPR, PR, PRL
and disease progression will be evaluated by  the cri teria listed in Table 15. Group A criteria 
define the tumor load and Group B criteria define the function of the hematopoietic system. 
Response must be confirmed by CT when available , and m ust last at l east2months without 
transfusio nal support or growth factor product to be considered a confirmed response.
7.2.3.1. Complete Response (CR)
All o f the following are required for a CR:
No si gnificant lymphadenopathy  (>1.5cm ) palpable on examinat ion or by  CT
No hepatospleno megaly on examinat ion or by  CT
No con stitutional symptoms ( ie, no fever >38ºC for ≥2 weeks, no ongoing unintent ional 
≥10% body  weight loss, no ni ght sweats for >1 month without other evidence o f 
infect ion, no fat igue interfering wit h work or usual activit ies)attributabl e to CLL.
Neutrophils >1500/µL, pl atelets >100,000/μL, and Hgb >11g/dL without recent growth 
factor or transfusio ns
ALC <4,000/µL
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 90Marrow aspirate and biopsy must be performed after all other criteria meet the definit ion of CR. 
To define a CR, the marrow sample must be at least norm ocellular for age, with less than 30% of 
nucleated cells being lymphocy tes. B -lympho id nodules should be absent.
In addit ion, in subjects with a CR, MRD should be performed on both peripheral blood and bone 
marrow aspirate to evaluate MRD status.
Tabl e 15. Criteria for Clinical Response Categories
Parameter CR PR PD
Group A
LymphadenopathyaNone; ≤1.5cm Decrease ≥50% increase ≥50%
Hepatomegaly None Decrease ≥50%increase ≥50% or 
new hepatomegaly
Splenomegaly None Decrease ≥50%increase ≥50% or 
new splenomegaly
Blood ly mphocy tes <4000/µLDecrease ≥50% 
from baselineincrease ≥50% 
over baselinec
MarrowbNormocellular, 
<30% ly mphocy tes, 
no B ly mphoid nodules.
Hypocellular defines CRid
in a patient with cytopenias
Group B
Platelet count >100,000/µL>100,000/µL or increase 
≥50% over baselineDecrease of ≥50% from 
baseline secondary to CLL
Hemoglobin >11 g/dL>11g/dL or increase 
≥50% over baselineDecrease of >2g/dL from 
baseline secondary to CLL
Neutrophils >1500/µL>1500/µL or increase 
≥50% over baselineN/A
a. Sum of the products of multiple lymph nodes (as evaluated by CT scans) or the longest diameter of one target lymph 
node
b. This parameter is not relevant for the PD category unless confirming cytopen ic progression.
c. Subjects with treatment -related lymphocytosis should remain on study treatment in the absence of other criteria for 
progressive disease (see Section 7.2.1.2 ).
d. Hypocelluar marrow is a C Riwhen peripheral blood cytopenias not meeting Group B criteria are present. CRi requires at 
least one abnormal Group B criteria.
Note: Group A defines the tumor load and Group B defines the function of the hematopoietic system
CR: all of the criteria need to be met and subjects have to lack disease related constitutional symptoms. 
Bone marrow and aspirate is required to confirm CR.
PR: At least two of the G roup A parameters must be met; with two exceptions: 1) subjects who only have 
abnormal lymph nodes at baseline, or 2) subjects who have only abnormal lymph node and abnormal lymphocyte 
count (ALC) at baseline. For these two exceptions, subjects will only n eed to meet the lymph node response 
criteria. 
In addition to the Group A criteria, all subjects must also have a response in at least one of the Group B criteria.
SD:the absence of PD and the failure to achieve a response.
PD: at least 1 of the above criteria from Group A or B are met or development of transformation to a more 
aggressive histology
Cross reference: Hallek 2008 ,Hallek et al. June 2012 e -letter , Halle k 2013
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 917.2.3.2. Complete Response with an Incomplete Marrow Recovery (CRi)
Com plete response with an inco mplete m arrow recovery  (CRi ) is defined as a CR with an 
incomplete recovery  of the subject’s bone marrow ,manifested by persistent cy topeni as. Subjects 
who have a CRi fulfill all criteria for a CR, but continue to have persistent anemia, 
thrombocy topenia, or neutropeni a. These cy topenias are due to drug toxi city in the bone marrow 
and are not due to any  evidence of CLL. If the marrow is hypocel lular, a repeat determinat ion 
shoul d be perform ed after 4 weeks, or when peripheral blood counts have recovered. However, 
this time interval should not exceed 6 months.
7.2.3.3. Nodular Partial Response (nPR)
Nodul ar parti al response (nPR ) is a response where subjects meet criteria for a CR, but the bone 
marrow bi opsy  shows that there are still B -lymphoid nodules, which may represent a clonal 
infiltrate. These nodules or aggregates are residual disease and therefore the subject is termed a n 
nPR. Immunohistochemistry  may be perform ed to define whether the nodules or aggregates 
comprise primarily  T cells, B cells other than CLL cells, or CLL cells. If nodules or aggregates 
are not composed of CLL cells, a CR can be documented provided all oth er cri teria are m et.
7.2.3.4. Partial Response (PR)
At least two of the fo llowing parameters must be met; with two except ions: 1) subjects who only 
have abnorm al lymph nodes at baseline, or 2) subjects who have only  abnorm al lymph node and 
abnorm al lymphocy te count (ALC) at baseline. For these two exceptions, subjects will only need 
to meet the lymph node response criteria. 
≥50% decrease in the sum products of up to 6 lymph nodes, a ≥50% decrease in the 
longest di ameter of the single lymph node, or normalizat ion oflymphadenopathy  when 
compared to baseline.
○With no new enlarged lymph nodes by  physical  examinat ion or CT AND no increase 
in any lymph node by  CT. Note :  In a small lymph node <2 cm, an increase of less 
than 25% i s not considered to be significant.
When a bnorm al, a ≥50% decrease in the enlargement of the spleen and/or liver fro m 
baseline or normalizat ion by CT
If abnorm al a ≥50% drop in lymphocy te coun t from baseline or ≤4000/µL
In addit ion to the criteria above, the subject must also have a response in at least one of the 
following evaluable criteria independent of growth factor support or transfusio n.
Neutrophils >1500/µL or ≥50% improvement over baseline
Platelets >100,000/μL or ≥50% improvement over baseline
Hgb >11 g/dL or ≥50% improvement over baselin e
* Note: For criterion to be considered inresponse evaluat ion, it must have been evaluable at 
baseline
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 927.2.3.5. PR with Lymphocytosis (PRL)
Subjects achieve all PR criteria with the except ion of  lymphocy te cri teria.
7.2.3.6. Stable Disease (SD)
Not meet ing criteria for CR , CRi, nPR, PR, PRL, or progressive disease.
7.2.3.7. Progressive Disease (PD)
A CT scan is required to evaluate all cases of suspected progressive disease for this protocol 
regardl ess of the m odali ty of disease progression ( eg, lymph node, lymphocy tosis, or 
transf ormati on). Progressive disease requires at least ONE of fo llowing:
New enlarged nodes >1.5cm, new hepatomegaly  or splenom egaly; or other organ 
infiltrates
≥50% increase fro m nadir in exist ing lymph node (must reach >1.5 cm in the longest 
diameter) or ≥50% increase fro m nadir in sum o f product of diameters of mult iple nodes
≥50% increase fro m nadir in enlargement of liver or spleen
≥50% increase fro m the baseline ALC count and at least 5 x 109/L
New cy topeni a (hemoglobin or platelets) attributable to CLL. The progression of any 
cytopeni a (unrelated to autoimmune cy topenia, drugs, or bleeding), as documented by  a 
decrease of Hgb levels fro m baseline by more than 20 g/L (2 g/dL) or to less than 100 g/L 
(10 g/dL) and lower than baseline, or by  a decrease of pl atelet counts from  baseline by 
≥50% or to less than 100 × 109/L (100,000/μL) and lower than baseline in the presence o f 
active CLL, defines disease progression ; a marrow biopsy must demonstrate an infiltrate 
of clonal CLL cells if no other evidence of dis ease progressi on is present on CT scan.
Transformat ion to a m ore aggressive histology  (eg, Richter’s Transformat ion). 
Whenever possible, this diagnosis should be established by biopsy.
Suspected progressive disease (eg,by PE or ALC) must be confirmed by a serial  exam  at least 
2weeks later , and confirmed by imaging .
7.2.4. Hematological Improvement
Hem oglobin and pl atelet counts will  be evaluated.
7.2.5. Radiographic Images Assessment
Radiological efficacy  assessments, for the purpose of the study  resul t analys es, will be performed 
by the Invest igator .For the MRD and Fixed Durat ion cohort s, ima gingwill be collected and 
stored centrally. The Sponsor m ay utilize IRC for independent review of efficacy  withdetails to
be outlined in the separate IRC charter .
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 93The baseline disease assessment will include all areas of known and suspected disease with use 
of the m ost appropri ate and reproducible radio logical  technique.
Radiological imaging by CT wi th contrast is required and m ust include the neck, chest, 
abdo men, and pelvis. S ubjects who are intolerant to IV CT contrast agents will have CT scans 
perform ed wi th oral contrast. When possible, all subjects should have radiographic tumor 
measurements performed at the participating study center or an acceptable alternate imaging 
facility using an i dentical  imaging protocol  and similar equi pment. The sam e imaging equipment 
shoul d be utilized for all scans whenever possible. The same radiologist should be assigned to 
read all the scans for a given subject throughout the study  as much as possible.
Magnet ic resonance imaging (MRI) may be used to evaluate non -target lesio ns that cannot be 
adequately  imaged using CT (in cases where MRI is desirable, the MRI must be obtained at 
baseline and at all subsequent response evaluations). If MRI is r equired for any  other reason, this 
must be discussed with the study  Medical Monitor first.
CT scans will be performed unt il disease progression regardless of whether or not the subject 
remains on treatm ent. In the event disease progressio n is suspected due to physical examinat ion 
or laboratory  test, a CT scan must be performed to confirm disease progression.
There m ust be radi ographically measurable disease at Screening (at least one lymph node 
>1.5 cm in the lo ngest di ameter) as outlined in Secti on 7.2.2 . If the sole lesio n lies within the 
field of prior radiotherapy , there m ust be evi dence of di sease progressi on in that lesio n.
Up to 6 measurable lymph nodes (target lesio ns >1.5 cm in the lo ngest diameter), clearly  
measurable in 2 perpendicular dimensio ns, will be fo llowed as target l esions f or each subject. 
Measurable sites of disease should be chosen such that they  are representative of the subject’s 
disease. In addit ion, select ion of targe t lesions shoul d be f rom as disparate regi ons of the body  as 
possible when these areas are significant ly involved. If addit ional lesions are present but are not 
included in the target lesio n assessment, they  can be added as non -target l esions followed 
throughout the study.
The cranial -caudal measurement of the spleen and lo ngest di ameter of the liver will be assessed 
at Screening and all subsequent response evaluations .
7.3. Suspected Disease Progression
The schedule of assessments is provided in Appendix Aand Appendix B.Any suspected case of 
disease progressi on will prom pt proc edures performed in a Suspected Disease Progression visit 
(Secti on8.5). Disease progression should be confirmed with a CT scan (or MRI, if CT is 
contraindicated) and should be reported to the S ponsor within 24 hours of di scovery . If disease 
progression is suspe cted based on the results of a single examinat ion or a single laboratory  
param eter, thi s finding shoul d be confirmed by  a subsequent eval uation at least 2 weeks later and 
confirmed by  imaging .
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 94Study  treatm ent shoul d be cont inued and new ant i-cancer therapy withheld , if clinically 
appropriate, until disease progression is confirmed by the Invest igator . Subj ects shoul d cont inue 
to adhere to all study -related procedures including response evaluat ions and procedures to 
confirm disease progression unt il clinical progressive disease is confirmed by theInvest igator . 
When disease progression has been confirmed by the Invest igator , study  treatm ent shoul d be 
discontinued.
If there is uncertaint y regarding whether there is disease progression, the subject should cont inue 
study  treatm ent and remain under close observat ion (eg, evaluated at 2 -4 week intervals). 
Transient worsening of disease during temporary  interruption of study  therapy  (eg, for drug -
related toxi city, intercurrent illness, or surgery ) may not indicate d isease progression.  
7.4. Sample Collection and Handling
The actual  dates and times of sample co llection must be recorded in source documents for 
transcri ption to the eCRF or laboratory  requisi tion form. Refer to the Schedule of Assessments 
(Appendix A, Appendix B,Appendix C,Appendix D, and Appendix E) for the timing and 
frequency  of all sam ple collect ions.
Instructi ons for the collect ion, handling, and shipment of samples are found in the Laboratory  
Manual.
8. STUDY PROCEDURES
8.1. Screening Period
Screening procedures will be performed up to 30 days prior to init iation of study  drug, unl ess 
otherwi se specified. All subjects must first read, understand, and sign the IRB/REB/IEC -
approved ICF before any study -specific screening procedures are performed. All study  tests and 
procedures should be performed at the study  center at whi ch the subject was enrolled and will be 
receiving treatment. After signing the ICF, and bein g deemed eligible for entry , subjects m ay be 
enrolled in the study .
8.1.1. Screening Visit
The fo llowing procedures will be performed at the Screening Visit within 30 days prior to 
enrollment unless otherwise noted:
Obtain signed, written informed consent
Medical history  including demographic information 
Perform  a com plete physical examinat ion, including height and weight (may  use pri or 
height measurement if available in source documents)
Evaluat ion of ECOG performance status
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 95Obtain vital signs (including blood p ressure, heart rate, and body  temperature) after the 
subject has rested in the sitting posit ionfor at least 3 minutes
Obtain triplicate 12 lead ECG ( ≥1 minute apart) after the subject has been in a supine 
position and resting for at least 10 minutes.
Reco rd concomitant medicat ion history  including over -the-counter drugs, vitamins and 
herbs 
Adverse events (record as Medical History  on eCRF form)
Imaging by CT or other modalit y as described in Secti on 7.1.3.2 (if not perform ed wi thin 
6weeks prior to enrollment )
Obtain a bone marrow aspirate and biopsy (if not performed wit hin 90 days prior to
enrollment )(local and central  labs[MRD Cohort ]; local la bs [FD Cohort])
Obtain blood specimens for the fo llowing laboratory  tests:
○Hem atology
○Serum  chemistry  (including creat inine clearance)
○Coagulation panel (PT/INR, aPTT)
○Hepati tis serol ogies 
○Obtain serum pregnancy test for women of childbearing potential on ly
8.2. MRD Cohort
For the MRD cohort, the study  is divided into a Screening Phase, a Pre -randomizat ion Treatm ent 
Phase, a Rando mizat ion Phase, and a Post -PD Follow- up Phase. The Schedule of Assessments 
(Appendix A) summarizes the frequency and timing of efficacy , PK,  and safet y 
measurements applicable to this study . The timing of all visits will be based on using Cycle 1 
Day 1 (C1D1) as the anchor visit and all subsequent visits should use the C1D1 date as the basis 
for scheduling.
MRD Cohort: Pre -Randomization Treatment Phase
Refer to the Schedule of Assessments ( Appendix A) for a com plete list of procedures to be 
perform ed at each scheduled study  visit.
Following com pletion of the Screening Visit and once eligibilit y has been confirmed (per 
inclusio n/excl usion criteria), subjects will init iate ibrutinib treatm ent. Venetoclax will be added 
to ibrut inib treatment and init iated after completion of 3 cycles of ibrut inib. The ven etoclax dose 
will be ramped up over 5 weeks per standing dosing recommendations (see Section5.3.1 for 
ibrutinib and ven etoclax dosing).
Subjec ts who are unable to complete at least 12 cycles of combinat ion therapy  will not be 
eligible for Rando mizat ion but will continue to follow the same visit schedule unt il disease 

IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 96progression. After disease progression subjects will enter the Post -PD Follow up Phase 
(Section8.8).
8.2.1. Treatment Visits
8.2.1.1. Cycle 1 Day 1 ( C1D1 ) Visit
Pre-Dose
The fo llowing procedures will be performed prior to dosing (within 3 days) of the C1D1 Visit. 
Please note, C1D1 Visit procedures done at Screening will not need to be repeated if done 
within 3 days of first dose with study drug.
Confirm eligibilit y (per inclusio n/exclusio n criteria) and enro ll subject . Dosing should 
occur wi thin 3 days of confirmat ion.
Adverse events
Physical examinat ion
Vital signs
ECOG performance status
Concomitant medicat ions
Hem atology
Serum  chemistry  (includ ing creat inine clearance)
Tumor Lysis Risk assessment ( use Screening CT and C1D1 ALC. see Appendix Hfor 
risk assessment categories )

IGHV (if IGHV sample is not informat ive for any  reason, another peri pheral  blood 
sample should be drawn and sent to the central lab at the next appropriate timepo int)
FISH panel
Kary otype
Buccal Swab
MRD in peripheral blood
Perform  urine pregnancy  test f or wom en of childbearing potential only
Dosing and Post First Dose
In-clinic administration of ibrut inib 
Dispense ibrut inib for offsi te use and provi de study  drug com pliance instructions

IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 978.2.1.2. Cycles 2 and 3 Visits
Pre-Dose
The fo llowing procedures will be performed on Day 1 (±3 days) of each cycle (except for 
CT/MRI) : 
Adverse events
Concomitant medicat ions
Study  drug com pliance review
Physical exam
Vital signs
ECOG
CT/MRI (to assess response and lymph node sum of the product of the diameters [ SPD]
for TLS ri sk assessme nt, Cycle 3 only –to be obtained as close to the beginning of 
Cycle 4 as possible, while still allowing for appropriate TLS risk -guided interventi ons 
including hospi talizati onif appropriate )
Hem atology
Serum  chemistry  

Pharmacokinet ics sample (Cycle 2 only. See Section 7.1.4.1 for Pharm acokinet ics 
Sample Collect ion Schedule)
Dosing and Post Dose
In-clinic administrati on of  ibrutinib(Cycle 2 only)
Collect ion of post dose pharmacokinetics samples per Section 7.1.4.1 (Cycle 2 only)
Dispense ibrut inib for offsi te use and provi de study  drug com pliance instructions
8.2.1.3. Cycle 4 Visits
8.2.1.3.1. Pre-Cycle 4 (Pre-initiation of Venetoclax)
The fo llowing procedures will be performed 2- 3 days (±3 day s) prior to Cy cle 4:
Overall response assessment
Hem atology
Serum  Chemistry
Tumor Lysis Risk assessment (see Appendix Hfor risk assessment categories )
Tumor Lysis Syndrom e prophylaxis (see Section 5.4.2.2 for prophylaxis schedule based 
on risk)

IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 98The fo llowing procedures will be performed 1 day  prior to Cycle 4:
Tumor Lysis Syndrom e prophylaxis (see Section 5.4.2.2 for prophylaxis schedule based 
on risk)
8.2.1.3.2. Cycle 4 Week 1Day 1
Pre-Dose
The fo llowing procedures will be performed on Day  1 (±3 days) of Cycle 4, Week 1:
Adverse events
Concomitant medicat ions
Study  drug com pliance review
Physical exam
Vital signs
ECOG
Hem atology 
Serum  chemistry  
Creatinine clearance (Cockcroft -Gault)
Tumor Lysis Risk assessment (see Appendix Hfor risk assessment categories )
Tumor Lysis Syndrom e prophylaxis (see Section 5.4.2.2 for prophylaxis schedule based 
on risk, venetocl ax administration setting, and frequency o f serum  chemistry  monitoring 
assessments )
  assays
Dosing and Post First Dose of Venetoclax
In-clinic administration of ibrut inib
In-clinic administration of venetocl ax20 m g for low and m edium risk TLS subjects
Consider hospitalization for first dose of ven etoclax 20 m g in medium risk TLS subjects 
with a CrCl  < 80 m L/min
In-hospi tal administrati on of  first dose of ven etoclax 20 m g for high risk TLS subjects
Dispense ibrut inib and venetoclax for offsite use and provide study  drug com pliance 
instructi ons
8.2.1.3.3. Cycle 4 Week 1 Day 2
Pre-Dose
Adverse events
Hem atology 
Serum  chemistry  

IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 99Tumor Lysis Syndrom e prophylaxis (see Section 5.4.2.2 for prophylaxis schedule based 
on risk and frequency  of serum  chemistry  monitoring assessments)
8.2.1.3.4. Cycle 4 (Week 2 –Week 4 ) Visits
The fo llowing procedures will be performed on Day 1 (±3 days) of Cycle 4, Weeks 2, 3, and 4
(coincides wit h venetoclax standard dose ram p-up of 50 m g (W2D1), 100 mg (W3D1 ), and 
200mg (W4D1)
Pre-
Dose
Adverse events
Concomitant medicat ions
Study  drug com pliance review
Physical exam
Vital signs
ECOG
Hem atology 
Serum  chemistry  
Creatinine clearance (Cockcroft -Gault)
Tumor Lysis Syndrom e Risk assessment (see Appendix Hfor risk assessment categories )
Tumor Lysis Syndrom e prophylaxis (see Section 5.4.2.2 for prophylaxis schedule based 
on risk and frequency  of serum  chemistry  monitoring assessments)
Dosing and Post -Dose
In-clinic administration of venetoclax 50 m g(Week 2), 100 mg (Week 3) and 200 mg 
(Week 4) for low and m edium  TLS risk subjects
Consider hospitalization for first dose of ven etoclax 50 m g in medium risk TLS subjects 
with a CrCl  < 80 m L/min
In-hospi tal administrati on of  first dose of ven etoclax 50 m g dose at week 2 for high risk 
TLS subjects ; in-clinic administration of venetoclax 1 00 m g (Week 3) and 200 mg 
(Week 4) for high ri sk TLS subjects
Dispense venetocl ax for off site use and provi de study  drug com pliance instructions
8.2.1.3.5. Cycle 4 Week 2 Day 2
Pre-Dose
Adverse events
Hem atology 
Serum  chemistry  
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 100Tumor Lysis Syndrom e prophylaxis (see Section 5.4.2.2 for prophylaxis schedule based 
on risk and frequency  of serum  chemistry  monitoring assessments)
8.2.1.4. Cycle 5 Visits
8.2.1.4.1. Cycle 5 Week 1and Week 3 Visit s
Pre-Dose
The fo llowing procedures will be performed on Day  1 (±3 days) of Cycle 5, Week 1 and 
Week 3:
Adverse events
Concomitant medicat ions
Study  drug com pliance review
Physical exam
Vital signs
ECOG
Hem atology 
Serum  chemistry  
Creatinine clearance (Cockcroft -Gault)
Tumor Lysis Syndrom e Risk assessment (see Appendix Hfor risk assessment categories)
(Week 1 Only)
Tumor Lysis Syndrom e prop hylaxis (see Section 5.4.2.2 for prophylaxis schedule based 
on risk, venetocl ax administration setting, and frequency o f serum  chemistry  monitoring 
assessments) (Week 1 Only)
Dosing and Post -Dose
In-clinic administratio n of venetoclax
Dispense ibrut inib and venetoclax for offsite use and provide study  drug com pliance 
instructi ons(Week 1 only)
8.2.1.5. Cycle 6 
–Cycle 9 Visits
Pre-Dose
The fo llowing procedures will be performed on Day  1 (±3 days) of Cycles 6, 7, 8, and 9 :
Adverse events
Concomitant medicat ion
Study  drug com pliance review
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 101Physical exam
Vital signs
ECOG
Hem atology 
Serum  chemistry  
Overall response assessment (by  PE/CBC Cycle 7only)
MRD in peripheral blood (Cycle 7 only )
  assays 
Pharmacokinet ics sample (Cycle 6only. See Section 7.1.4.1 for Pharm acokinet ics 
Sample Collect ion Schedule)
Dosing and Post -Dose
In-clinic administ ration of  ibrutinib (Cycle 6only)
In-clinic administration of venetoclax (Cy cle 6only)
Collect ion of post dose pharmacokinetics samples per Section 7.1.4.1 (Cycle 6only)
Dispense ibrut inib and venetoclax for offsite use and provide study  drug com pliance 
instructi ons
8.2.1.6. Cycle 10 & Cycle 13 Visits
Pre-Dose
The fo llowing procedures will be performed on Day  1 (±3 days) of Cycles 10and13 :
Adverse events
Concomitant medicat ions
Study  drug com pliance review
Physical exam
Vital signs
ECOG
Hem atology 
Serum  chemistry  
CT/MRI (Cy cle 10only)
Overall r esponse assessment 
MRD assessment (in peripheral blood)
  assays 

IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 102Post-Dose
Dispense ibrut inib and venetoclax for offsite use and provide study  drug com pliance 
instructi ons
8.2.1.7. Cycle 1 6Day 1 Visit
Pre-Dose
The fo llowing procedures will be performed on Day  1 (±3 days) of Cycle 16:
Adverse events
Concomitant medicat ions
Study  drug com pliance review
Physical exam
Vital signs
ECOG
Hem atology
Serum  chemistry
CT/MRI
Overall response assessment
Bone m arrow bi opsy  (unless co llected prior for CR assessment, and confirmed 
MRD -negat ive in BM)
MRD assessment (bone marrow aspirate and peripheral blood ). Bone m arrow aspirate 
can be drawn ±14 days fro m C16D1.
 assays
Post-Dose
Dispense ibrut inib and venetoclax for offsite use and provide study  drug com pliance 
instructi ons
MRD Cohort: Randomization Phase
Refer to the Schedule of Assessments ( Appendix A) for a com plete list of procedures to be 
perform ed at each scheduled study  visit.
At Cycle 17 (following 3 cycles of ibrut inib lead-in, completion of 12 cy cles of ibrut inib + 
venetoclax combinat ion treatment , plus 1 cy cle to evaluate MRD status )or wi thin 3 days before 
Cycle 17 Day 1 visit , subjects will be rando mized based on their MRD status. Rando mizat ion 
will occur via Interactive Resp onse Technology  (IRT) or al ternat ive system provided by the 
Sponsor.

IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 103MRD -neg subjects will be randomized to either ibrutinib orplacebo , and therapy  should be 
continued until MRD -positive rel apse, disease progressio n, unacceptable treatment -related 
toxicity, or other reasons outlined in Section9.2.
Subjects not obtaining confirmed MRD -neg responses (considered MRD -pos) will be
rando mized to eitheribrutinib + venetoclax or ibrutinib alone . Ibrutinib and /orvenetoclax
shoul d be continued unt il disease progression, unacceptable treatment -related toxicit y, or other 
reasons outlined in Section9.2.
Central  labs for MRD assessment will be used to inform randomization strata , and re -
introducti on of  therapy . Local  labs will be used to guide all other dosing -related deci sions. In the 
event of rising MRD assessments, or of clinically  suspected disease progressi on, the subject 
shoul d continue to receive study medicat ion, at the discret ion of the Invest igator, until 
MRD -positive relapse or disease pr ogressi on is confirmed respect ively.
8.2.2. Cycle 17Randomizat ion Visit and Every 3 Cycles Thereafter
The fo llowing procedures will be performed on Day  1 (±3 days) of Cycles 17 and every  3 cycles 
thereafter (unless indicated otherwise) until disease progression,
unacceptable treatment -related 
toxicity, or other reasons outlined in Section9.2:
Pre-Dose
Adverse events
Concomitant medicat ions
Study  drug compliance review
Physical exam
Vital signs
ECOG
Hem atology 
Serum  chemistry  
CT/MRI (Cy cle 23, Cy cle 29, Cy cle 35 ,andthenannually thereafter )
Overall response assessment 
Bone m arrow bi opsy  ( ±14 days from C29 unless collected prior for CR assessment, and 
confirmed MRD -negat ive in BM)
MRD assessment (by  PB starting Cycle 20
, 23, 26, 29 ,and every  6 cycles thereafter ; by 
bone marrow aspirate [BMA ] at Cy cle 29 in randomized subjects , and inanysubject with 
MRD -negconver sion in PB ; BMA can be drawn ±14 days from C29D1. ) 
 assays 

IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 104Post-Dose
Dispense randomizat ion specific study  medicat ion to subject for off-site use and provi de 
study  drug com pliance instructi ons
8.2.3. Suspected MRD -positive Relapse Vis it(Any Time )
If MRD -positive rel apse is suspected, subject should return to clinic as soon as possible and the
following procedures will be performed:
Adverse events
Concomitant medicat ions
Study  drug com pliance review
Physical exam
Vital signs
ECOG
Hem atology 
Serum  chemistry
Overall response assessment 
MRD assessment (by  PB)
  assays
8.3. Fixed Duration Cohort
Fixed Duration C ohort : Treatment
The Schedule o f Assessments ( Appendix B)summari zes the frequency and timing of efficacy , 
 and safety  measurements applicable to this study . The timing of all visit s will be 
based on using Cycle 1 Day  1 (C1D1) as the anchor visit and all subsequent visits shoul d use the 
C1D1 date as the basis for scheduling.
Following com pletion of the Screening visit and once eligibilit y has been confirmed (per 
inclusio n/excl usion criteria), subjects will init iate ibrutinib treatment. Venetoclax will be added 
to ibrut inib treatm ent and init iated after completion of 3 cycles of ibrut inib. The venetoclax dose 
will be ramped up over 5 weeks per standard dosing recommendations (see Secti on 5.3for 
ibrutinib and venetoclax dosing).
After complet ion of 15cycles of treatm ent, subjects will co me o ff treatment and will cont inue to 
be followed for efficacy . 
Subjects that are unable to complete all 12cycles of co mbinat ion 
therapy will cont inue to follow the same visit sche dule until disease progression. After di sease 
progression ,subjects will enter the Post -PD Follo w up Phase ( Secti on 8.9).

IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 1058.3.1. Treatment Visits
8.3.1.1. Cycle 1 Day 1 (C1D1) Visit
Pre-Dose
The fo llowing procedures will be performed prior to dosing (within 3 days) of the C1D1 Visit. 
Please note, C1D1 Visit procedures done at Screening will not need to be repeated if done 
within 3 days of first dose with study drug.
Confirm eligibilit y (per inclusio n/exclusio n criteria) and enro ll subject. Dosing should 
occur wi thin 3 days of confirmat ion.
Adverse events
Physical examinat ion
Vital signs
ECOG performance status
Concomitant medicat ions
Hem atology
Serum  chemistry  (including creat inine clearance)
  2-microglobulin
Tumor Lysis Risk assessment ( use Screening CT and C1D1 ALC. see Appendix Hfor 
risk as sessment categories )
  assays 
IGHV -will be derived fro m a sample (if IGHV resul tis not informative for 
any reason, another peripheral blood sample should be drawn and sent to the central lab 
at the next appropriate timepo int)
FISH pan el
Kary otype
MRD in peripheral blood 
Perform  urine pregnancy  test f or wom en of childbearing potential only
Dosing and Post First Dose
In-clinic administration of ibrut inib 
Dispense ibrut inib for offsi te use and provi de study  drug com pliance instructions

IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 1068.3.1.2. Cycles 2 and 3 Visits
Pre-Dose
The fo llowing procedures will be performed on Day  1 (±3 days) of each cycle (except for 
CT/MRI) :
Adverse events
Concomitant medicat ions
Study  drug com pliance review
Physical exam
Vital signs
ECOG
CT/MRI (to assess response and lymph node sum of the product of the diameters [SPD]
for TLS ri sk assessment , Cycle 3 only –to be obtained as close to the beginning of 
Cycle 4 as possible, while still allowing for appropriate TLS risk -guided interventi ons 
including hospi talizati onif appropri ate)
Hem atology 
Serum  chemistry
Dosing and Post -Dose
In-clinic administration of ibrut inib(Cycle 2 only)
Dispense ibrut inib for offsi te use and provi de study  drug com pliance instructions
8.3.1.3. Cycle 4 Visits
8.3.1.3.1. Pre-Cycle 4 (Pre -initiation of Venetoclax )
The fo llowing procedures will be performed 2- 3 days (±3 day s) pri or to Cy cle 4:
Overall response assessment
Hem atology
Serum  Chemistry
 assays 
Tumor Lysis Risk assessment (see Appendix Hfor risk assessment categories )
Tumor Lysis Syndrom e prophylaxis (see Section 5.4.2.2 for prophylaxis schedule based 
on risk)
The fo llowing procedures will be performed 1 day  prior to Cycle 4:
Tumor Lysis Syndrom e prophylaxis (see Section 5.4.2.2 for prophylaxis schedule based 
on risk)

IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 1078.3.1.3.2. Cycle 4 Week 1 Day 1
Pre-Dose
The fo llowing procedures will be performed on Day  1 (±3 days) of Cycle 4, Week 1:
Adverse events
Concomitant medicat ions
Study  drug com pliance review
Physical exam
Vital signs
ECOG
Hem atology 
Serum  chemistry  
Creatinine clearance (Cockcroft -Gault)
Tumor Lysis Risk assessment (see Appendix Hfor risk assessment categories)
Tumor Lysis Syndrom e prophylaxis (see Section 5.4.2.2 for prophylaxis schedule based 
on risk, venetocl axadministration setting, and frequency o f serum  chemistry  monitoring 
assessments)
Dosing and Post First Dose of Venetoclax
In-clinic administration of ibrut inib 
In-clinic administration of venetoclax 20 mg for low and medium risk TLS subjects
Consider ho spitalizati on for first dose of ven etoclax 20 m g in medium risk TLS subjects 
with a CrCl  < 80 m L/min
In-hospi tal administrati on of  first dose of venetoclax 20 mg for high risk TLS subjects 
Dispense ibrut inib and venetoclax for offsite use and provide stud y drug com pliance 
instructi ons
8.3.1.3.3. Cycle 4 Week 1 Day 2
Pre-Dose
Adverse events
Hem atology 
Serum  chemistry  
Tumor Lysis Syndrom e prophylaxis (see Section 5.4.2.2 forprophylaxis schedule based 
on risk and frequency  of serum  chemistry  monitoring assessments)
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 1088.3.1.3.4. Cycle 4 (Week 2 –Week 4) Visits
The fo llowing procedures will be performed on Day  1 (±3 days) of Cycle 4, Weeks 2, 3, and 4 
(coincides wit h venetocl axstandard dose ramp -up of  50 m g (W2D1), 100 mg (W3D1), and 
200mg (W4D1):
Pre-Dose
Adverse events
Concomitant medicat ions
Study  drug com pliance review
Physical exam
Vital signs
ECOG
Hem atology 
Serum  chemistry  
Creatinine clearance (Cockcroft -Gault)
Tumor Lysis Syndro me Risk assessment (see Appendix Hfor risk assessment categories)
Tumor Lysis Syndrom e prophylaxis (see Section 5.4.2.2 for prophylaxis schedule based 
on risk and frequency  of serum  chemistry  monitoring assessments)
Dosing and Post -Dose
In-clinic administration of venetoclax 50 mg (Week 2), 100 mg (Week 3) an d 200 m g 
(Week 4) for low and medium TLS risk subjects
Consider hospitalization for first dose of ven etoclax 50 m g in medium risk TLS subjects 
with a CrCl  < 80 m L/min
In-hospi tal administrati on of  first dose of venetoclax 50 mg dose at W eek 2 for high risk
TLS subjects; in -clinic administration of venetoclax 100 mg (Week 3) and 200 mg 
(Week 4) for high ri sk TLS subjects
Dispense venetocl ax for off site use and provi de study  drug com pliance instructions
8.3.1.3.5. Cycle 4 Week 2 Day 2
Pre-Dose
Adverse events
Hem atology 
Serum  chemistry  
Tumor Lysis Syndrom e prophylaxis (see Section 5.4.2.2 for prophylaxis schedule based 
on risk and frequency  of serum  chemistry  monitoring assessme nts)
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 1098.3.1.4. Cycle 5 Visits
8.3.1.4.1. Cycle 5 Week 1 and Week 3 Visits
Pre-Dose
The fo llowing procedures will be performed on Day  1 (±3 days) of Cycle 5, Week 1 ,and 
Week 3:
Adverse events
Concomitant medicat ions
Study  drug com pliance review
Physical exam
Vital signs
ECOG
Hem atology 
Serum  chemistry  
Creatinine clearance (Cockcroft -Gault)
Tumor Lysis Syndrom e Risk assessment (see Appendix Hfor risk assessment categories) 
(Week 1 Onl y)
Tumor Lysis Syndrom e prophylaxis (see Section 5.4.2.2 for prophylaxis schedule based 
on risk, venetocl ax administration setting, and frequency o f serum  chemistry monitoring 
assessments) (Week 1 Only)
Dosing and Post -Dose
In-clinic administration of venetoclax
Dispense ibrut inib and venetoclax for offsite use and provide study  drug com pliance 
instructi ons (Week 1 only)
8.3.1.5. Cycle 6 –Cycle 9 Visits
Pre-Dose
The fo llowing procedures will be performed on Day 1 (±3 days) of Cycles 6, 7, 8, and 9:
Adverse events
Concomitant medicat ion
Study  drug com pliance review
Physical exam
Vital signs
ECOG
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 110Hem atology 
Serum  chemistry  
CT/MRI (Cy cle 7only)
Overal l response assessment ( Cycle 7 only)
MRD assessment (in peripheral blood Cycle 7 only )
Dosing and Post -Dose
Dispense ibrut inib and venetoclax for offsite use and provide study  drug com pliance 
instructi ons
8.3.1.6. Cycle 10 and Cycle 13 Visits
Pre-Dose
The fo llowing procedures will be performed on Day  1 (±3 days) of Cycles 10 and13:
Adverse events
Concomitant medicat ions
Study  drug com pliance review
Physical exam
Vital signs
ECOG
Hem atology 
Serum  chemistr
y
b2-microglobulin (at Cycle 10 only )
CT/MRI (C 10 and C 13)
Overall response asse ssment (by imaging C10 andC13)
MRD assessment (in peripheral blood)
Bone m arrow aspi rateand biopsy (C10) . Bone m arrow MRD should be assessed 
whenever a BM aspirate is co llected. Bone marrow can be collected ±14 days from 
scheduled C10D1.
Post-Dose
Dispense ibrut inib and venetoclax for offsite use and provide study  drug com pliance 
instructi ons
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 1118.3.2. Fixed Duration Cohort: Post treatment visits
For subjects who complete all 15cycles of fixed durati on regimen, t he fo llowing procedures will 
be perform ed on Day 1 (±3 day s) of Cycle s 19 (P ost Completion of Cycle 15therapy ), 25, 28, 
31,and every 6 mo nths thereafter (or as indicated below) until disease progression, unacceptable 
treatm ent-related toxicit y, or other reasons outlined in Section9.2.
Subjects who discont inue treatment before completing the fixed duration regimen will cont inue 
to com e in for response follow-up visits per schedul e until confirmed disease progression.
Physical exam
Vital signs
ECOG
Hem atology 
Serum  chemistri es
CT/MRI (Cy cle 19, Cy cle25, Cycle31, and annually thereafter)
Overall response assessment
MRD assessment ( by PB at Cy cle 19, 25, 28*, 31,and annually  thereafter ;by PBand 
BMA at Cycle 19; BMA can be drawn ±14 days from C 19D1 ) :
Bone Marrow Biopsy  (Cycle 19only)
 assays 
* NOTE:  Cy cle 28 MRD collect ion isnot required for patients who have co mpleted 
these respect ive vi sits pri or to Amendment 3 site approval and any required reconsent
8.4. Reintroduction of Study Drug (MRD and FD Cohorts)
Subjects in the MRD cohort who are randomized and subjects in the Fixed Duration cohort who 
complete the fixed duration treatment may  have study  drug reintroduced if they  becom e MRD 
positive (MRD cohort) or have co nfirmed progressive disease (either cohort). See 
Secti on5.4.2.2 , 
and Section 7.1.1.10 for TLS ri sk assessment and prophylaxis, respect ively
Imaging for resta ging is required prior to reintroduction. Medical Monitor appr oval is requi red 
prior to reintroduction of any study  drug.
Creatinine clearance, Coagul ation panel (PT/INR, aPTT) (for ibrutinib reintroduction) , 
IGHV, 
karyotype, FISH, and  will be assessed at the first reintroduction visit. Prior to 
reintroduction, ECG and Echo/MUGA will be obtained, and cardio logy consul tation pri or to 
reintroduction should be considered for patients with cardiac comorbid condit ions or si gnificant 
cardi ac risk factors. The fo llowing procedures will be performed prior to reintroduction, and 
every 4 m onths for the first y ear, then every  6 months unt il PD, unless otherwise indicated.
Physical exam
Vital signs and Weight 

IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 112ECOG
Hem atology
Serum  chemistry
CT/MRI ( refer to Appendix Dand Appendix Efor specific timepo ints)
Overall response assessment A dverse events
Concomitant medicat ions
Study  drug com pliance review
Bone Marrow assessment (only at visit if needed to confirm CR, or if clinically indicated to 
confirm PD)
 Assay 
ECG (prior to reintroducti on then as clinically  indicated)
Echocardi ogram  or MUGA scan (pri or to reintroducti onto allow sufficient time for 
subsequent evaluat ionand clinicaldecisio nmaking , and then as clinically indicated)
Subjects will fo llow the schedule for their retreatment as outlined in Appendix C, Appendix D, 
and Appendix E. Retreatment with ibrutinib or venetoclax or combinat ion can be cont inued for 
the duration indicated, until disease progression as determined by invest igator or un til they  meet 
criteria for withdrawal  in Section 9.2. Subjects must meet all o f the criteria for reintroducti on 
listed below. Per investiga tordiscret ionand in communicat ion withmedical mo nitor,initiation 
of reintroduction can be delayed unt il indication fo r treatm ent per I WCLL cri teria is present.
Criteria for Reintroduction of Study Drug
Inclusions
1.ECOG P erformance Status≤2
2.Platelet coun t >30,000/µL (30,000 cells/mm3or 30 x 109/L) 
3.Adequate hepat ic and renal funct ion defined as:
a)Serum  aspartate transaminase (AST) or alanine transaminase (ALT) ≤3.0 x upper limit of 
norm al (ULN)
b)Creatinine Clearance (CrCl) ≥60 m L/min ( eg,as estimated by Cockcroft -Gault)
c)Bilirubin ≤1.5 x ULN (unless bilirubin rise is due to Gilbert’s syndro me or of non -hepatic 
origin)
4.Prothrombin t ime (PT)/International normal rat io (INR) <1.5 x (upper limit of normal) ULN 
and PTT (activated partial thromboplast in time [aPTT]) <1.5 x ULN (unless abnormalit ies 
are unrelated to c oagul opathy  or bl eeding disorder). 
5.Female subjects of reproductive potential must have a negat ive serum pregnancy test upon 
study  entry .
6.Male and female subjects of reproductive potential who agree to use both a highly effective 
method of birth control ( eg,implants, injectables, combined oral contraceptives, some 

IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 113intrauterine devices [IUDs], complete abst inence3, or sterilized partner) and a barrier method 
(eg, condom , cervical ring, sponge, etc.) during the period of therapy  and for 90 days after 
the last dose of study  drug. Mal e subjects m ust agree to refrain from sperm donat ion unt il 
90days after the l ast dose of study  drug.
Exclusions
1.Development of other malignancies, except: 
a)Malignancy  treated wi th curative intent and with no known active disease p resent and felt 
to be at l ow ri sk for recurrence by  the treating physician
b)Adequately treated non -melanoma skin cancer or lent igo maligna wit hout evidence of 
disease
c)Adequately treated carcinoma in situ without evidence o f disease 
2. Known or suspected histo ry of Richter’s transformation.
3.Recent infect ion requiring systemic treatment that is ongo ing or any uncontrolled active 
systemic infect ion.
4.History  of stroke or intracranial hemorrhage wit hin 6 m onths pri or to enrollment.
5.Any life -threatening illness, med ical condit ion, or organ sy stem  dysfunct ion that, in the 
investigator’s opinion, could co mpro mise the subject’s safet y.
6.Current ly act ive, clinically significant cardiovascular disease, such as uncontrolled 
arrhy thmia or Cl ass 3 or 4 congest ive heart failur e as defined by  the New York Heart 
Associ ation Functional Classificat ion; or a history  of myocardial infarct ion, unstable angina, 
or acute coronary  syndrom e within 6 mo nths.
7.Requi res treatm ent wi th a strong cy tochrom e P450 (CYP) 3A inhibitor (see Appendix G). 
8.Current ly act ive, clinically significant hepat ic impairment Child- Pugh Class B or C 
according to the Child Pugh classificat ion (Appendix K).
9.Uncontrolled autoimmune hemo lytic anemia or idiopathic thrombocy topeni a purpura, or the 
need for daily  prednisone >20 mg daily  (or corti costeroi d equivalent) to treat or control the
autoimmune disease.
                                               
3Complete abstinence is a highly effective method only if defined as refraining from heterosexu al intercourse 
during the entire period of risk associated with the study treatments. The reliability of sexual abstinence needs to be 
evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the subject. 
http:// www hma.eu/fileadmin/dateien/Human_Medicines/01 
About_HMA/Working_Groups/CTFG/2014_09_HMA_CTFG_Contraception.pdf
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 114Categories of Reintroduction
Ibrutinib: Appendix C
Subjects in the MRD cohort who are MRD -negative and have been rando mized to
placebo; OR
Subjects in the Fixed Duration cohort who have completed the fixed duration of 
treatm ent.
Venetoclax: Appendix D
Subjects in the MRD c ohort who are MRD -posit ive and have been rando mized to 
ibrutinib only; OR
Subjects in the MRD cohort who are in MRD -negative arms and have previously had 
ibrutinib reintroduced.
Ibrutinib + venetoclax: Appendix E
Subjects in the Fixed Duration cohort who have completed the fixed duration of 
treatm ent (subj ects will take combination for the same fixed durat ion in the protocol 
[15months]).
8.5. Suspected PD Visit (Any Time )
The fo llowing procedures will be performed when Disease Progression is suspected:
Adverse events
Concomitant medicat ions
Study  drug com pliance review
Physical exam
Vital signs
ECOG
CT/MRI scan (For confirmat ion of PD)
Bone m arrow bi opsy /aspirateas clinically indicated
Overall response assessment 
Hem atology
Serum  chemistry
  assays (MRD and FD cohort , including with bone marrow biopsy when 
obtained )

IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 1158.6. Suspected CR Visit
The fo llowing procedures will be performed (along with regular ly scheduled study  assessments) 
when Co mplete Response by imaging is suspected:
Bone marrow biopsy and aspirate (for CR confirmation)
  assays (MRD cohort only )
MRD assessment (by PB and bone marrow aspirate)
8.7. End-of-Treatment Visit
The fo llowing will be performed 30 (±3) day s after di scontinuati on of  therapy (if the assessments 
do not coincide wit h regularly scheduled study  assessments) or at start of new ant icancer 
therapy , whichever occurs earlier . For the Fixed Duration Cohort, if subject compl etes fixed 
durati on regimen, thi s visi t will take pl ace at Cy cle 17Day 1 .
Adverse events
Concomitant medicat ions
Study  drug com pliance review
Physical exam
Vital signs
ECOG
Hem atology
Serum  chemistry  
MRD (peri pheral  blood)
  assays (MRD cohort only )
Subjects that withdraw fro m treatm ent for reasons other than clinical progressive disease in 
eithercohort should continue to participate in ongoing Response Fo llow-Up visi tsuntil 
confirmed disease progression.
8.8. Response Follow -Up Visit s
Subjects who discont inue treatment for reasons other than disease progression will cont inue to 
come in every  3 months (or per assi gned treatment schedule) until disease progression or study  
closure, whichever i s earlier. Subjects will undergo the followi ng procedures:
Physical exam
Vital signs
ECOG
Hem atology
Serum  Chemistry

IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 116MRD (peri pheral  blood) every 6 months for one year, then annually thereafter until 
initiation of subsequent ant i-cancer therapy
Overall Response Assessment
CT/MRI scan ( every 6 mo nths for one y ear, then annually  thereafter)
Other malignancies
Any subsequent anti -cancer therapy
If an alternat ive ant i-cancer therapy  is init iated, response to all s ubsequent ant i-cancer therapies 
including best overall response for each regimen, whether the subject progressed fo llowing each 
regimen, and date of PD if appl icable will be assessed.
8.9. Post-PDFollow -Up Phase
Once subjects experience dis ease progressi onand di scontinue study  treatm ent, they will be 
contacted approximately  every  3months (±14 days) ,or as needed ,by clinic visit or telephone to 
assess survival and the use of alternat ive anti-cancer therapy (response to all subsequent 
anti-cancer therapies including best overall response for each regimen, whether the subject 
progressed fo llowing each regimen, and date of PD if appl icable), and other malignancies.
Subjects will be contacted until death, subject withdrawal, lost to fo llow-up, or study  terminat ion 
by the Sponsor, whichever occurs first.
9. SUBJECT COMPLETION AND WITHDRAWAL
9.1. Completion
Asubject will be considered to have co mpleted the study  if he or she has died before the end of 
the study , has not been lost to fo llow up, or has not withdrawn consent before the end of study . 
9.2. Withdrawal from Study Treatment
Study  treatm ent will be discon tinued in the event of any of the fo llowing events:
Confirmed progressive disease
Unacceptable toxicit y: an intercurrent illness or AEthat prevents further study  drug 
administration   
Withdrawal o f consent for treatment by  subject
Invest igator decisio n (such as chronic nonco mpliance, significant protocol deviat ion, or 
best interest of the subject)
Study  terminat ion by Sponsor
Subject beco mes pregnant
Death
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 117Subjects in the Rando mization Phase of the MRD cohort or subjects in the Fixed Duration cohort 
who elect to not reintroduce therapy  after confi rmed PD, or have a confirmed PD after 
reintroduction of therapy , will  be withdrawn from  study  treatm ent.
All subjects, regardless of reason for discont inuat ion of study  treatm ent will undergo an 
End-of-Treatme nt Visit and be fo llowed for progression and survival. 
The invest igator should notify the Sponsor within 24 hours if a subject discont inues ibrut inib 
and/orvenetoclax treatm ent due to di sease progression and should provide documentation of 
disease progressi on for revi ew by  the Sponsor’s Medical Monitor. If  a subject shows signs of 
disease progressi on on physical examinat ion or l aboratory  assessment, the subject may  cont inue 
study  treatm ent until disease progression is confirmed. These subjects should stay  in the study  to 
be followed for survival. 
9.3. Withdrawal from Study
Withdrawal fro m study  (including all fo llow-up) will  occur under the following circumstances:
Death
Withdrawal o f consent for fo llow-up observat ion by the subject
Lost to follow -up
Study  terminat ion by Sponsor
If a subject is lost to follow -up, every  reasonable effort shoul d be made by  the study  site 
personnel to contact the subject. The measures taken to follow up shoul d be docum ented.
When a subject withdraws before complet ing the study, the fo llowing information should be 
docum ented in the source documents:
Reason for withdrawal;
Whether the subject withdraws full consent ( ie, withdraws consent to treatm ent and all 
further contact) or partial consent ( ie, withdraws consent to treatment but agrees to 
participate in fo llow -up visi ts)
10. STATISTICAL METHODS AND ANALYSIS
Statistical analysis will be done by the Sponsor or under the authority o f the Sponsor. A general 
descript ion of the statist ical methods to be used to analyze the efficacy and safet y data is outlined 
below. Specific details including the testing procedure for the secondary  endpoints will be 
provi ded in the Statist ical Analysis Plan (SAP) .
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 11810.1. Subje ct Information
The analysis populat ions are defined as:
All treated population s:defined as all enrolled subjects who received at least 1 dose of study  
drug in either the MRD cohort orthe Fixed Duration cohort and will be used in both e fficacy and 
safet y analysis.
MRD -negative randomized population: defined as all subjects in the MRD cohort who achieve 
confirmed MRD -negat ive response at the end of the pre-randomizat ion phase and are 
rando mized to either placebo arm or ibrut inib arm for the double -blind tre atment. Subj ects in this 
popul ation will be analyzed according to the treatment to which they  are randomized.    
MRD -positive randomized population: defined as all subjects in the MRD cohort who do not 
achieve confirmed MRD -negat ive response at the end of thepre-rando mizat ion phase and are 
rando mized to either single -agent ibrutinib arm or ibrutinib + venetoclax combinat ion treatm ent 
arm for a prol onged open label treatment. Subjects in this population will be analyzed according 
to the treatment to which they are randomized.    
Pharmacokinetic -evaluable population: defined as all enrolled subjects who received at least 
1dose of study  drug and had at l east 1 pharm acokinet ic sample obtained post -treatm ent in 
pre-randomizat ion phase .
 population: defined as all enrolled subjects whose  is available.
10.2. Endpoints 
10.2.1. MRD Cohort:
Primary Endpoint:
1-year disease -free rate in MRD -negat ive rando mized subjects
Secondary Endpoints:
MRD -negat ive response rate
Overall response rate
Com plete response rate(CR / CRi )
Durat ion of  response
TLS ri sk reduct ion
Progression free survival
Overall survival
Pharmacokinet ics of ibrutinib and venetoclax when dosed in combinat ion
Safety and tol erabil ity

IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 119Exploratory Endpoints:
10.2.2. Fixed Duration Cohort:
Primary Endpoint:
Com plete response (CR/CRi )rate
Secondary Endpoints:
Durati on of  response
MRD -negat ive response rate
Overall response rate
TLS ri sk reduct ion
Progression free survival
Overall survival
Safety and tol erabil ity
Exploratory Endpoints:
10.3. Sample Size Determination
MRD Cohort
The study  will be powered based on the primary  endpoint of randomizat ion phase, 1- year 
disease -free rate in MRD -negat ive rando mized subjects (ibrutinib vs placebo). The total sample 
size will be based on both MRD -negat ivity clinical response rate fro m the Pre-randomizat ion 
Phase and the sample size assump tion from Randomizat ion Phase.
Sixty rando mized subjects with confirmed MRD -negative status will provide approximately 80% 
power to detect a 30% improvement in the 1 -year disease -free rate, assuming the 1-year 
disease -free rate i s 60% for the control (placebo) arm, at a 2-
sided significant level of 0.05.

IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 120Assuming a 40% MRD- negat ive response rate for the ibrut inib and venetoclax co mbinat ion 
therapy  in the Pre -randomization Phase, 150 subjects will be enro lled in the Pre- randomizat ion 
Phase in order to have 60 subjects achieve confi rmed MRD -negative response and to be 
rando mized. Final sample size may be adjusted based on an early assessment of the 
MRD -negat ive response rate among the first 30 subjects who c omplete 9 cy cles of treatm entin 
Pre-randomizat ion Phase (See Section 3.1.1 ).
Fixed Duration Cohort
Assuming the CR rate for ibrut inib + venetoclax is 50%, 125subjects withoutdel17pwill 
provi de 83% power to ensure the rate is > 3 7% at 1 -side alpha 0.025 .A CR rate of 50% would 
represent meaningful improvement compared to the CR rate seen with the fixed duration 
combinat ion of bendamust ine + rituximab (31%), and woul dbe an improvement over the CR 
rate seen wit h the standard of care fixed duration regimen fludarabine, cyclophosphamide and 
rituximab (40%) which were obtained in the CLL10 study ,which included only patient swithout 
del17p ( Eichhorst 2016).
10.4. Efficacy Analysis 
In general, the MRD cohort and the Fixed Duration cohort will be analyzed separately . Analysis 
details will be provided in the SAP.
Descript ive statistics and subject list ings will be used to summarize the data. For continuous 
variables, the number of observat ions, m eans, standard deviations, medians, and ranges will be 
reported . For discrete variables, frequency  will be summarized andthe 95% confidence interval 
will be estimated . For time -to-event variables, Kaplan -Meier est imates will be provided. No 
inferential tests will be performed for pre -randomization phase. The primary  endpoint, 1-year 
disease -free rate i n MRD -negat ive rando mized subjects, will be tested between placebo and 
ibrutinib arms at a 2 -sided al pha l evel of 0.05 All the stratified analyses will be based on the 
rando mizat ion stratificat ion factor, immunoglobulin heavy -chain variable region (IGHV) status.
10.4.1. MRD -
Negative Re sponse Rate 
MRD -negat iveresponse rate is defined as the proportion of subjects who achieve 
MRD -negat ivity (definit ion in Section 7.2.1.4 ). 
In theMRD cohort ,and the Fixed Duration cohort, MRD -negat ive response rate is the secondary 
endpo int. Theanalysis of MRD negativit ywill be based on the all treated populat ion.  
will be summarized as an 
exploratory  analysis.
10.4.2. Disease- Free Survival (DFS)  
Disease -free survival (DFS) is the primary endpo int for randomizat ion phase of the MRD cohort 
and willbe analyzed in MRD -negat ive rando mized subjects. DFS is defined as the time that 

IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 121subjects remain in MRD -negat ive status without meeting MRD -positive relapse criteria 
(definit ion in Section 7.2.1 .4.2), or disease progressio n (assessed by invest igator per IWCLL 
2008 criteria) or death from any cause. The primary analysis will be performed when all 
rando mized subjects have had the opportunity  to com plete at l east 12 cy cles of rando mized 
treatm ent or fo llow-up. 1- year and 2 -year disease -free survival ratewill be explored. Analysis 
detail swill be provi ded in the SAP.  
10.4.3. Overall Response Rate (ORR)
Overall response rate ( ORR )is defined as the proportion of subjects who achieve a CR, CRi, 
nPR, PR, or PR Las evaluated by invest igatorusing IWCLL 2008 criteria. Subjects who do not 
have any post- baseline response assessment will be consider ed as non -responders. It is a 
secondary  endpoint for the MRD cohort and the Fixed Duration cohort .  
 as exploratory endpo ints.A pooled 
analysis in co mbinat ion with another dataset (eg, CLL3011; GLOW) may be performed for 
ibrutinib retreatment . Details of the statist ical analysis will be described in a separate SAP as 
applicable.
10.4.4. Complete Response Rate (CRR)
Com plete response rate ( CRR) is defined as the proportion of subjects who achieve a CR or CRi 
as evaluated by  invest igator using IWCLL 2008 criteria. Subjects who do not have any 
post-baseline response assessment will be considered as non -responders. It is the primary  
endpo int for the Fixed Duration cohort, and secondary  endpoint for the MRD cohort and will be 
summarized in theall treated popul ation.
10.4.5. Duration of Response (DOR)
Duration of  
response will be calculated for subjects achieving a response (CR, CRi, nPR, PR) 
based on IWCLL response criteria and defined as the interval between the date of init ial 
docum entati on of  a response including PR with lymphocy tosis, unt il disease progression or death 
from any cause, whiche ver occurs first.Kaplan -Meyer methodol ogy will be used to estimate 
event -free curves , median ,and landmark est imates .
10.4.6. Progression -Free Survival (PFS)  
Progression -free survival (PFS) is defined as the time fro m the first dose date of study  treatm ent 
until disease progression (per IWCLL 2008 criteria) or death from any cause, whichever occurs 
first. 
In the MRD cohort and the Fixed Durat ion cohort, PFS i s a secondary endpo int and will be 
analyzed in the all treated populat ion. Di stribut ion of PFS will be e stimated using Kaplan -Meier 
method. Median PFS, landmark estimates ,and their corresponding 95% CI will be provided.

IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 12210.4.7. Overall Survival (OS)
Overall survival (OS) is defined as the time fro m the first dose date of study  treatm ent unt il date 
of death due to a ny cause. 
In the MRD cohort , and the Fixed Duration cohort, OS is a secondary endpoint and will be 
analyzed in theall treated populat ion. Di stribut ion of OS will be est imated using Kaplan -Meier 
method. Median OS, landmark est imates and their correspondin g 95% CI will be provided.
10.4.8. Tumor Lysis Syndrome (TLS) Risk Reduction Rate
TLS ri sk reduct ionrateis defined as the reducti on in the proporti on of  subjects who are at high
riskof TLSafter the 3-cycle lead -in of single agent ibrut inib, com pared to the proportion of 
patients who are at hi gh risk of TLS at baseline .A reduction in TLS risk fro m high risk to 
medium or low risk is clinically meaningful because there is a reduction in the extent of TLS 
monitoring and ri sk of hospi talizati on.TLS risk ca tegor y is defined in the protocol in Table 4, 
where Tumor Burden category  is equated to TLS risk cate gory. TLS ri sk reduct ionisa
secondary  endpoint for th e MRD cohort and the FD cohort, and will be summarized in the all 
treated population.
10.4.9.
10.4.10.
10.4.11. Safety An alysis
In the MRD cohort, a nalysis o f safet y data will be conducted on the all treated popul ation in pre-
rando mizat ion phase and safet y popul ationin the rando mizat ion phase. An overall summary  
across both pre -randomizat ion and rando mizat ion phase may also be provided as appropriate.
The baseline value is defined as the last value collected on or prior to the first dose date of study 
drug. In the Fixed Durat ion cohort, safet y analysis willbe based on all treated populat ion.

IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 123The safet y variables to be analyzed include exposure of study  drugs, AEs, clinical laboratory  test 
resul ts (hematol ogy and chemistry ), ECOG performance, physical examinat ion,and vital signs 
measurements. In general, continuous variables will be summarized using descript ive statist ics 
(n, m ean, m edian, standard deviat ion, standard error and range). Categorical variables will be 
summarized using frequencies and percentages. No formal statist ical testing is planned. 
Adverse Events
Adverse event parameters to be evaluated are the type, incidence, and intensit y of AEs; the 
relationship of AEs to study  treatm ent; an d the action taken with respect to study  treatm ent due 
to AEs.
The verbat im terms used in the eCRF by invest igators to ident ify AEs will be coded using the 
Medical Dict ionary for Regulatory  Activities (MedDRA). 
Treatment -emergent period is defined as the period of time fro m the first dose of study  treatm ent, 
until the earlier of: 
Thirtydays fo llowing the l ast dose of ibrut inib or 30days following the l ast dose of
venetoclax , whichever occurs later
AND
The start date of a new ant i-cancer therapy .
The treatm ent-emergent AEs ( TEAEs )are those events that:
Are not present prior to the treatment -emergent period and occur during the treatment -
emergent peri od,
The onset dates are missing ,and end dates are during the treatm ent-emergent peri od,
Are considered related to study  drug by  the invest igator regardless of the start dates of the 
events, or
Arepresent pri or to the treatm ent-emergent period but worsen in severit y during the 
treatm ent-emergent period or are subsequent ly considered related to study  drug b y the 
investigator.
All treatment -emergent AEs will be included in the analysis. For each AE, the number and 
percentage of subjects who experience at least one occurrence of the given event will be 
summarized. The number and percent of subjects with TEAEs will be summarized according to 
intensity (CTCAE, v4.03) or IWCLL for hematologic toxicit y, and drug rel ationship, as well as 
categori zed by  system  organ cl ass and preferred term. Summaries, list ings, datasets, or subject 
narratives may  be provi ded, as ap propri ate, for those subjects who die, who discont inue 
treatm ent due to an AE, or who experience a severe AE or a SAE.
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 124Clinical Laboratory Tests
Laboratory  tests will  be summarized separately for hematology  and serum chemistry . Local  
laboratory  resul ts will  be standardi zed using the International System SI unit. Selected 
hematol ogic and chemistry  laboratory  parameters are detailed in Section 7.1.2 . Hematologic 
param eters including platelet counts, hemoglobin, and neutrophils will be assessed by  the 
grading scale for hematologic toxicit y in CL L studies in the IWCLL 2008 guidelines. All other 
gradable laboratory  parameters will be graded using the NCI CTCAE v4.03 . 
Unless otherwise specified, only  baseline and post- baseline lab values collected during the 
treatm ent-emergent period will be includ ed in the analysis. Descriptive statist ics will be used.
For selected laboratory  param eters, the worst post baseline toxicit y grade will be summarized. 
Analysis for hepatic impairment and renal impairment will be provided.
10.5. Pharmacokinetic Analysis
10.5.1. Ibrutini b
Ibrutinib and PCI -45227 bioanalyt ical data will be used in nonco mpartmental PK analysis. 
Plasma concentrations below the lowest quantifiable concentration will be treated as zero in the 
summary statist ics. All subjects and samples excluded fro m the analy sis will be clearly 
docum ented in the PK report.
Descript ive statistics will be used to summarize ibrutinib and PCI -45227 concentrations at each 
sampling t ime point and PK parameters of ibrut inib and PCI -45227 (including, but not limited 
to: C max, Tmax, AU Clast, and t 1/2)at each dosing interval .
Individual and mean plasma ibrut inib and PCI -45227 concentration time profiles will be plotted.
Ibrutinib data from this study  may also be combined with data from other studies performed with 
ibrutinib in subjects with hematol ogic malignancies as part of a populat ion-PK analysis using 
nonlinear mixed effects models. For the populat ion-PK analysis, covariates that could potentially 
correl ate wi th plasma PK param eters will  be evaluated. The results of the populat ion-PK 
analyses (if performed) will be presented in a separate report.
Steady -state ibrutinib PK data when administered alone in the lead in period will be compared to 
the data when administered in combinat ion with venetocl ax to expl ore the potenti al for a 
pharmacokinet ic interacti on between ibrut inib in combinat ion use with venetoclax. 
Ibrutinib model -derived exposure parameters (PK parameters) may be used to explore PK/PD 
correl ation between the exposure of ibrutinib with relevant clinical  inform ation to 
assess effectiveness and toxicit y.  

IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 12510.5.2. Venetoclax
Venetoclax bioanalyt ical data will be used in noncompartmental PK analysis. Plasma 
concentrations below the lowest quantifiable concentration will be treated as zero in the 
summary statist ics. All subjects and samples excluded fro m the analysis will be clearly 
docum ented in the PK report.
Descript ive statistics will be used to summarize venetoclax concentrations at each sampling time 
point and PK parameters (including, but not limited to: C max, Tmax, and AUC) at each dosing 
interval .
Individual and mean plasma venetoclax concentratio n time profiles will be plotted.
Venetoclax data from this study  may also be combined with data fro m other studi es perform ed 
with ibrutinib in subjects wi th hematol ogic malignancies as part of a population -PK analysis 
using nonlinear mixed effects models. For the populat ion-PK analysis, covariates that could 
potenti ally correl ate wi th plasma PK parameters will be evaluated. The results of the 
popul ation-PK analyses (if per formed) will be presented in a separate report.
Venetoclax model -derived exposure parameters (PK parameters) may be used to explore PK/PD 
correl ation between the exposure of venetoclax wit h relevant clinical inform ation 
to assess effect iveness and toxi city.
10.6.  
 
 
Descript ive statistic s will be used to summarize these exploratory  endpoints. 
The detail will be given in SAP. R esults will  be presented in a separate report.
10.7. Data Review Committee (DRC)
A DRCwill be established to m onitordata in the MRD Cohort Safety Run -in Period(defined as 
the date of first dose of ibrutinib at Cycle 1 Day  1 thr ough the DLT evaluat ion peri od)to ensure 
the safety of the subjects enrolled in this novel combinat ion study . The committee will meet 
periodically  to review safet y data. After the review of the first 6 evaluable subjects who have 
completed the combinat ion of ibrut inib+ dose ramp -up of venetoclax with an addi tional week of 
follow up , the D RC maymake recommendat ions regarding the recommended doses and 
continuat ion of the study . A follow-up DRC review will occur after all subjects in the Safet y 
Run-in Period have ei ther discont inued therapy and/or have co mpleted the venetoclax dose ramp 
up and 1 week fo llow up, then the DRC may make additional recommendat ions regarding the 
recommended dose s.
The D RC will consist of the Medical Monitor or designee , a Drug Safety representative , a
biostatistician , and at l east 2 parti cipat ing Invest igators . 

IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 12611. ADVERSE EVENT REPORTING
Timely, accurate, and complete reporting and analysis o f safet y information fr om clinical  studies 
are crucial for the protection of subjects, invest igators, and the Sponsor, and are mandated by 
regul atory  agencies worl dwide. The Sponsor has established Standard Operating Procedures in 
conformit y with regul atory  requi rements worl dwid e to ensure appropriate reporting o f safety  
inform ation; all clinical studies conducted by  the Sponsor or i ts affiliates will be conducted in 
accordance with those procedures.
11.1. Definitions 
11.1.1. Adverse Events
An AE is any  untoward m edical occurrence in a subjec tadministered a pharmaceut ical product 
and which does not necessarily have a causal relat ionship wit h this treatm ent. An AE can 
therefore be any  unfavorable and unintended sign (including a clinically significant abnormal 
laboratory  finding, for example), symptom, or disease tem porally  associated wi th the use of an 
investigat ional study  drug, whether or not considered related to the study  drug ( ICH- E2A, 1995).
For the purposes of this clinical study , AEs include events which are either new or represent 
detectable exacerbations of pre -exist ing condit ions.
The term  “disease progression” should n otbe reported as an AEterm.As an example,
"worsening of CLL/SLL "or theclinical diagnosis that is associated with disease prog ression
shoul d be reported .
Adverse events may include, but are not limited to:
Subject ive or object ive symptoms provi ded by the subject and/or observed by the 
investi gator or study  staff including laboratory  abnorm alities of clinical significance.
Any AEs experi enced by the subject through the complet ion of final study  procedures.
AEs not previously observed in the subject that emerge during the protocol -specified AE 
reporting period, including signs or symptoms associated with the underlying disease that 
were not present before the AE reporting period 
Com plicat ions that occur as a result of protocol -mandated intervent ions (eg, invasive 
procedures such as biopsies).
The fo llowing are NOT considered AEs:
Pre-Existing Condition: A pre -exist ing condit ion (docum ented on the medical history  
CRF) is not considered an AE unless the severit y, frequency , or character of the event 
worsens during the study  period.
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 127Pre-Planned or Elective Hospitalization: A hospitalizat ion planned before signing the 
ICFis not considered an SAE, but rather a therapeutic intervent ion. However, if during 
the pre -planned hospitalizat ion an event occurs, which prolongs the hospitalizat ion or 
meets any other SAE criteria, the event will be considered an SAE. Surgeries or 
intervent ions th at were under consideration, but not performed before enro llment in the 
study , will not be considered serious if they  are perform ed after enrollment in the study  
for a condi tion that has not changed from its baseline level. Hospi talizati on requi red per 
protocol  for subj ects at hi gh risk for TLS (hi gh tum or burden, or those wi th CrCl  
<80mL/min) are not considered AEs unless the hospit alization is prol onged >24 hours or 
if addit ional intervent ion, not described as mandatory  prophylaxis in Table 4, is requi red. 
Elect ive hospitalizat ions for soci al reasons, sol ely for the administrati on of  therapy , or 
due to l ong travel  distances are also not SAEs.
Diagnost ic Testing and Procedures: Testing and procedures should not to be reported 
as AEs or SAEs, but rather the cause for the test or procedure should be reported.
Asymptomatic Treatment Related Lymphocytosis: This event should also not be 
considered an AE. Subjects with treatment -related lymphocy tosis shoul d remain on study  
treatm ent and continue with all study -related procedures.
11.1.2. Serious Adverse Events
A serious adverse event (SAE )based on International Conference on Harmonisat ion (ICH
)and 
EU Gui delines on Pharm acovi gilance for Medi cinal  Products for Hum an Use is any  untoward 
medical occurrence that at any  dose:
Results in death ( ie, the AE actually  causes or l eads to death).
Is life -threatening. Life -threatening i s defined as an AE in which the subject was at risk 
of death at the time of the event. It does not refer to an event which hypothetically  might 
have caused death if it were more severe. If eit her the invest igator or the Sponsor believes 
that an AE meets the definit ion of life -threatening, it will be considered life -threatening.
Requi res unplanned in-patient hospi talizati on >24 hours or prol ongat ion of exist ing 
hospi talizati on.
Results in persistent or significant disabilit y/incapacit y (ie, the AE resul ts in substant ial 
disrupt ion of the subject ’s abilit y to conduct normal life funct ions).
Is a congenital ano maly/birth defect.
Is an important medical event that may not result in death, be immediately 
life-threatening or require hospitalizat ion, but may  be considered an SAE when, 
based upon appropriate medical judgment, the event may jeopardize the subject or 
subject may require intervention to prevent one of the other outcomes listed in this 
definit ion. Examples of such events are intensive treatment in an emergency  departm ent 
or at hom e for allergic bronchospasm, blood dy scrasias, or convulsio n that does not result 
in hospi talizati on; or development of drug dependency or drug abuse.
Given that the invest igator’s perspective may be informed by having actually observed the event, 
and the Sponsor i s likely to have broader knowledge of the drug and its effects to inform its 
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 128evaluat ion of the significance of the event, if either the Sponsor or the investigator believes that 
the event is serious, the event will be considered serious.
11.1.3. Severity Criteria (Grade 1 - 5)
Definit ions found in the Hematologic Adverse Event Grading Scheme ( Hallek 2008 ) will  be 
used for grading the severit y of hematol ogic AEs. Refer to Appendix Lfor the grading of 
hematol ogic AEs.
Definit ions found in the Co mmo n Termino logy Cri teria f or Adverse Events versio n 4.03
(CTCAE v4.03) will be used for grading the severity  (intensit y) of nonhematologic AEs. The 
CTCAE v 4.03 displays Grades 1 through 5 with unique clinical descriptions of severit y for each 
referenced AE. Should a subject experience any AE not listed in the CTCAE v4.03 , the 
following grading system should be used to assess severit y:
Grade 1 (Mi ld AE) –experiences which are usually transient, requiring no special 
treatm ent, and not interfering with the subject ’s daily  activi ties
Grade 2 (Moderate AE) –
experiences which introduce some level of inconvenience or 
concern to the subject , and which m ay interfere with daily act ivities, but are usually  
ameliorated by  simple therapeut ic measures
Grade 3 (Severe AE) –experiences which are unacceptable or intolerable, significant ly 
interrupt the subject ’s usual daily act ivity, and requi re systemic drug th erapy  or other 
treatm ent
Grade 4 (Life -threatening or disabling AE) –experiences which cause the subject to be in 
imminent danger of death
Grade 5 (Death related to AE) – experiences which result in subject death
11.1.4. Causality ( Attribution)
The invest igator is to assess the causal relation ( ie, whether there is a reasonable possibilit y that 
the study  drug caused the event) using the fo llowing definit ions:
Not Related: Another cause of the AE is more plausible; a temporal sequence 
cannot be established with t he onset of the AE and administration 
of the invest igational product; or, a causal relat ionship is 
considered bio logically  implausible.
Unlikely: The current knowledge or information about the AE indicates that 
a relationship to the investigational produc t is unlikely.
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 129Possibly Related: There i s a clinically  plausible t ime sequence between onset of the 
AE and administration of the invest igational product, but the AE 
could also be attributed to concurrent or underlying disease, or the 
use of other drugs or procedures. Possibly related should be used 
when the invest igational product is one of several bio logically  
plausible AE causes.
Related: The AE is clearly related to use of the invest igational product.
11.2. Unexpected Adverse Events
An “unexpected” AE is an AE that is not listed in the IB/package insert or is not listed at the 
specificit y or severit y that has been observed. For example, hepatic necrosis would be 
“unexpected” (by  virtue of  greater severit y) if the IB referred only to elevated hepatic enzymes 
or hepatit is. Similarly, cerebral thromboembo lism and cerebral vasculit is would be “unexpected” 
(by virtue of greater specificit y) if the IB/package insert listed only cerebral vascular accidents. 
"Unexpected" also refers to AEs that are ment ioned in the IBasoccurring with a class o f drugs 
or as anticipated from the pharmaco logical properties of the drug, but are not specifically 
ment ioned as occurring wit h the study  drug under investigation.
11.3. Special Reporting Sit uations
Speci al reporting situat ionon a Sponsor study  may requi re expedi ted reporting and/or safet y 
evaluat ion include, but are not limited to:
Overdose of a nystudy  drug
Suspected abuse/misuse of a study  drug
Inadvertent or accidental exposure to a study drug
Medicat ion error invo lving a product (with or without subject exposure to the study drug, 
eg, nam e confusi on)
Occurrence of any special reporting situat ions should be recorded in the eCRF. If any special 
reporting situat ion meets the criteria of a nAE, itshoul d be recorded on the AEs eCRF. If the AE
is considered serious , itshoul d be recorded on the AEs eCRF as seri ous and shoul d be reported 
on the Seri ous Adverse Event Report Form.The Serious Adverse Event Report F orm shoul d be 
sent vi a email  or fax to Pharm acyclics Drug Safet y or designee within 24 hours of awareness.
11.4. Documenting and Reporting of Adverse Events and Serious Adverse Events by 
Investigators
11.4.1. Assessment of Adverse Events
Invest igators will assess the occurrence of AEs and SAEs at all subject eval uation timepoints 
during the study . All AEs and SAEs whether vo lunteered by  the subject, discovered by study  
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 130personnel during subject office visits, detected through physical examinat ion, clinically 
significant laboratory  test, or other means, will be recorded in the subject’s medical record and 
on the AEs eCRF and, when applicable, on the Serious Adverse Event Report Form .
Each recorded AEor SAE will be described by  its durati on (ie, start and end dates), severit y, 
regul atory  seriousness cri teria (if applicable), suspected relat ionship to the invest igational 
product, and any  actions taken.
11.4.2. Adverse Event Reporting Period
All AEs whether serious or non -serious, will be documented in the source documents fro m the 
time signed and dated ICF is obtai ned until 30 days following the last dose of study  drug. 
Adverse events noted during Screening period will be recorded in Medical History CRF .SAEs 
will be reported to the Sponsor on the SAE Report Form from the time of ICF signing until 30 
days fo llowing the last dose of study  drug .Both seri ous and non -serious AEs will be recorded in 
the eCRF fro m the first dose of study  drug until 30 day s after the l ast dose of study  drug. In the 
case of subjects who are transferring their ibruti nib treatment fro m this protocol  to another 
ibrutinib treatment protocol, AE collect ion under this protocol will stop at the time AE collect ion 
starts under the next protocol.
Serious adverse events reported after 30 day s following the last dose of study  drug shoul d also be 
reported if considered related to study  drug. Resoluti on informati on after 30 day s shoul d be 
provi ded. In the case of subjects who are transferring their ibrut inib treatment fro m this protocol  
to another ibrutinib treatment protocol, SAE collecti on under this protocol will stop at the time 
SAE collect ion starts under the next protocol.
Adverse event and SAE co llection will also stop at the time any subject starts a subsequent 
anticancer treatment within the first 30 day s after discontinui ng ibrut inib.
Progressive disease should NOT be reported as an event term, but instead symptoms/clinical 
signs of  disease progressi on m ay be reported. (See Secti on 11.1.1 )
All AEs, regardl ess of seriousness, severit y, or presumed rel ationship to study  drug, m ust be 
recorded using medical termino logy in the source document. All records will need to capture the 
details o f the duration and the severit yof each episode, the acti on taken wi th respect to the study  
drug, invest igator’s evaluation o f its relationship to the study drug, and the event outcome. 
Whenever possible, diagnoses should be given when signs and symptoms are due to a commo n 
etiology (eg, cough, runny  nose, sneezing, sore throat, and head congest ion shoul d be reported as 
"upper respiratory  infecti on"). Invest igators must assess the relat ionship of the AE/SAE to the 
study  therapy  and record their opini on in the CRF. All measures required for AE/SAE
management must be recorded in the source document and reported according to Sponsor 
instructi ons.
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 131All deaths should be reported with the primary  cause of death as the AE term, as death is 
typically  the outcom e of the event, not the event itself. Autopsy  and postm ortem  reports m ust be 
forwarded to the Sponsor, or designee, as outlined above , if allowed per l ocal regulatory  
guidelines .
If a death occurs within 30 days after the last dose of study  drug, the death m ust be reported to 
the Sponsor as a SAE . 
11.4.3. Expediting Reporting Requirements for Serious Adverse Events
All SAEs(initial and fo llow-up inform ation) will be reported on the Serious Adverse Event 
Report F ormand sent vi a email  or fax to Pharm acyclics Drug Sa fety, or desi gnee, wi thin 
24hours of the discovery  of the event or information. Pharmacyclics may request fo llow-up and 
other addit ional informat ion from the investigator ( eg, hospital admissio n/discharge notes and 
laboratory  resul ts). The contact inform ation (phone, em ail,and fax) for Pharmacyclics Drug 
Safety can be found on the Serious Adverse Event Report F ormand instructions.
All SAEsthat have not resolved by the end of the study , or that have not resolved upon 
discontinuat ion of the subject's part icipation in the study, must be fo llowed unt il any of the 
following occurs:
The event resolves
The event stabilizes
The event returns to baseline, if a baseline value/status is available
The event can be attributed to agents other than the study  drug or to factors unrelated to 
study  conduct.
It becomes unlikely that any  addi tional information can be obtained (subject or health 
care practi tioner refusal  to provi de addi tional informat ion, lost to follow up after 
demonstrati on of  due diligence wi th follow-up efforts)
The Sponsor assum es responsibilit y for appropri ate reporting of AEs /SAEs to the regul atory  
authori ties and governing bodies according to the local regulations.
The invest igator (or Sponsor where required) must report these events to the appropriat e 
Independent Ethics Committee/Inst itutional Review Board (IEC/IRB) that approved the protocol 
unless otherwise required and documented by the IEC/IRB .
11.4.4. Pregnancy
Before study  enrollment, subjects must agree to take appropriate measures to avoid pregnancy. 
However, should a pregnancy occur in a female study  subject, or a female partner of a male 
study  subject, consent to provide fo llow-up informati on regarding the o utcome of the pregnancy 
and the health o f the infant until 30 days old will be requested.
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 132A female subject must immediately  inform the investigator if she beco mes pregnant fro m the 
time of consent to 90days after the last dose of study drug. A male subjec t must immediately 
inform  the investigator if his partner beco mes pregnant fro m the time of consent to 90 day safter 
the last dose of study  drug. Any female subjects receiving study  drug(s) who become pregnant 
must immediately  discontinue study  drug. The investigator should counsel the subject, 
discussing any  risks of cont inuing the pregnancy and any possible effects on the fetus. 
Although pregnancy  itself is not regarded as an AE, the outcome will need to be documented. 
Any pregnancy  occurring in a subjec t or subj ect’s partner from the time of consent to 90days 
after the l ast dose of study  drug m ust be reported. Any occurrence of pregnancy  must be 
recorded on the Pregnancy Report Form Part I and sent via email or fax to Pharmacyclics Drug 
Safety, or desig nee, wi thin 24 hours of learning of the event. All pregnancies will be followed 
for outcom e, which is defined as elect ive termination of the pregnancy, miscarriage, or delivery 
of the fetus. For pregnancies with an outcome of live birth, the newborn infant will be followed 
until 30 days o ld by co mpleting the Pregnancy Report Form Part II. Any congenital 
anomaly/birth defect noted in the infant must be reported as a SAE .
11.4.5. Other Malignancies
All new m alignant tum ors including solid tumors, skin malignancies an d hematol ogic 
malignancies will be reported for the duration of study  treatm ent and during any  
protocol -specified fo llow-up peri ods incl uding post -progression fo llow-up for overall survival.
Ifobserved, enter data in thecorresponding eCRF.
11.4.6. Adverse Events of Special Interest (AESI)
Specific AEs, or groups of AEs, will be foll owed as part of standard safet y monitoring act ivities 
by the Sponsor. These events (regardless of seriousness) should be reported on the Serious 
Adverse Event Report Form and sent vi a email  or fax to Pharm acyclics Drug Safet y, or desi gnee, 
within 24 hours of awareness. 
11.4.6.1. Major Hemorrhage
Major hem orrhage is defined as any o f the following: 
Any treatment -emergent hem orrhagic AEs of Grade 3 or higher *. 
Any treatment -emergent seri ous adverse events of bleeding of any grade
Any treatment -emergent central nervous system hemorrhage/hematoma of any grade
*All hemorrhagic events requiring transfusion of red blood cells should be reported as Grade 3 or higher AE per 
CTCAE v
4.03.
Events meet ing the definit ion of major hemorrhage will be captured as an event of special 
interest according to Secti on11.4.6 above.
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 13312. STUDY ADMINISTRATION AND INVESTIGATOR OBLIGA TIONS   
12.1. Regulatory and Ethical Compliance
This clinical study  was designed and will be implemented in accordance with the protocol, 
theICH Harmonized Tripartite Guidelines for Good Clinical Pract ices, with applicable local 
regul ations (including US Code of Federal Regulatio ns [CFR] Ti tle 21 and European Direct ive 
2001/20/EC), and with the ethical principles laid down in the Declarat ion of Helsinki. 
12.2. Institutional Review Board (IRB), Research Ethics Board (REB) and Independent 
Ethics Committee (IEC) Approval
The invest igator will submit this protocol, the ICF, IB, and any other relevant supporting 
inform ation (eg, all advert ising materials or materials given to the subject during the study ) to the 
appropriate IRB/REB/IEC for review and approval before study  initiation. Amendments to the 
protocol  and ICFmust also be approved by the IRB/REB/IEC before the implementation of 
changes in this study .
The investigator is responsible for providing the IRB/REB/IEC with any required informat ion 
before or during the study , such as SAE expedited reports or study  progress reports.
The IRB/REB/IEC must comply wit h current United States (US) regulat ions (§21 CFR 56) as
well as country -specific nat ional regulat ions and/or local laws.
The fo llowing docum ents m ust be provi ded to Pharm acyclics or its authorized representative 
before entering subjects in this study : (1) a copy  of the IRB/REB/IEC letter that grants formal 
approval; and (2) a copy  of the IRB/REB/IEC -approved ICF. 
12.3. Informed Consent
The ICF and process must comply wit h the US regulat ions (§ 21CFR Part 50) as well as country  
specific nat ional regulat ions and/or local laws. The ICF will document the study -specific
inform ation the investigator or his/her designee provides to the subject and the subject’s 
agreem ent to parti cipate. 
The invest igator or designee (designee must be listed on the Delegat ion of Authorit y log), 
must explain in terms understandable to the su bject the purpose and nature of the study , 
study procedures, anticipated benefits, potential risks, possible AEs, and any  discomfort 
participat ion in the study may entail. This process must be documented in the subject’s source 
record. Each subject must pr ovide a signed and dated ICF before any study -related (nonstandard 
of care) activit ies are performed. The original and any amended signed and dated consent forms 
must remain in each subject’s study  file at the study site and be available for verificat ion by 
study  monitors at any  time. A copy  of each signed consent form must be given to the subject at 
the time that it is signed by  the subject.
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 13412.4. Quality Control and Quality Assurance
Sponsor shall implement and maintain qualit y control  and qualit y assurance pro cedures to ensure 
that the study  is conducted and data are generated, documented and reported in co mpliance wit h 
the protocol, GCP, and applicable regulatory  requirem ents. Thi s study  shall  be conducted in 
accordance with the provisio ns of the Declarat ion of Helsinki (October 2008) and all revisio ns 
thereof, and in accordance wit htheFood and Drug Administration ( FDA )regul ations (21 CFR 
Parts 11, 50, 54, 56, and 312, Subpart D –Responsibilit ies of Sponsors and investigators) and 
with the ICH gui delines on GCP (ICH E6). 
12.5. Protected Subject Health Information Authorization
Inform ation on m aintaining subject confident iality in accordance to individual local and nat ional 
subject privacy regulat ions m ust be provi ded to each subject as part of the informed consen t 
process (refer to Section 7.1.1.1 ), either as part of the ICF or as a separate signed document 
(forexample, in the US, a site -specific HIPAA consent m ay be used). The invest igator or 
designee must explain to each subject that for the evaluat ion of study  resul ts, the subject’s 
protected healt h informat ion obtained during the study  may be shared wi th Pharmacyclics and its 
designees, regulatory  agenc ies, and IRBs/REBs/IECs. As the study  Sponsor, Pharm acyclics will 
not use the subject’s protected health information or disclose it to a third party  without applicable 
subject authorizat ion. It i s the invest igator’s or designee’s responsibilit y to obtain w ritten 
permission to use protected health informat ion from each subject. If a subject withdraws 
permission to use protected health informat ion, it is the invest igator’s responsibilit y to obtain the 
withdrawal  request in wri ting fro m the subject andto ensure that no further data will be 
collected from the subject. Any data collected on the subject before withdrawal will be used in 
the analysis o f study  resul ts.
During the review of source documents by  the m onitors or audi tors, the confident iality of the 
subject will be respected with strict adherence to professio nal standards and regulat ions.
12.6. Study Files and Record Retention
The invest igator must keep a record of allsubjects who have consented to enroll in the study . 
For those subjects subsequent ly excluded from enrollment, the reason(s) for exclusion is to be 
recorded.
The invest igator/study staff must maintain adequate and accurate records to enable the conduct 
of the study  to be fully docum ented and t he study data to be subsequent ly verified. Essent ial 
docum entati on includes, but is not limited to, the IB, signed protocols and amendments, 
IRB/REB/IEC approval letters (dated), signed Form FDA 1572 and Financial Disclo sures, 
signed ICFs (including subjec t confident iality information), drug dispensing and accountabilit y 
records, shipping records of invest igational product and study -related materi als, signed 
(electroni cally ), dated and com pleted case report forms ( CRFs ), and documentati on of  CRF 
correcti ons, SAE forms transmitted to Pharmacyclics and notification of SAEs and related 
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 135reports, source documentation, normal laboratory  values, decoding procedures for blinded 
studi es, curri cula vi tae for study  staff, and all relevant correspondence and other docum ents 
pertaining to the conduct of the study .
All essential documentation will be retained by the invest igator for at least 2 years after the date 
the last marketing applicat ion is approved for the drug for the indication for which it is being 
investigated and unt il there are no pending or contemplated marketing applicat ions; or, if no 
applicat ion is to be filed or if the application is not approved for such indication, unt il 2 y ears 
after formal discont inuat ion of clinical development of the drug. 
The investigator must notify Pharmacyclics and obtain written approval fro m Pharm acyclics 
before destroying any clinical study  docum ents or images ( eg, scan, radiograph, ECG tracing) at 
any time. Should an invest igator wish to assign the study records to another p arty or m ove them  
to another location, advance written notice will be given to Pharmacyclics. Pharmacyclics will 
inform  the investigator of the date that study  records m ay be destroyed or returned to 
Pharmacyclics.
Pharmacyclics must be notified in advance of, and Pharmacyclics must provide express written 
approval  of, any change in the maintenance of the foregoing documents if the invest igator wishes 
to move study  records to another location or assign responsibilit y for record retenti on to another 
party . If the investigator cannot guarantee the archiving requirements set forth herein at his or her 
study  site for all  such docum ents, special  arrangements m ust be made between the invest igator 
and Pharmacyclics to store such documents in sealed containers away from the study  site so that 
they can be returned sealed to the invest igator for audit purposes.
12.7. Case Report Forms and Record Maintenance
The c ase report forms will be used to collect the clinical study  data and m ust be com pleted for 
each enro lled subject w ith all required study  data accurately recorded such that the informat ion 
matches the data contained in medical records ( eg, physicians’ notes, nurses’ notes, clinic charts ,
and other study -specific source documents). Authorized study  site personnel  (ie, listed on the 
Delegati on of  Authori ty log) will  com plete CRFs designed for this study  according to the 
completion gui delines that will be provided. The investigator will ensure that the CRFs are 
accurate, complete, legible, and completed within a reasonable period of  time . At all  times, the 
investi gator has final responsibilit y for the accuracy  and authent icity of all clinical data.
The CRFs exists within an electronic data capture (EDC) system with controlled access managed 
by Pharmacyclics or its authorize d representative for this study . Study  staff will be appropriately 
trained in the use of CRFs and applicat ion of electronic signatures before the start of the study 
and before being given access to the EDC sy stem . Original  data and any  changes of data will be 
recorded using the EDC sy stem , with all changes tracked by  the system  and recorded in an 
electroni c audi t trail . The invest igator attests that the informat ion contained in the CRFs is true 
by providing electronic signature within the EDC system. After database lock, the invest igator 
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 136will receive a copy  of the subject data ( eg, paper, CD, or other appropriate media) for archiving 
at the study  site.
12.8. Investigational Study Drug Accountability
Ibrutinib , placebo ,and venetoclax must be kept in a locked limit ed access room . The study  drug 
must not be used outside the context of the protocol. Under no circumstances should the 
investi gator or other si te personnel supply  ibrut inib, placebo ,or venetocl axto other investigators, 
subjects, or clinics or allow supplies to be used other than as directed by  this protocol  without 
prior authori zation from Pharm acyclics.
Accountabilit y records for ibrutinib , placebo ,and venetoclax must be maintained and readily 
available for inspect ion by representatives of Pharmacy clics and are open to inspect ions by 
regul atory  authori ties at any  time. 
An Invest igational Drug Accountabilit y Log m ust be used for drug accountabilit y. For accurate 
accountabilit y, the fo llowing informat ion must be noted when drug supplies are used duri ng the 
study :
1.Study  identificat ion number (PCYC -1142- CA)
2.Subject identificat ion number
3.Lot number(s) of ibrutinib /placebo dispensed for that subject
4.Lot number(s) of venetoclax dispensed for that subject
5.Date and quant ity of drug (s)dispensed
6.Any unused dr ug(s) returned by the subject
At study  initiation, the monitor will evaluate and approve the site’s procedure for investigational 
product disposal/destruction to ensure that it complies wit h Pharmacyclics’ requirements. If the 
site cannot m eet Pharm acyclic s’ requirements for disposal/destruction, arrangements will be 
made between the site and Pharmacyclics or its representative, for return of unused 
investigat ional product. Before disposal/destruction, final drug accountabilit y and reconciliat ion 
will be pe rformed by  the m onitorif allowed by institutional po licy.
All study  supplies and associated documentation will be regularly reviewed and verified by the 
monitor.
12.9. Study Monitoring/Audit Requirements
Representatives of Pharmacyclics or its designee will mo nitor thi s study  until com pletion.  
Moni toring will be conducted through personal visits wit h the invest igator and site staff, remote 
monitoring, as well as any appropriate communications by  mail, fax, em ail, or tel ephone.  
Thepurpose of monitoring is to e nsure that the study is conducted in co mpliance with the 
protocol , standard operating procedures (SOPs), and other written instructions and regulatory  
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 137guidelines, and to ensure the qualit y and integri ty of the data. This study  is also subject to 
reviews or audits.
To assure the accuracy  of data collected in the CRFs, it is mandatory  that the m onitor/audi tor 
have access to all original source documents, including all electronic medical records (EMR) at 
reasonable times and upon reasonable notice. If access t o the EMR cannot be granted to the 
monitor, the si te must ensure that all certified copies of documents are available during 
monitoring visits for all screened and enro lled subjects. During the review o f source documents, 
every effort will be made to maint ain the anonymit y and confident iality of all subjects during 
this clinical study . However, because of the experimental nature of this treatment, the 
investi gator agrees to allow the IRB/REB/IEC, representatives of Pharmacyclics, its designated 
agents and a uthorized em ployees of the appropri ate Regul atory  Authori ty to inspect the facilit ies 
used in this study  and, for purposes of verificat ion, allow direct access to the hospital or clinic 
records of all subjects enro lled into this study. A statement to this effect will be included in the 
inform ed consent and permissio n form authori zing the use of protected health informat ion.
Pharmacyclics or its authorized representative may perform an audit at any  time during or after 
completion of this study . All study -related docum entati on m ust be m ade available to the 
designated auditor. In addit ion, a representative of the FDA or other Regulatory  Agencies may  
choose to inspect a study  site at any  time before, during, or after complet ion of the clinical study . 
In the even t of such an inspect ion, Pharmacyclics will be available to assist in the preparation. 
All pertinent study  data shoul d be made available as requested to the Regulatory  Authori ty for 
verification, audit, or inspect ion purposes.
12.10. Investigator Responsibilities
A co mplete list of investigator responsibilit ies isoutlined in the clinical trial research agreement 
and the Statement of Invest igator Form FDA 1572, both of which are signed by the invest igator 
before commencement of the study . In summary , the invest igator will  conduct the study  
according to the current protocol; will read and understand the IB; will obtain IRB/REB/IEC 
approval  to conduct the study; will obtain informed consent from each study  parti cipant; will 
maintain and supply to the Sponsor or desig nee, auditors and regulatory agencies adequate and 
accurate records of study  activity and drug accountabilit y for study -related m onitoring, audi ts, 
IRB/REB/IEC reviews and regulatory  inspecti ons; will  report SAEs to the Sponsor or designee 
and IRB/ REB/IEC according to the specifics outlined in this protocol; will personally conduct or 
supervise the study; and will ensure that colleagues participat ing in the study are informed about 
their obligat ions in meet ing the above commit ments.
12.11. Sponsor Responsibilities
A co mplete list of the Sponsor responsibilit ies is outlined in the clinical trial research agreement 
and in the laws and regulat ion of the country  in which the research is conducted. In summary , the 
Sponsor will select qualified investigat ors, provide them wit h the informat ion they  need to 
properly conduct the study , ensure adequate monit oring of the study , conduct the study  in 
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 138accordance with the general invest igational plan and protocols and prompt ly inform 
investi gators, heal th and regul atory  agencies/authori ties as appropriate of significant new adverse 
effects or risks wit h respect to the drug.
12.12. Financial Disclosure
A separate financial agreement will be made between each principal  i nvest igator and 
Pharmacyclics or its authorized represe ntative befo re the study  drug i s delivered.
For thi s study , each investigator and sub-invest igator (as designated on the Form FDA1572) will 
provi de a personally signed Financial Disclosure Form in accordance wit h § 21 CFR 54. Each 
investi gator will notify Pharmacyclics or i ts authorized representative of any  relevant changes in 
financial disclosure informat ion during the conduct of the study and for 1 y ear after the study  has 
been co mpleted.
12.13. Liability and Clinical Trial Insurance
In the event of a side effe ct or inj ury, appropri ate medical care as determined by  the 
investi gator/desi gnee will be provi ded.
The ICF will include a descript ion oftreatm ent in the event of a study  related injury and 
handling of the costs associated therewith , incorporating country -specific national regulat ions 
and/or local laws. Financial co mpensat ion for lost wages, di sabili ty,or discomf ort due to the 
study  is not available.
Clinical trial insurance has been undertaken according to the laws of the countries where the 
study will be conducted. An insurance cert ificate will be made available to the participat ing sites 
at the time of study  initiation.
12.14. Protocol Amendments
Pharmacyclics will init iate any  change to the protocol  in a protocol amendment document. 
Theamendment will  be submitted to the IRB/REB/IEC together with, if applicable, a revised 
model ICF. Wri tten documentati on of  IRB/REB/IEC and required site approval must be received 
by Pharmacyclics before the amendment may take effect at each site. Addit ionally, under this
circumstance, inform ation on any change in risk and/or change in scope must be provided to 
subjects al ready  actively participat ing in the study, and they must read, understand and sign each 
revised ICF confirming willingness to remain in the trial.
No oth er significant or consistent change in the study procedures, except to eliminate an 
immediate hazard, shall be effected without the mutual agreement of the invest igator and 
Pharmacyclics.
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 13912.15. Publication of Study Results
Pharmacyclics may use the results of th is clinical study  in registrati on docum ents f or Regul atory  
Authori ties in the US or abroad. The results may also be used for papers, abstracts, posters, or 
other m aterial presented at sci entific meet ings or published in pro fessio nal journals or as part of 
an academic thesis by an invest igator. In all cases, to avoid disclo sures that could jeopardize 
propri etary  rights and to ensure accuracy  of the data, Pharm acyclics reserves the right to preview 
all manuscripts and abstracts related to this study , allowing Pharmacyclics sufficient time to 
make appropriate comments before submissio n for publication.
In most cases, the invest igators at the sites with the highest accruals of eligible subjects shall be 
listed as lead authors on manuscripts and reports of study  resul ts. The Medical  Monitor, s tudy 
director and/or l ead statistician may also be included in the list of authors. This custom can be 
adjusted upon m utual  agreement of the authors and Pharmacyclics and in accordance wit h 
current standards for authorship as recorded in professio nal conference and journal submissio n 
instructi ons.
12.16. Study Discontinuation
The Sponsor reserves the right to terminate the study  at any  time. Should this be necessary, 
both the Sponsor and the invest igator will arrange discontinuat ion procedures. In terminat ing the 
study , the Sponsor and the invest igator will assure that adequate considerat ion is given to the 
protecti on of  the subjects’ interests.
13. REFERENCES
Borner C.  The Bcl -2 protein family:  sensors and checkpoints for life -or-death decisions.  Molecular 
Immunology.  2003;39:615 -647.
Bosch F, Abrisqueta P, Villamor N, et al. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: 
a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. J Clin Oncol. 
2009; 27:4578 -84.
Bottcher S, Ritgen M, Fischer K, et al.  Minimal Residual Disease Quantification is an Independent 
Predictor of Progression -Free and Overall Survival in Chronic Lymphocytic Leukemia: AMultivariate 
Analysis from the Randomized GCLLSG CLL8 Trial .  J Clin Oncol 2012;30:990-988.
Bryan J, Borthaker G. Role of rituximab in first -line treatment of chronic lymphocytic leukemia. 
Therapeutics and Clinical Risk Management 2011:7: 1 –11.
Bulian P, Rossi D, Forcoi F, et al.  IGHV gene mutational status and 1 7p deletion are independent 
molecular predictors in a comprehensive clinical -biological prognostic model for overall survival 
prediction in chronic lymphocytic leukemia. J Transl Med .2012; 10:18 .
Burger J A, Tedeschi A, Barr PM, et al. Ibrutinib as Initial Therapy for Patients with Chronic 
Lymphocytic Leukemia. N Engl J Med. 2015 Dec 17;373:2425 -
37.
Byrd JC, Brown JR, O'Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid 
leukemia. N Engl J Med. 2014 Jul 17;371:213 -23. 
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 140Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J 
Haematol. 2004;127(1):3 -11.
Calin G A, Cimmino A, Fabbri M, et al. MiR-15a and miR -16-1 cluster functions in human leukemia.  
Proc Natl Acad Sci.  2008;105:5166 -71.
Casak SJ, Lemery SJ, Shen YL, et al. U.S. Food and drug administration approval: rituximab in 
combination with fludarabine and cyclophosphamide for the treatment of patients with chronic 
lymphocytic leukemia. Oncologist. 2011;16:97 -104.
Cervante s-Gomez F, Lamothe B, Woyach JA, et al. Pharmacological and Protein Profiling Suggests 
Venetoclax (ABT -199) as Optimal Partner with Ibrutinib i n Chronic Lymphocytic Leukemia. Clin Cancer 
Res 2015 Aug 15;21:3705- 15. 
Chanan -Khan A, Cramer P, Demirkan F, et al.  Ibruti nib combined with bendamustine and rituximab 
compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic 
leukaemia or small lymphocytic lymphoma (HELIOS): a randomized , double -blind, phase 3 study. 
Lancet Oncol. 2016; 17: 200-11
Cheson BD, Byrd JC, Rai KR, et al. Novel targeted agents and the need to refine clinical end points in 
chronic lymphocytic leukemia. J Clin Oncol 2012; 23:2820 -2.
Child CG, Turcotte JG. “Surgery and portal hypertension”. In Child CG. The liver and p ortal 
hypertension. Philadelphia:Saunders. 1964. pp. 50-64.  
Chiorazzi N, et al Chronic Lymphocytic Leukemia. N Engl J Med 2005, 352:804 -15.
Cimmino A, Calin GA, Fabbri M, et al.  miR -15 and miR -16 induc e apoptosis by targeting BCL2. Proc 
Natl Acad Sci US A.  2005;102:13944 -9.
Coiffier B, Altman A, Pui CH, et al. Guidelines for the management of pediatric and adult tumor lysis 
syndrome: an evidence -based review. J Clin Oncol.2008;26(16):2767-78.
Cory S, Adams JM.  The Bcl -2 family:  regulators of the cellul ar life -or-death sw itch. Nature Reviews. 
Cancer. 2002;2:647 -656.
Cory S, Huang DCS, Adam JM.  The Bcl -2 family:  roles in cell survival and oncogenesis. Oncogene. 
2003;22:8590 -8607.
Deng J, Isik E, Fernandes SM, et al.  Ibrutinib therapy Increases BCL -2 De pendenc eand Enhances 
Sensitivity to Venetoclax in CLL.  Blood 2015:126. Abst 490 .Published ahead of print December 3, 2015
http://www.bloodjournal.org/content/126/23/490.
Dighier o G, Maloum K, Desablens B, et al. Chlorambucil in indolent chronic lymphocy tic leukemia. 
French Cooperative Group on Chronic Lymphocytic Leukemia. N Engl J Med. 1998;338:1506 –14.
Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic 
leukemia. N Engl J Med. 2000;343:1910 -
6.
Eichhorst B, Fink AM, Bahla J, et al. First-line chemoimmunotherapy with bendamustine and rituximab 
versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic 
leukaemia (CLL10): an international, open -label, randomised, phase 3, non- inferiority trial. Lancet Oncol 
2016:17: 928 -42
Ferrajoli A, O'Brien S M, Wierda W, al e. Treatment of patients with CLL 70 years old and older: a single 
center experience of 142 patients . Leuk Lymphoma. 2005;46(S86).
Fischer K, Bahlo J, Fink AM, et al.  Long -Term Remissions after FCR Chemoimmunotherapy in 
Previously Untreated Patients with CLL: Upda ted Results of the CLL8 Trial. Blood 2016;127:208 -215.
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 141Fischer K, Cramer P, Busch R, et al. Bendamustine in combination with rituximab for previously 
untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic 
Lymphocytic Leukemia Study Group. J Clin Oncol. 2012;30:3209 -16.
Fische r K, Fink AM, Bishop H, et al. Results of the Safety Run -in Phase of CLL14 (BO24323): A 
Prospective, Open -Label, Multicenter Randomized Phase III Trial to Compare the Efficacy and Safety of 
Obinutuzumab and Venetoclax (GDC -0199/ABT -199) with Obinutuzumab and Chlorambucil in Patients 
with Previously Untreated CLL and Coexisting Medical Co nditions. Blood 2015:126. Abst 496.
Published ahead of print December 3, 2015. http://www.bloodjournal.org/content/126/23/496.
Fraser G, Cramer P, Demirkan F, Silva RS, Grosicki S, Janssens A, Mayer J, Dilhuydy MS, Pylypenko H, 
Loscertales J, Goy A, Avigdo r A, Rule S, Phelps C, Mahler M, Salman M, Howes A, Hallek M.  Ibrutinib 
plus bendamustine and rituximab in previously treated chronic lymphocytic leukemia/small lymphocytic 
lymphoma (CLL/SLL): 2- year follow -up including MRD from the HELIOS study. Haematol ogica Jun 
2016, 101 (s1), abstract S430. Presented at the 21stCongress of the European Hematology Association 
Copenhagen, Denmark, June 9- 12, 2016.
Hallek M. Signaling theendof chronic lymphocytic leukemia: new frontline treatment strategies. Blood. 
2013 ;122:3723-34.
Hallek M, Cheson BD, Catovsky D, et al. Response assessment in chronic lymphocytic leukemia treated 
with novel agents causing an increase of peripheral blood lymphocytes. Blood 2012 (letter; published 4 
June 2012). http://www.bloodjournal.org/content/111/12/5446.e -letters#response -assessment -in-chronic -
lymphocytic -leukemia -treated -with-novel -agents- causing -an-increase -of-peripheral -blood -lymphocytes . 
Accessed 01 June 2016
Hallek M, Fischer K, Fingerle -Rowson G, et al. Addition of rituximab to fludarabine and 
cyclophosphamide in patient s with chronic lymphocytic leukaemia: a randomised, open -label, phase 3 
trial. Lancet. 2010;376:1164 -1174.
Hallek M, Cheson BD, Catovsky D, et al.  Guidelines for the diagnosis and treatment of chronic 
lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia 
updating the National Cancer Institute -Working Group 1996 guideline. Blood 2008; 111: 5446–5456.
Herman SE, Gordon AL, Hertlein E, et al. Bruton tyrosine kinase represents a promising therapeutic 
target for treatme nt of chronic lymphocytic leukemia and is effectively targeted by PCI -32765. Blood. 
2011;117:6287-96.
Hillmen P. Chronic lymphocytic leukaemia —moving towards cure? Lancet. 2010;376:1122 -4.
Hillmen P, Rawstron A, Munr T, et al. The initial report of the Blo odwise TAP CLARITY study 
combining ibrutinib and venetoclax in relapsed, refractory CLL shows acceptable safety and promising 
early indications of efficacy. Presented at the 22nd Annual Congress of the European Hematology 
Association, Madrid Spain, June 22 -25, 2017. Abtract S770.
Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med 2011; 364:1844 -54.
IMBRUVICA®(ibrutinib) Prescribing Information, Pharmacyclics, LLC. Sunnyvale, CA 94085; Revised 
05/2016
Investigator’s Brochure. Ibrutinib. Ver sion 12: 11December 2018. Pharmacyclics LLC; Janssen Research 
& Development, LLC.
International Conference on Harmonization (ICH) Guideline for Industry: Clinical Safety Data 
Management: Definitions and Standards for Expedited Reporting (ICH -E2A). March 1995.
Jain N, Thompson PA, Ferrajoli A, Burger JA, et al. Combined venetoclax and ibrutinib for patients with 
previously untreated high- risk CLL, and relapsed/refractory CLL: A phase II trial. Blood 2017; 130:429.
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 142Kay NE, Geyer SM, Call TG, et al. Combinat ion chemoimmunotherapy with pentostatin, 
cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in 
previously untreated B chronic lymphocytic leukemia. Blood. 2007;109:405 -411.
Keating M, O' Brien S, Albitar M, et al. Early Results of a Chemoimmunotherapy Regimen of 
Fludarabine, Cyclophosphamide, and Rituximab as Initial Therapy for Chronic Lymphocytic Leukemia. 
JClin Oncol. 2005;23:4079 -4088.
Krober A, Seiler T, Benner A, et al. V(H) mutation status, CD38 express ion level, genomic aberrations, 
and survival in chronic lymphocytic leukemia.Blood 2002;100:1410 -6.
Levin A, Warnock DG, Mehta RL, et al. Improving outcomes from acute kidney injury: report of an 
initiative. Am J Kidney Dis. 2007; 50:1 –4. 
Ma S, Brander DM , Seymour JF, et al.  Deep and Durable Responses Following Venetoclax (ABT -199 / 
GDC -0199) Combined with Rituximab in Patients with Relapsed / Refractory Chronic Lymphocytic 
Leukemia: Results from a Phase 1b Study. Blood. 2015;126, abst 830. Published ahea d of print 
December 3, 2015 http://www.bloodjournal.org/content/126/23/830
M
üller-Hermelink H, Montserrat E, Catovsky D, Harris NL. Chronic lymphocytic leukemia/small 
lymphocytic lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Or ganization 
Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid 
Tissues. Lyon, France: IARC Press; 2001 . pp 127 -130.
National Cancer Comprehensive Network (NCCN). NCCN Clinical Practice Guidelines in Oncology 
(NCCN Guidelines) Non -Hodgkin’s Lymphomas. Version I. 2016. NCCN.org.
https://www.nccn.org/professionals/physician_gls/pdf/nhl.pdf
O’Brien S,.Wierda WG, Faderl S, et al. FCR -3 as frontline therapy for patients with chronic lymphocytic 
leukemia (CLL). Blood (ASH Annual Meeting Abstracts). 2005;106:2117.
http://www.bloodjournal.org/content/106/11/2117.full.pdf
Oken, MM, Creech RH, Tormey DC, et al.: Toxicity And Response Criteria Of The Eastern Cooperative
Oncology Group. Am J Clin Oncol. 5:649-55, 1982.
Pan Z, Scheerens H, Li SJ, et al. Discover y of selective irreversible inhibitors for Bruton's tyrosine kinase. 
ChemMedChem. 2007;2:58 -61.
Parikh S, Keating MJ, O'Brien S, et al. Frontline chemoimmunotherapy with fludarabine, 
cyclophosphamide, alemtuzumab, and rituximab for high -risk chronic lymphocytic leukemia. Blood. 
2011;118:2062-8.
Pflug N, Bahlo, J, Sharafelt TD, et al.  Development of a comprehensive prognostic index for patients 
with chronic lymphocyt ic leukemia. Blood 2014;124:49-62.
Pugh RN, Murray- Lyon IM, Dawson L, et al. “Transection of the oesophagus for bleeding oesophageal 
varices”. The British journal of surgery. 1973;60:646 -9.
Rawstron A, Munir T, Dalal S, et al.  The LLRTAP IcICLLe Trial Assessing Biological Response to 
Ibrutinib in CLL: Immediate Disease Redistribution Precedes Cell Cycle Arrest by 2 Weeks with 
Reduced Bone Marrow Infiltration by 6 Months.  Haematologica June 2015 100 (supplement 1): 331: 
abst S792. http://www.haematologica.org/content/100/supplement_1/1.full.pdf+html
Reynolds C, Di Bella N, Lyons RM, et al. A phase III trial of fludarabine, cyclophosphamide, and 
rituximab v s pent ostatin, cyclophosphamide, and rituximab in B -cell chronic lymphocytic leukemia. 
Invest New Drugs. 2012;30:1232- 40.
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 143Roberts AW, Davids MS, Pagel JM, et al.  Targeting BCL2 with Venetoclax in Relapsed Chronic 
Lymphocytic Leukemia. N Engl J Med. 201 5; 374:311 - 22.
Seymour JF, Davids MS, Pa gel JM, et al. ABT -199 (GDC -0199) in relapsed/refractory chronic 
lymphocytic leukemia and small lymphocytic lymphoma: high response rates among patients with high 
risk disease features including unmutated IGHV. Haematologica 2014; 99(s1):249. Abstract S702 .
http://www.haematologica.org/content/99/supplement_1#abstract -book
Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood 
cell growth factors: An evidence -based clinical practice guideline. J Clin Oncol. 20 06;24:3187 -205. 
Souers AJ, Leverson JD, Boghaert ER, et al.  ABT -199, a potent and selective BCL -2 inhibitor, achieves 
antitumor activity while sparing platelets.  Nat Med.  2013;19:202 -208.
Stilgenbauer S, Eichhorst BF, Schetelig J, et al.  Venetoclax (A BT-199 / GDC -0199) Monotherapy 
Induces Deep Remissions, Including Complete Remisson and Undetectable MRD, in Ultra0High Risk 
Relapsed / Refractory chronic Lymphocytic Leukemia with 17p Deletion: Results of the Pivotal 
International Phase 2 Study. Blood 201 5, abst LBA6. Published ahead of print December 3, 2015. 
http://www.bloodjournal.org/content/126/23/LBA -6.
Strati P, Keating MJ, O’Brien SM, et al.  Eradication of Bone Marrow Minimal Residual Disease May 
Prompt Early Treatment Discontinuation in CLL.  Blo od 2014: 123:3727 -3732.
Surveillance, Epidemiology and End Results (SEER). Stat Fact Sheets —Ch ronic Lymphocytic Leukemia. 
http://seer.cancer.gov/statfacts/html/clyl.html. Accessed June 06 , 201 6.
Tam CS, Roberts AW, Anderson MA, et al.  The combination of i brutinbib and ven etoclax (ABT -199) 
rapidly achieves comlete remissions in patients with relapse / refractory mantle cell lymphoma: 
preliminary result of the Phase II AIM study. J Clin Oncol 34, 2016 (suppl: abstr 
7548) http://meetinglibrary.asco.org/content/166012 -176. [poster presentation] Annual Meeting of the 
Amer ican Society of Clinical Oncology, June3 -7, 2016; Chicago, IL. Abstract 7548.
http://meetinglibrary.asco.org/content/123352?media=vm&poster=1.
Tam CS, O'Brie n S, Wierda W, et al. Long term results of the fludarabine, cyclophosphamide & 
rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008;112:975 -
80
Thompson PA, Tam CS, O’Brien SM, et al.  Fludarabine, cyclophosphamide, and rituxima b treatment 
achieves long -term disease -free survival in IGHV -mutated chronic lymphocytic leukemia. Blood. 2016; 
127:303 -309.
Venetoclax Investigator’s Brochure, Seventh Edition, February 2016.
VENCLEXTA™ (venetoclax) Prescribing Information, AbbVie Inc. No rth Chicago, IL 60064; 2016.
Wierda WG. Making advances in first -line chronic lymphocytic leukemia treatment. J Clin Oncol. 
2012;30:3162 -4.
Wierda WG, Byrd JC, O’Brien SO, et al. Tumor Debulking and Reduction in Tumor Lysis Syndrome 
Risk: Analyses From Sin gle-Agent Ibrutinib Studies. Poster presented at the XVII International 
Workshop on Chronic lymphocytic Leukemi a, May 12 -15, 2017, New York, NY. Poster 106  
Wierda WG, O’Brien S, Wang X, et al.  Multivariable model for time to first treatment in patients with 
chronic lymphocytic leukemia. J Clin Oncol .2011;29:4088 -95
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 144Willis S, Day CL, Hinds MG, et al. The Bcl -2-regulated apoptotic pathway. J Cell Sci.  
2003;116(Pt 20):4053 -6.
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 - Final
Pharmacy clics LLC Proprietary  and Confidential Page 14514. APPENDICES
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 -Final
Pharmacy clics LLC Proprietary  and Confidential Page 149Randomization Phase
Study VisitsRandomi -
zation(1 cycle = 28 days)Suspected 
MRD -positiveSuspected 
PDsEnd-of-
TreatmentResponse 
Follow -UpPost PD
Follow Up
Cycles 17 until disease progression
(every 3 cycles)As soon as 
possible after 
MRD -positive 
relapseAs soon as 
possible after 
suspected PD 30 Days vEvery 3 
months Every 3 months
12-lead ECGnIf clinically indicated (eg, subjects with palpitations, lightheadedness)
Survival, including other 
malignanciesX (other 
malignancies)X
Any new anti -cancer therapy X X
Footnote:
a. Cycle 1 D1: To be collected pre -dose or within +/ -3 days, unless otherwise specified.
b. Ibrutinib: Day 1 dose of Cycle 1, Cycle 2, Cycles 4 and Cycle 6 should be administered at the investigational site. Subsequen t daily doses may be self -administered at home.
c. Venetoclax: Day 1 dose of Cycle 4 Weeks 1 -4, Cycle 5 Week 1 and Cycle 6 should be administered at the investigational site. Subsequent daily doses may be self -
administered at home.
d. Confirmation of eligibility and enrollment may occur within 3 days of Day 1 of Cycle 1.
e. Adverse Events: AEs are reported from the time the subject signs the Informed Consent Form until 30 days following last dose of study drug. AEs that occur prior to first 
dose should be entered as Medical History. In addition to all rou tine AE reporting, all new malignant tumors including solid tumors, skin malignancies and hematologic 
malignancies are to be reported as adverse events.
f. Study  Drug Compliance: Includes subject instruction and routine review of study drug diary and evalu ation of contents of study drug containers from home administration.
g. Physical Exam: Height will only be collected in the Screening Period. Vital signs will be collected through end of treatment only. ECOG collected through disease 
progression.
h. CT Sca n: Baseline CT scan can be performed up to 6 weeks prior to enrollment. Cycle 3 CT scan should be performed and assessed prio r to starting venetoclax at Cycle 4 and 
are obtained for TLS risk assessment. Cycle 3 CT scans should be obtained as close to the b eginning of Cycle 4 as possible, while still allowing for appropriate TLS risk -
guided interventions including hospitalizations if appropriate. Please reference Section 7.1.3.2 for details.
i. Bone marrow biopsy: should be performed at Screening or up to 90 days before the first dose of study drug before enrollment, Cycle 16 (±14 days) [unless collected prior for 
CR assessment, and confirmed MRD -negative in BM], Cycle 29 (±14 days), and as needed to confirm complete response (CR) or evaluate cytopenia. All bone marrow 
biopsies will be assessed by local laboratory. A portion of bone marrow biopsies collected at  should be sent to  central lab. 
An additi onal bone marrow sample will be sent to central laboratory for karyotype (if ALC ≤ 4000) if BM was collected within 90 days p rior to screening and at Day 1 of 
reintroduction of study drug (see Section 7.1.3.5 ). Bone marrow aspirate for  will be derived from MRD bone marrow aspirate, no additional sample needs to be 
collected.
j. MRD Assessment: should be performed in peripheral blood (PB) at Cycle 1, Cycle 7, 10, 13, 16, 20, 23, 26, 29 and every 6 cycles thereafter. MRD assessment confirmation 
by both peripheral blood and bone marrow aspirate (BMA) will be performed at Cycle 16 (±14 days). An additional BMA (after suspected CR or C16) can be collected in 
consented subjects prior to randomization to serially confirm MRD -negativity in the bone marrow compartment.  For all randomized subjects, and any subjects with MRD -
neg conversion in PB, an additional BMA should be collected at Cycle 29 (±14 d ays).
k. Local labs: Hematology, chemistry, Creatinine Clearance, Hepatitis serologies (see Section 7.1.2.4 ), serum and urine pregnancy and Coagulation panel may b e performed at 
local labs.
l. Cytogenetics, FISH panel: If local lab FISH results are not available or if site cannot perform del17p and del11q testing, sa mple should be sent to Central Lab. 
m. IGHV: Send to central lab at Cycle 1. If IGHV sample is not i nformative for any reason, another peripheral blood sample should be drawn and sent to the central lab at the 
next appropriate timepoint. Must have IGHV result in order to be randomized.

IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 -Final
Pharmacy clics LLC Proprietary  and Confidential Page 150n. ECG: At Screening, 12 -lead ECGs will be done in triplicate (≥1 min ute apart). ECG’s may be performed at the investigator’s discretion, particularly in subjects with 
arrhythmic symptoms (eg, palpitations, lightheadedness) or new onset of dyspnea.
o. PK (ibrutinib): Day 1 of Cycle 2 and Cycle 6: to be collected pre -dose, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post -dose. PK should only be drawn when ibrutinib is at 
steady state plasma levels. If any dose of ibrutinib was withheld in the week prior to C2D1 and/or C6D1, then PK assessments should be rescheduled to the next study visit 
day after doses have been consistently administered for ≥1 week (see Table 12).
p. PK (venetoclax ): Day 1 of Cycle 6: to be collected pre -dose, 1 hour, 2 hours, 4 hours, 6 hours and 8 hours post -dose. PK should only be drawn when venetoclax is at steady 
state plasma levels. If any dose of venetoclax was withheld in the week prior to C6D1, then PK asse ssments should be rescheduled to the next study visit day after doses have 
been consistently administered for ≥1 week ( see Table 12)
.
q. Tumor Lysis Sy ndrome Risk Assessment: Please see Appendix Hfor risk assessment categories. For baseline risk assessment, use Screening CT and C1D1 ALC.
r. Tumor Lysis Syndrome Prophylaxis: Please see Section 5.4.2.2 for TLS prophylaxis schedule, venetoclax administration setting and frequency of serum chemistry monitoring
assessments.
s. Suspected PD: Follow same procedures in Pre -Randomization and Randomization phases.
t. Reintroduction: Reintroduce ibrutinib (MRD -negative placebo arm) if MRD -positive relapse or IWCLL confirmed disease progression. Reintroduce venetoclax (MRD -
negative ibrutinib arm) per standard dose ramp up if MRD -positive relapse or IWCLL confirmed disease progression. Reintroduce venetoclax (MRD -positive ibrutinib arm) 
per standard dose ramp up if IWCLL confirmed disease progression.
u. Hematology and Serum Chemistry may be collected up to 24 hours prior to each venetoclax ramp -up (Cycle 4 Weeks 2 -4 and Cycle 5 Week 1), to allow for flexibility in start 
of ramp -up dose.  Hematology and serum chemistry can be drawn on day of dosing to allow for comparison s, but results are not required before dosing decision is made. For 
subjects at high risk for TLS, additional hematology and serum chemistry samples will need to be collected 6 -8 and 24 hours post -1stdose at Cycle 4 Weeks 3 and 4, and 
Cycle 5 Week 1 as part of TLS risk assessment.  Please see Table 4for serum chemistry monitoring assessments.
v. End-of-Treatment Visit: may be sooner if subject is scheduled to start a new anti -cancer treatment.
w. Karyotype: will be assessed from peripheral blood or bone marrow aspirate samples.
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 -Final
Pharmacy clics LLC Proprietary  and Confidential Page 156Footnote:
a. Adverse Events: AEs are reported from the time the subject restarts study drug until 30 days following last dose of study drug. In addition to all routine AE reporting, all new 
malignant tumors including solid tumors, skin malignancies and hematologic malignancies are to be reported as adverse events.
b. Study  Drug Compliance: Inclu des subject instruction and routine review of study drug diary and evaluation of contents of study drug containers from home administration
c. Physical Exam: Vital signs will be collected through end of treatment only. ECOG collected through disease progre ssion.
d. CT Scan: CT scans should be performed approximately within 6 weeks of reintroduction for restaging ,at the end of 4 months, at the end of 12 months, and annually 
thereafter, and as clinically indicated .Please reference Section 7.1.3.2 for details .
e. Cytogenetics, FISH panel: Central lab if local FISH lab results are not available or if site cannot perform del17p and del11q testing .
f. IGHV sample will be derived from one of the samples collected .
g. Karyotype: will be assessed from peripheral blood or bone marrow aspirate samples .
h. Local labs: Hematology, chemistry, Creatinine Clearance, and Coagulation panel may be performe d at local labs .
i. ECG : 12-lead ECGs will be done in triplicate (≥1 minute apart) before reintroduction .In addition ,ECG’s may be performed at the investigator’s discretion, particularly in 
subjects with arrhythmic symptoms (eg, palpitations, lightheaded ness) or new onset of dyspnea.
j. ECHO or MUGA scan should be obtained prior to reintroduction (to allow sufficient time for su bject evaluation ) and then as clinically indicated.
k. End-of-Treatment Visit: may be sooner if subject is scheduled to start a new anti -cancer treatment.

IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 -Final
Pharmacy clics LLC Proprietary  and Confidential Page 158Footnote:
a. Day 1: To be collected pre-dose or within +/ -3 days, unless otherwise specified. FISH, Karyotype, IGHV, and  only on Week 1 D1
b. Venetoclax: Day 1 dose of Cycle 4 Weeks 1 -4, and Cycle 5 Week 1 should be administered at the investigational site.  Subsequent daily dose s may  be self -administered at 
home.
c. Adverse Events: A es are reported from the time the subject restarts study drug until 30 days following last dose of study drug. In addition to all routine AE reporting, all new 
malignant tumors including solid tumors, skin malignancies and hematologic malignancies are to be reported as adverse events.
d. Study  Drug Compliance: Includes subject instruction and routine review of study drug diary and evaluation of contents of stud y drug containers from home administration
e. Physical Exam: Vital signs will be collected through end of treatment only. ECOG collected through disease progression. 
f. CT Scan: CT scans should be performed prior to reintroduction for restaging, at the end of 4 months, at the end of 12 months, an d annually thereafter, and as clinically 
indicated. C4 CT Scan should be collected at C4D -3, while still allowing for appropriate TLS risk- guided interventions including hospitalizations if appropriate.  
g. Cytogenetics, FISH panel: Central lab if local FISH lab results are not available or if site cannot perform del17p and del11q testing. 
h. Tumor Lysis Syndrome Risk Assessment: Please see Appendix Hfor risk assessment categories. For baseline risk assessment, use Screening CT and C1D1 ALC.
i. Tumor Lysis Syndrome Prophylaxis: Please see Section 5.4.2.2 for TLS prophylaxis schedule,  administration setting and frequency of serum chemistry monitoring 
assessments.
j. Hemato logy and Serum Chemistry may be collected up to 24 hours prior to each  ramp -up (Cycle 4 We eks 1 -4 and Cycle 5 Week 1), to allow for flexibility in start of ramp -
up dose.  Hematology and serum chemistry can be drawn on day of dosing to allow for comparisons, but results are not required before dosing decision is made. For subjects 
at high risk f or TLS, additional hematology and serum chemistry samples will need to be collected 6 -8 and 24 hours post -
1stdose at Cycle 4 Weeks 3 and 4 and Cycle 5 
Week 1 as part of TLS risk assessment.  Please see Table 4for serum chemistry monitoring assessments.
k. IGHV sample will be derived from one of the samples collected
Karyotype: will be assessed from peripheral blood or bone marrow aspirate sa mples.
l. ECG: 12-lead ECGs will be done in triplicate (≥1 minute apart) before reintroduction. In addition ). ECG’s may alsobe performed at the investigator’s discretion, particularly 
in subjects with arrhythmic symptoms (eg, palpitations, lightheadedness) or new onset of dyspnea.
m. ECHO or MUGA scan should be obtained prior to reintroduction (to allow sufficient time fo r subject evaluation )and then as clinically indicated. 
n. MRD Assessment: should be performed in peripheral blood (PB) a t Cycle 1, Cycle 7, Cycle 10, Cycle 13, End of Treatment (30 days after last dose of study drug or C17), 
C
17 for reintroduction (3 months after completion of therapy), C25, C28, C31 and annually thereafter.  MRD assessment confirmation by both periphera l blood and bone 
marrow aspirate (BMA) will be performed at Cycle 10, and C19 (3 months after completion of therapy [±14 days]). Bone marrow a spirate MRD should be performed if bone 
marrow is obtained to confirm CR.
o. End-of-Treatment Visit: may be sooner if subject is scheduled to start a new anti -cancer treatment.

IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 -Final
Pharmacy clics LLC Proprietary  and Confidential Page 1604thmonth 5thmonth Every 4 months for 
the first year, then 
every 6 months 
until PD (Day 1 of 
each visit)Suspected PD 
(assoon as 
possible after 
suspected PD)End-of-
Treatment Post PD 
Follow -up 
(Every 
4months)Week 1 Weeks 1 -2 Wks 3 -4Wks 1 & 3
1stmonth –
Day 1aD-3 or 
D-2 D-1 D1 D2 D1 30 Daysq
Study  Visit Windows ± 3 days± 3 days (minimum of 7 days at each dose level of 
venetoclax) ± 3 daysAnytime (as soon 
as possible after 
suspected PD) ±3 days ±14 d
Survival, including other X
Any new anti -cancer therapy X
12-lead ECGnX If clinically indicated 
ECHO or MUGA scanoX If clinically indicated 
Footnote:
a. Day 1: To be collected pre -dose or within +/ -3 days, unless otherwise specified
b. Venetoclax: Day 1 dose of Cycle 4 Weeks 1 -4, and Cycle 5 Week 1 should be administered at the investigational site.  Subsequent daily doses may be self -admini stered at 
home.
c. Adverse Events: AEs are reported from the time the subject restarts study drug until 30 days following last dose of study dru g. In addition to all routine AE reporting, all new 
malignant tumors including solid tumors, skin malignancies a nd hematologic malignancies are to be reported as adverse events.
d. Study  Drug Compliance: Includes subject instruction and routine review of study drug diary and evaluation of contents of stud y drug containers from home administration
e. Physical Exam: Vital signs will be collected through end of treatment only. ECOG collected through disease progression. 
f. CT Scan: CT scans should be performed approximately within 6 weeks of  reintroduction for restaging, at 4 months, 12 months, and annually thereafter, and as clinically 
indicated. C4 CT Scan should be collected at C4D -3, while still allowing for appropriate TLS risk- guided interventions including hospitalizations if appropri ate.  
g. Cytogenetics, FISH panel: Central lab if local FISH lab results are not available or if site cannot perform del17p and del11q testing. 
h. Tumor Lysis Syndrome Risk Assessment: Please see Appendix Hfor risk assessment categories. For baseline risk assessment, use Screening CT and C1D1 ALC.
i. Tumor Lysis Syndrome Prophylaxis: Please see Section 5.4.2.2 for TLS prophylaxis schedule, venetoclax administration setting and frequency of serum chemistry monitoring 
assessments.
j. Hematology and Serum Chemistry may be collected up to 24 hours prior to each venetoclax ramp -up (Cycle 4 Weeks 1 -4 and Cycle 5 Week 1), to allow for flexibility in start 
of ramp -up dose.  Hematology and serum chemistry can be drawn on day of dosing to allow for comparisons, but results are not required before dosing decision is mad e. For 
subjects at high risk for TLS, additional hematology and serum chemistry samples will need to be collected 6 -8 and 24 hours post -1stdose at Cycle 4 Weeks 3 and 4, and 
Cycle 5 Week 1 as part of TLS risk assessment.  Please see Table 4for serum chemistry monitoring assessments.
k. IGHV sample will be derived from one of the  samples collected
l. Karyotype: will be assessed from peripheral blood or bone marrow aspirate samples.
m. Local labs: Hematology, chemistry, Creatinine Clearance, and Coagulation panel may be performed at local labs
n. ECG: 12-lead ECGs will be done in triplicate (≥1 minute apart) before reintroduction .In addition, ECG’s may be performed at the investigator’s discretion, particularly in 
subjects with arrhythmic symptoms (eg, palpitations, lightheadedness) or new onset of dyspnea.
o. ECHO or MUGA scan should be obtained prior to reintroduction (to allow sufficient ti me for subject evaluation ) and then as clinically indicated. 
p. MRD Assessment: should be performed in peripheral blood (PB) at Cycle 1, Cycle 7, Cycle 10, Cycle 13, End of Treatment (30 da ys after last dose of study drug or C17), 
C17 for reintroduction ( 3 months after completion of therapy), C25, C28, C31 and annually thereafter.  MRD assessment confirmation by both peripheral blood and bone 
marrow aspirate (BMA) will be performed at Cycle 10, and C19 (3 months after completion of therapy [±14 days]). Bon e marrow aspirate MRD should be performed if bone 
marrow is obtained to confirm CR.  
q. End-of-Treatment Visit: may be sooner if subject is scheduled to start a new anti -cancer treatment.

IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 -Final
Pharmacy clics LLC Proprietary  and Confidential Page 161Appendix F. ECOG Status Scores
Status Eastern Cooperative Oncology Group (ECOG) Performance Status**
0 Fully active, able to carry on all predisease perform ance without restriction.
1Restricted in physically strenuous activity but ambulatory and able to carry out work of a 
light or sedentary nature, eg, light housework, office work.
2Ambulatory and capable of all self -care, but unable to carry out any work activities.  Up and 
about more than 50% of waking hours.
3 Capable of only limited self -care, confined to bed or chair more than 50% of waking hours.
4 Completely disabled.  Cannot carry on any self -care.  Totally confined to bed or chair.
5 Dead.
** Oken MM, Creech RH, Tormey DC, et al: Toxicity And Response Criteria Of The Eastern Cooperative Oncology Group. 
Am J Clin Oncol .5:649 -655, 1982.
Available at: http://www.ecog.org/general/perf_stat html .  Accessed J une 6 , 2008.
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 -Final
Pharmacy clics LLC Proprietary  and Confidential Page 164Appendix H. TLS Risk Category 
For the management of tumor lysis syndro me prophylaxis, subjects will be classified in 3 risk 
categori es ba sed on the risk for developing medically  concerning TLS wi th venetocl ax 
administration. The Cycle 3 tumor burden assessed by the nodal disease and abso lute 
lymphocy te count will be used to define each category  as described below:
Low Risk Medium Risk High Risk
Lymph Nodes All measurable 
lymph nodes with 
the largest diameter 
<5cm by 
radiographic 
assessmentPresence of any 
single measurable 
lymph node with the 
largest diameter
≥5cm and <10 cm by 
radiologic assessmentA single 
measurable lymph 
node with th e 
largest diameter 
≥5cm by 
radiologic 
assessment.Any single 
measurable lymph 
node with the 
largest diameter
≥10 cm by 
radiologic 
assessment
AND OR AND
Absolute 
Lymphocyte Count< 25 × 109/L ≥ 25 × 109/L ≥ 25 × 109/L
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 -Final
Pharmacy clics LLC Proprietary  and Confidential Page 165Appendix I. Howard Criteria1for Laboratory and Clinical TLS
Metabolic AbnormalityCriteria for Classification of 
Laboratory Tumor Lysis SyndromeCriteria for Classification of 
Clinical Tumor Lysis Syndrome
Hyperuricemia Uric acid >8.0 mg/dL
(475.8 μmol/liter) in adults or above 
the upper limit of the normal range for 
age in children
Hyperphosphatemia Phospho rus >4.5 mg/d L
(1.5mmol/liter) in adults or
>6.5 mg/d L(2.1 mmol/liter) in 
children
Hyperkalemia Potassium >6.0 mmol/liter Cardiac dysrhythmia or sudden death 
probably or definitely caused by 
hyperkalemia
Hypocalcemia  Corrected calcium <7.0 mg/d L
(1.75mmol/liter) or ionized calcium 
<1.12 (0.3 mmol/liter)†Cardiac dysrhythmia, sudden death, 
seizure, neuromuscular irritability 
(tetany , paresthesias, muscle twitching, 
carpopedal spasm, Trousseau’s sign, 
Chvostek’s sign, laryngospasm, or 
bronchospasm), hypotension, or heart 
failure probably or definitely caused by 
hypocalcemia
Acute kidney injury‡ Not applicable Increase in the serum creatinine level of 
0.3 mg/dL (26.5 μmol/liter) (or a single 
value >1.5 times the upper limit of the 
age-appropriate normal range if no 
baseline creatinine measurement is 
available) or the presence of oliguria, 
defined as an average urine output of 
<0.5 mL/kg/hr for 6 hr
* In laboratory tum or lysis syndrome, two or more metabolic abnormalities must be present during the same 24 -hour 
period within 3 days before the start of therapy or up to 7 days afterward. Clinical tumor lysis syndrome requires the 
presence of laboratory tumor lysis syndrom e plus an increased creatinine level, seizures, cardiac dysrhythmia, or death.
† The corrected calcium level in milligrams per deciliter = measured calcium level in milligrams per deciliter 
+ 0.8 × (4 − albumin in grams perdeciliter).
‡ Acute kidney injur y is defined as an increase in the creatinine level of at least 0.3 mg per deciliter (26.5 μmol per liter) or 
a period of oliguria lasting 6 hours or more. By definition, if acute kidney injury is present, the patient has clinical tumo r 
lysis sy ndrome. Dat a about acute kidney injury are from Levin , 2007 .
1Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med 2011; 364:1844 -54
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 -Final
Pharmacy clics LLC Proprietary  and Confidential Page 166Appendix J. Example of Recommendations for Initial Management of Electrolyte 
Abnor malities and Prevention of Tumor Lysis Syndrome (TLS)
Section 1: First Dose of Venetoclax or Dose Escalation
Within the first 24 hours after either the first dose or dose escalat ion, if any laboratory  
criteria below are met, the patient should be hospitalized for monitoring and the 
investigator notified. No additional venetoclax doses should be administered unt il 
resol ution. A rapidly rising serum potassium is a medical emergency.
Nephro logy (or other acute dialysis service) should be notified (per institutional standards 
to ensure emergency  dialysis is available) on admissio nfor any  subject hospi talized 
prophylact ically or in response to laboratory changes.
IV fluids ( eg, D5 1/2 normal saline) should be init iated at a rate of at least 1 mL/kg/hr 
rounded to the nea rest 10 m L (target 150 to 200 mL/hr; not <50 mL/hr). Modificat ion of 
fluid rate shoul d also be considered for individuals with specific medical needs.
Moni tor for sym ptoms or si gns of TLS ( eg, fever, chills, tachycardia, nausea, vomiting, 
diarrhea, di aphor esis, hypotensio n, muscle aches, weakness, paresthesias, mental status 
changes, confusio n, seizures). If any  clinical features are observed, recheck potassium, 
phosphorus, uric acid, calcium and creatinine.
Vital signs shoul d be taken at time of all blood draws or any Intervent ion.
The m anagement recommendat ions below focus on the minimum init ialresponses 
requi red. If a di agnosis of TLS i s established, ongoing intensive monitoring and mult i-
disciplinary management will be per inst itutional protocol s
In addition to the recommendations in the table below:
For potassium increase ≥0.5 mmo l/L from baseline, or any  value >5.0 mm ol/L, recheck 
potassi um, phosphorus, uri c acid, cal cium  andcreatinine and fo llow first gui deline.
For phosphorus increase of >0.5 mg/dL AND >4.5 m g/dL, administer phosphate binder 
and recheck potassium, phosphorus, uric acid, calcium and creat inine.
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 -Final
Pharmacy clics LLC Proprietary  and Confidential Page 167Abnormality Management Recommendations1,2
Hyperkalemia (including rapidly rising potassium)
Potassium ≥ 0.5 mmol/L increase
from prior value (even if potassium
within normal limits [WNL])Recheck potassium, phosphorus, uric acid, calcium and
creatinine. If further ≥0.2 mmol/L increase in potassium, but 
still <upper limit of normal (ULN), manage as per potassium 
≥ULN. Otherwise recheck.
Resume per protocol testing if change in potassium is
<0.2 mmol/L, and potassium < ULN, and no other evidence of 
tumor lysis.
At discretion of Investigator, may recheck prior to
hospitalization. If stable or decreased, and still WNL,
hospitalization is at the discretion of the Investigator.
Potassium, phosphorus, uric acid, calcium and creatinine must 
be rechecked within 24 hours.
Potassium > upper limit of normal Perform STAT ECG and commence telemetry.
Nephrology notification with consideration of initiating
dialysis.
Administer Kayexalate 60 g (or Resonium A 60 g).
Administer furosemide 20 mg IV × 1.
Administer calcium gluconate 100 –200 mg/kg IV slowly if 
there is ECG/telemetry evidence of life-threatening 
arrhythmias.
Recheck potassi um, phosphorus, uric acid, calcium and
creatinine.
oIf potassium < ULN 1 hour later, repeat potassium, 
phosphorus, uric acid, calcium and creatinine 1, 2 and 
4hours, if no other evidence of tumor lysis.
Potassium ≥ 6.0 mmol/L
(6.0mEq/L) and/or symptomatic
(eg,muscle cramps, weakness,
paresthesias, nausea, vomiting,
diarrhea)Perform STAT ECG and commence telemetry.
Nephrology (or other acute dialysis service) notified with 
consideration of initiating dialysis.
Administer Kayexalate 60 g ( or Resonium A 60 g).
Administer furosemide 20 mg IV × 1.
Administer insulin 0.1 U/kg IV + D25 2 mL/kg IV.
Administer sodium bicarbonate 1 to 2 mEq/kg IV push.
If sodium bicarbonate is used, rasburicase should not be 
used as this may exacerbate calcium phosphate 
precipitation.
Administer calcium gluconate 100 to 200 mg/kg IV slowly if 
there is ECG/telemetry evidence of life-threatening 
arrhythmias. Do not administer in same IV line as sodium 
bicarbonate.
Recheck potassium, phosphorus, uric acid, calcium and
creatinine .
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 -Final
Pharmacy clics LLC Proprietary  and Confidential Page 168Abnormality Management Recommendations1,2
Hyperuricemia
Uric acid ≥ 8.0 mg/dL (476 μmol/L) Consider rasburicase (0.2 mg/kg as an intravenous infusion 
over 30 minutes).
If rasburicase is used, sodium bicarbonate should not be 
used as this may exacerbate calcium phosphate 
precipitation.
Recheck potassium, phosphorus, uric acid, calcium and
creatinine.
Uric acid ≥ 10 mg/dL (595 μmol/L)
OR
Uric acid ≥ 8.0 mg/dL (476 μmol/L)
with 25% increase and creatinine
increase ≥ 0.3 mg/dL 
(≥0.027mmol/L) from pre -dose 
levelAdminister rasburicase (0.2 mg/kg as an intravenous infusion 
over 30 minutes).
When rasburicase is used, sodium bicarbonate should not 
be used as this may exacerbate calcium phosphate 
precipitation.
Notify nephrology (or other acute dialysis service).
Recheck potassium, phosphorus, uric acid, calcium and
creatinine.
If uric acid < 8.0 mg/dL 1 hour later, repeat potassium,
phosphorus, uric acid, calcium and creatinine 2 and 4 hours 
later, if no other evidence of tumor lysis.
Hypocalcemia
Calcium ≤ 7.0 mg/dL 
(1.75 mmol/L)
AND
Patient symptomatic ( eg, muscle
cram ps, hypotension, tetany, cardiac
arrhythmias)Administer calcium gluconate 50 to 100 mg/kg IV slowly with 
ECG monitoring.
Telemetry.
Recheck potassium, phosphorus, uric acid, calcium and
creatinine.
If calcium normalized 1 hour later, repeat potassium,
phosphorus, uric acid, calcium and creatinine 2 and 4 hours 
later, if no other evidence of tumor lysis.
Calculate corrected calcium and check ionized calcium if 
albumin low
Hyperphosphatemia
Phosphorus ≥ 5.0 mg/dL
(1.615 mmol/L) with ≥ 0.5 mg/dL
(0.16 mmol/L) increaseAdminister a phosphate binder ( eg, aluminum hydroxide, 
calcium carbonate, sevelamer hydroxide, or lanthanum 
carbonate).
Nephrology (or other acute dialysis service) notification 
(dialysis required for phosphorus ≥10 mg/dL).
Recheck potassium, phosphorus, uric acid, calcium and
creatinine.
If phosphorus <5.0 mg/dL 1 hour later, repeat potassium, 
phosphorus, uric acid, calcium and creatinine 2 and 4 hours
later, if no other evidence of tumor lysis.
Creatinine
Increase ≥ 25% from baseline Start or increase rate of IV fluids.
Recheck potassium, phosphorus, uric acid, calcium and
creatinine.
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 -Final
Pharmacy clics LLC Proprietary  and Confidential Page 169Section 2: Ongoing Dosing of Venetoclax
Management of electroly te changes from  last val ue at intervals >24 hours after either the first 
dose or dose escalation ( eg, 48 or 72 hours) are as below.
Note : If the patient is hospitalized, no addit ional venetoclax doses should be administered until 
resol ution.
For p otassi um, admi t pati ent for any  increase ≥1.0 mmo l/L (1.0 mEq/L), or any  level 
>upper limit of normal.
○Refer to the management guidelines for electrolyte changes observed wit hin the first 
24 hours after either the first dose or dose escalation (see table above ).
If a smaller potassium increase is observed that does not meet the criteria for admissio n 
above, recheck potassium, phosphorus, uric acid, calcium and creatinine in 24 hours and 
confirm no evidence of tumor lysis prior to further venetoclax dosing.
For uric aci d, calcium , phosphorus and creatinine, refer to the management guidelines for 
electroly te changes observed wit hin the first 24 hours after either the first dose or dose 
escalat ion (see table above ).
References
1.Coiffier B, Altman A, Pui CH, et al. Guidelines for the management of pediatric and adult tumor lysis 
syndrome: an evidence -based review. J Clin Oncol.2008;26(16):2767 -78.
2.Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 
2004;127(1):3 - 11.
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 -Final
Pharmacy clics LLC Proprietary  and Confidential Page 170Appendix K. Child -Pugh Score for Subjects with Liver Impairment
Measure 1 point 2 points 3 points
Total bilirubin, μmol/L (mg/dL) <34 (<2) 34-50 (2 -3) >50 (>3)
Serum albumin, g/L (g/dL) >35 (>3.5) 28-35 (2.8 -3.5) <28 (<2.8)
PT/INR <1.7 1.71-2.30 >2.30
Ascites None Mild Moderate to Severe
Hepatic encephalopathyNoneGrade I -II (or suppressed 
with medication)Grade III -IV 
(or refractory)
Points Class
5-6 A
7-9 B
10-15 C
Source:
1.Child CG, Turcotte JG .“Surgery and portal hypertension”. In Child CG. The liver and portal hypertension. 
Philadelphia: Saunders. 1964. pp. 50 -64.
2.Pugh RN, Murray -Lyon IM, Dawson L, et al. “Transection of t he oesophagus for bleeding oesophageal 
varices”. The British journal of surgery , 1973;60: 646 -9.
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 -Final
Pharmacy clics LLC Proprietary  and Confidential Page 171Appendix L. Hem atologic Adverse Event Grading Scheme ( Hallek 2008)
An evaluat ion of the hematologic toxicit y in pat ients wi th advanced CLL/SLL must consider the
high frequency of marrow invo lvement and previo us exposure to chemotherapy  with consequent
medullary  com promise at the init iation o f therapy . The standard hematologic grading system for
solid tumors cannot, therefore, be directly applied. A substantial proportion of pat ients woul d be
considered to have Grade 2 to 4 hematologic toxicity before any  therapy is given. Therefore, the
following modified schema will be used to quantitate hematologic deterioration in pat ients with
CLL/SLL.
Hematologic Grading Scheme
Decrease in Platelets or Hgb (Nadir) 
from Pre -treatment Value, % ANC/μL (nadir)cToxicity Grade
0 - 10%a≥ 2000 0
11 - 24%a,b≥ 1500 and < 2000 1
25 - 49%a,b≥ 1000 and < 1500 2
50 - 74%a,b≥ 500 and < 1000 3
> 75%a,b< 500 4
a. Platelet counts must be below normal levels to be Grades1 to 4. If at any level of decrease, the platelet count falls below 
20×109/L, toxicity will be considered Grade 4. If the baseline platelet count is <20×109/L, platelet toxicity cannot be 
evaluated.
b. Hemogl obin levels must be below normal levels to be Grades 1 to 4. Baseline and subsequent Hgb values must be 
determined the day of any given transfusion.
c. If the ANC was <1000/µL before therapy, the patient is not evaluable for toxicity referable to the ANC.
IMBRUVICA®(ibrutinib) PCYC -1142-CA Amendment 4 02December 2022 -Final
Pharmacy clics LLC Proprietary  and Confidential Page 172Appendix M. Rai Staging
Rai Stage
0
Lymphocytes (L) in blood (>5000/µL)
I
L + enlarged lymph nodes (LN)
II
L + spleen and/or liver (LN positive or negative)
III
L + anemia (Hgb <11g/dL)
IV
L + thrombocytopenia (platelets <100,000/μL)